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SUMMARY 
Bioavailability of topical ophthalmic products is, apart from drug properties, substantially 
determined by the type and concentration of excipients. In addition to the use in conventional 
ophthalmic formulations, excipients are increasingly utilized in the development of innovative 
nanosystem-based ophthalmic formulations, in which excipients are supramolecularly 
organized into nano-sized structures, which can specifically interact with the anterior eye 
segment barriers and enhance the drug eye-related bioavailability. Evaluation of the drug 
transcorneal permeability is a critical step in predicting eye-related bioavailability of topical 
ophthalmic drugs. In this thesis, the effect of unimers and supramolecular aggregates of the 
ophthalmic excipients on corneal barrier properties and ophthalmic drug permeability was 
evaluated, using in vitro (HCE-T cell-based) and/or ex vivo (excised porcine cornea) corneal 
models. Histological and functional characterization of the in vitro corneal model revealed 
variability of the HCE-T barrier phenotype, which highlights the important aspects to be 
considered in the further model development. HCE-T cell-based model of a specific 
histological structure, but showing improved barrier tightness and a very strong correlation of 
ophthalmic compounds permeability with excised porcine cornea, was shown to be suitable 
for the ophthalmic drug permeability evaluation considering the influence of ophthalmic 
excipients. Biopharmaceutical evaluation of melatonin-loaded nanosystems using HCE-T 
cell-based models revealed significant influence of chitosan on nanosystems 
biopharmaceutical properties. In lecithin/chitosan nanoparticles the presence of chitosan 
ensured mucoadhesive properties and prolonged melatonin release, controlling melatonin in 
vitro transcorneal permeation, which may provide enhanced melatonin eye-related 
bioavailability and therapeutic effect. The in vitro/ex vivo evaluation of the effect of nonionic 
surface active ophthalmic excipients on the ophthalmic drug permeability revealed their 
concentration-dependent permeability-decreasing effect, which was potentially related to the 
association of ophthalmic drugs with self-aggregates of surface active ophthalmic excipients. 
The results of this thesis provide valuable insight into the effect of ophthalmic excipients on 
ophthalmic drug transcorneal permeability, which may contribute to more directed and 
economical development of both conventional and innovative topical ophthalmic products.  
KEYWORDS: ophthalmic drugs, ophthalmic excipients, surfactants, nanosystems, drug 
permeability, eye-related bioavailability, in vitro/ex vivo corneal models, HCE-T. 
  
  
SAŽETAK 
Uvod: Razvoj topikalnih oftalmičkih pripravaka veliki je izazov farmaceutske industrije zbog 
različitih anatomskih i fizioloških barijera prednjeg segmenta oka koje značajno ograničavaju 
apsorpciju i bioraspoloživost topikalno primijenjenog oftalmičkog lijeka. Zbog izravne 
primjene topikalnog oftalmičkog lijeka na površinu rožnice preko koje se odvija permeacija 
lijeka do ciljnog mjesta djelovanja, sastav oftalmičke formulacije, odnosno vrsta i udio 
oftalmičkih ekscipijensa, značajno utječe na permeabilnost i bioraspoloživost topikalno 
primijenjenog oftalmičkog lijeka. Osim u konvencionalnim oftalmičkim oblicima, 
ekscipijensi sve više primjenu pronalaze u razvoju inovativnih oftalmičkih oblika temeljenih 
na terapijskim nanosustavima za dostavu lijeka. Naime, uslijed interakcija u određenim 
uvjetima ekscipijensi tvore supramolekulske strukture nanodimenzija, za koje je pokazano da 
mogu povećati bioraspoloživost lijeka prevladavanjem barijera prednjeg segmenta oka. 
Detaljno poznavanje utjecaja oftalmičkih ekscipijensa na permeabilnost oftalmičkih lijekova 
kroz barijeru rožnice može stoga značajno pridonijeti usmjerenosti i ekonomičnosti razvoja 
konvencionalnih i inovativnih oftalmičkih pripravaka. Cilj ovog doktorskog rada je 
korištenjem in vitro staničnog HCE-T modela epitela humane rožnice i ex vivo tkivnog 
modela rožnice svinje evaluirati biofarmaceutske značajke unimera i supramolekulskih 
agregata oftalmičkih ekscipijensa s obzirom na njihov potencijal promjene bioraspoloživosti 
topikalnih oftalmičkih lijekova, temeljem utjecaja na barijerna svojstva in vitro i ex vivo 
modela rožnice i permeabilnost oftalmičkih lijekova. 
Metode: In vitro HCE-T model epitela humane rožnice uzgajan je prema standardiziranom 
protokolu korištenjem komercijalno dostupnih Transwell® ploča. Za potrebe ex vivo 
ispitivanja permeabilnosti korištene su svježe izolirane rožnice svinje uz upotrebu vertikalnih 
difuzijskih ćelija. Histomorfološka analiza in vitro HCE-T modela epitela humane rožnice 
provedena je svjetlosnom i fluorescencijskom mikroskopijom prethodno fiksiranog i 
obojenog modela. Karakterizacija barijernih svojstava in vitro i ex vivo modela rožnice 
provedena je mjerenjima transepitelnog električnog otpora (TEER) te ispitivanjima 
permeabilnosti oftalmičkih supstancija (timolol maleat, diklofenak natrij, kloramfenikol, 
deksametazon, fluorescein natrij) različitih fizičko-kemijskih svojstava. Fizičko-kemijska 
karakterizacija priređenih nanosustava provedena je dinamičkim raspršenjem svjetlosti te 
laserskom Doppler anemometrijom, dok je za ispitivanje oslobađanja melatonina iz 
nanočestica primijenjena metoda dijalize. Biokompatibilnost nanočestica ispitana je 
korištenjem MTT testa vijabilnosti stanica na monosloju HCE-T stanica. Mukoadhezivnost 
  
nanočestica određena je ispitivanjem adhezije nanočestica na monosloju HCE-T stanica. 
Agregacijska svojstva oftalmičkih površinski aktivnih ekscipijensa određena su dinamičkim 
raspršenjem svjetlosti. Za kvantitativno određivanje oftalmičkih supstancija korištena je 
spektrofluorimetrija pomoću čitača mikrotitarskih ploča, kromatografija visoke djelotvornosti 
(HPLC) te kromatografija ultra-visoke djelotvornosti (UPLC). 
Rezultati: In vitro HCE-T model humanog epitela rožnice uzgajan je prema standardiziranom 
protokolu uz upotrebu dvije vrste polikarbonatne membrane različite veličine pora. 
Histomorfološkim ispitivanjima utvrđeno je postojanje dva različita fenotipa in vitro HCE-T 
modela humanog epitela rožnice, ovisno o veličini pora membrane. Model I (veličina pora 0,4 
µm) građen je od lipofilnog višeslojnog epitela HCE-T stanica na apikalnoj strani membrane. 
Model II (veličina pora 3,0 µm) građen je od lipofilnog monosloja HCE-T stanica u 
apikalnom dijelu te dodatnog lipofilnog monosloja migriranih HCE-T stanica u 
bazolateralnom dijelu membrane. Slaba barijerna svojstva te značajno viša permeabilnost 
oftalmičkih supstancija u usporedbi s ex vivo modelom rožnice svinje ukazuju na relativnu 
neprikladnost Modela I u ispitivanju permeabilnosti i predviđanju bioraspoloživosti topikalnih 
oftalmičkih lijekova. Model II karakterizira značajno čvršća epitelna barijera te vrlo dobra 
korelacija permeabilnosti oftalmičkih supstancija s ex vivo modelom rožnice, što upućuje na 
prikladnost Modela II za ispitivanje permeabilnosti i predviđanje bioraspoloživosti topikalnih 
oftalmičkih lijekova. Utvrđena međuovisnost temperature, TEER vrijednosti modela i 
permeabilnosti paracelularnog i transcelularnog obilježivača ukazuju na prikladnost Modela II 
za evaluaciju interakcije oftalmičkih ekscipijensa s epitelnom barijerom rožnice i 
posljedičnog utjecaja na permeabilnost oftalmičkih lijekova kroz barijeru rožnice. Rezultati 
ispitivanja ukazuju, međutim, na određenu varijabilnost in vitro HCE-T modela humanog 
epitela rožnice te potrebu za identifikacijom i standardizacijom čimbenika uzgoja u smislu 
utjecaja na barijerna svojstva modela i permeabilnost oftalmičkih supstancija.  
Model II korišten je u biofarmaceutskoj karakterizaciji dviju vrsta nanosustava za topikalnu 
oftalmičku primjenu melatonina, u okviru koje je evaluiran utjecaj pojedinih ekscipijensa na 
biofarmaceutska svojstva nanosustava. Ispitane su polimerne lecitinsko-kitozanske 
nanočestice (MLC) te Pluronic® F127/kitozanske micele (MFC) s uklopljenim melatoninom. 
Polimerne nanočestice bile su karakterizirane većom veličinom čestica (241,8 ± 0,8 nm), 
višim zeta potencijalom (22,7 ± 0,7 mV) te sporijim oslobađanjem melatonina (t50% = 1,75 h) 
u odnosu na micele (20,7 ± 0,3 nm, 4,3 ± 0,9 mV, t50% = 0,75 h). MTT ispitivanje vijabilnosti 
HCE-T stanica ukazuje na biokompatibilnost obje vrste nanosustava s epitelnim stanicama 
  
rožnice te sigurnost njihove topikalne oftalmičke primjene. Ispitivanjima adhezivnosti 
nanosustava na monosloju HCE-T stanica utvrđena su značajna mukoadhezivna svojstva 
polimernih nanočestica, koja su vrlo vjerojatno osigurana površinskim pozitivnim nabojem 
nanočestica posredovanim prisutnošću kitozana. Uklapanje melatonina u nanosustave 
rezultiralo je smanjenjem permeabilnosti melatonina preko HCE-T epitelne barijere rožnice u 
odnosu na kontrolnu otopinu melatonina, pri čemu je smanjenje permeabilnosti bilo izraženije 
za polimerne nanočestice (za oko 60%) nego za micele (za oko 30%). Rezultati ispitivanja 
permeabilnosti ukazuju na značajan utjecaj kitozana na permeabilnost melatonina. 
Uklapanjem kitozana u Pluronic
®
 F127 micele umanjen je utjecaj Pluronic
®
 F127 na 
povećanje permeabilnosti melatonina, dok je prisutnost kitozana u polimernim  
nanočesticama značajno smanjila brzinu oslobađanja melatonina, za koju je pokazano da 
kontrolira brzinu permeacije melatonina preko HCE-T epitelne barijere rožnice. Rezultati 
provedenih fizičko-kemijskih i biofarmaceutskih ispitivanja ukazuju na značajan utjecaj 
kitozana na biofarmaceutska svojstva lecitinsko-kitozanskih nanočestica, koje temeljem 
mehanizama mukoadhezije te kontroliranog oslobađanja i permeacije melatonina mogu 
potencijalno pospješiti bioraspoloživost i produljiti terapijski učinak topikalno primijenjenog 
melatonina. 
Korištenjem Modela II i ex vivo modela rožnice svinje ispitan je učinak vrste i koncentracije 
četiri različita oftalmička neionska površinski aktivna ekscipijensa (nPAE) na barijerna 
svojstva modela rožnice i permeabilnost četiri oftalmička lijeka različitih fizičko-kemijskih 
svojstava. Rezultati TEER mjerenja tijekom in vitro/ex vivo ispitivanja permeabilnosti 
ukazuju na odsutnost interakcije oftalmičkih nPAE s epitelnom barijerom rožnice. Prisutnost 
oftalmičkih nPAE uzrokovala je, međutim, smanjenje permeabilnosti pojedinih oftalmičkih 
lijekova, ovisno o vrsti i koncentraciji oftalmičkih nPAE. Rezultati ispitivanja agregacijskih 
svojstava oftalmičkih nPAE upućuju na interakciju oftalmičkih lijekova i agregata oftalmičkih 
nPAE kao mogući mehanizam smanjenja in vitro/ex vivo permeabilnosti oftalmičkih lijekova. 
Pri najnižoj ispitanoj koncentraciji oftalmičkih nPAE, pri kojoj je utvrđena odsutnost njihovih 
agregata, in vitro/ex vivo permeabilnost oftalmičkih lijekova nije bila promijenjena. Pri višim 
ispitanim koncentracijama oftalmičkih nPAE, pri kojoj je utvrđena prisutnost njihovih 
agregata, uočeno je, međutim, smanjenje in vitro/ex vivo permeabilnosti oftalmičkih lijekova. 
Najizraženiji učinak smanjenja in vitro/ex vivo permeabilnosti oftalmičkih lijekova zabilježen 
je za Cremophor EL, 2% m/V (za oko 90%), dok je slabiji učinak smanjenja in vitro/ex vivo 
permeabilnosti oftalmičkih lijekova uočen za Tiloksapol, 0,1% m/V (za oko 50%) i Polisorbat 
80, 0,2% m/V (za oko 30%). Pluronic
®
 F68, 1% m/V, nije imao statistički značajan utjecaj na 
  
in vitro/ex vivo permeabilnost oftalmičkih lijekova unutar ispitanog koncentracijskog raspona. 
Učinak oftalmičkih nPAE na in vitro/ex vivo permeabilnost oftalmičkih lijekova bio je 
izraženiji za lipofilne oftalmičke lijekove niže topljivosti. Za timolol maleat, oftalmički lijek 
bolje topljivosti i slabije lipofilnosti u odnosu na ostale ispitane oftalmičke lijekove, nije 
uočen utjecaj oftalmičkih nPAE na njegovu in vitro/ex vivo permeabilnost. Vrlo dobra in 
vitro/ex vivo korelacija utjecaja oftalmičkih nPAE na permeabilnost oftalmičkih lijekova 
upućuje na to da je uočen utjecaj usporedivog opsega i posredovan istim mehanizmom u oba 
modela rožnice. Rezultati istraživanja daju važan uvid u utjecaj oftalmičkih nPAE na 
permeabilnost oftalmičkih lijekova što može usmjeriti njihov odabir u budućem razvoju 
topikalnih oftalmičkih pripravaka s obzirom na potencijal promjene bioraspoloživosti 
topikalno primijenjenih oftalmičkih lijekova.  
Zaključak: Biofarmaceutska ispitivanja provedena u okviru doktorskog rada ukazuju na 
prikladnost in vitro HCE-T modela epitela humane rožnice za ispitivanje permeabilnosti 
topikalnih oftalmičkih lijekova s ciljem unaprjeđenja procesa optimizacije sastava 
konvencionalnih i inovativnih oftalmičkih pripravaka u ranim fazama razvoja. Provedena 
karakterizacija in vitro HCE-T modela rožnice u sklopu doktorskog rada ukazuje, međutim, 
na određenu varijabilnost modela te potrebu za dodatnom karakterizacijom čimbenika uzgoja 
u smislu utjecaja na barijerna svojstva modela, u okviru njegove daljnje optimizacije i 
standardizacije. Ispitivanje i klasifikacija pomoćnih tvari s obzirom na potencijal promjene 
permeabilnosti i bioraspoloživosti topikalno primijenjenih oftalmičkih lijekova ključan su 
korak za unaprjeđenje ciljanog i isplativog razvoja topikalnih oftalmičkih pripravaka. 
Rezultati doktorskog rada značajan su doprinos razumijevanju utjecaja oftalmičkih 
ekscipijensa na permeabilnost oftalmičkih lijekova, što može usmjeriti njihov odabir u 
budućem razvoju konvencionalnih i inovativnih topikalnih oftalmičkih pripravaka. 
KLJUČNE RIJEČI: oftalmički lijek, oftalmički ekscipijensi, površinski aktivni ekscipijensi, 
nanosustavi, permeabilnost, bioraspoloživost, in vitro/ex vivo modeli rožnice, HCE-T. 
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1. INTRODUCTION 
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1.1. Topical ophthalmic drug delivery 
1.1.1. Pharmacokinetic challenges of topical ophthalmic drug delivery  
Topical administration is, due to its ease of use, convenience and non-invasiveness, 
the most common drug administration route in the treatment of anterior eye segment diseases. 
Topical ophthalmic drug is applied directly to the ocular surface from which it has to enter 
and/or permeate the ocular surface tissue barriers to reach the target site. However, different 
physiological and anatomical barriers which protect the anterior segment of the eye from 
harmful effects of chemicals, particles and microorganisms, significantly limit the absorption 
and bioavailability of topically applied ophthalmic drugs. More precisely, anterior eye 
segment barriers such as tear turnover, reflex blinking, induced lachrimation, nasolacrimal 
drainage and tight corneal barrier (Figure 1), successfully eliminate topically applied 
ophthalmic product from the ocular surface and restrict the ophthalmic drug absorption, 
which results in low ophthalmic drug eye-related bioavailability and limited therapeutic 
activity. Overall, topically applied ophthalmic product is eliminated from the ocular surface in 
less than 5 minutes and less than 5% of the topical ophthalmic drug dose is absorbed and 
available at the target site (Järvinen et al., 1995). 
 
Figure 1. Schematic presentation of the main anterior eye segment barriers which a topically applied 
ophthalmic drug must overcome to reach the target site (reprinted from Alvarez-Trabado et al., 2017, 
with permission from Elsevier). 
The anterior ocular surface is covered with a thin layer of tears which are produced by 
the lachrymal gland at a rate of 0.5-2.2 μL/min (approximately 16%/min turnover rate) and 
are distributed over the ocular surface by blinking. The tear film is composed of an outer lipid 
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layer which prevents the tear evaporation and stabilizes the tear film, intermediate aqueous 
layer containing electrolytes, small molecules (urea, glucose), proteins, enzymes and soluble 
mucins, and the inner layer of mucins anchored to the corneal and conjunctival epithelium. A 
portion of the tears is lost through evaporation and the rest is drained through the lacrimal 
punctum and nasolacrimal duct to nasal cavity (Tsubota, 1998). A conventional ophthalmic 
eye drop dispensing bottle delivers a volume of 25-56 μL (1-2 drops) which mixes with the 
normal tear volume of 7 μL, however, maximal volume which human conjunctival sac can 
retain is approximately 30 μL. Larger instillation volumes result in partial ophthalmic product 
loss due to spillage over the anterior lid border to cheek skin. Furthermore, reflex blinking 
and lacrimation upon application of larger instillation volumes is induced, which enhances 
ophthalmic product elimination through nasolacrimal drainage system (Troy and Beringer, 
2006). Moreover, proteins and enzymes present in the tears can reduce the fraction of a 
topically applied ophthalmic drug available for absorption through anterior eye segment tissue 
barriers by forming drug-protein complexes or inducing drug degradation, respectively 
(Alvarez-Trabado et al., 2017).  
Additional substantial drug loss occurs by systemic absorption through conjunctiva. 
The conjunctiva is a highly vascularised mucous membrane composed of multi-layered 
epithelium and connective tissue, characterised by approximately 17 times higher surface area 
compared to cornea (Watsky et al., 1988). Tight junctions encircling conjunctival epithelial 
cells are much leakier than the tight junctions in the cornea which makes the conjunctiva 2 to 
30 times more permeable to both small and large molecules (Hämäläinen et al., 1997; Huang 
et al., 1989). Topically applied ophthalmic drug diffuses through conjunctival epithelial 
membrane and via conjunctival blood vessels enters systemic circulation. As a result, a 
significant portion of the ophthalmic drug is lost and unavailable for exerting therapeutic 
activity at the target site. However, due to wider paracellular space and higher permeability 
the conjunctiva represents an alternative route for the delivery of therapeutic hydrophilic 
macromolecules by direct absorption to vitreous through conjunctival-scleral-uveal tract 
pathway (Ahmed and Patton, 1985).  
In order to reach the target site located in inner ocular structures a drug must permeate 
through corneal barrier. However, cornea is a very tight multi-layered barrier which restricts 
the passage of small molecules and is almost impermeable to large molecules. Highly 
lipophilic small molecules easily permeate the outer lipophilic multi-layered epithelium, 
however, the hydrophilic stroma posterior to the epithelium strongly limits their further 
diffusion. The diffusion of small hydrophilic molecules through corneal epithelium is 
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confined to intercellular hydrophilic pores, however, tight junctions encircling epithelial cells 
strongly limit their diffusion, which results in their low corneal permeability. A monolayer of 
corneal endothelial cells located posterior to the stroma has a marginal barrier role in the 
permeation of both lipophilic and hydrophilic small molecules (Schoenwald and Huang, 1983; 
Shih and Lee, 1990).  
Once a drug permeates the cornea, it enters the aqueous humour compartment where it 
undergoes further distribution to intraocular tissues and elimination through local blood 
circulation. The aqueous humour volume of 300 μL is continuously produced and eliminated 
at a rate of 2-3 μL/min. The aqueous humour turnover, however, has a minor role in drug 
elimination from aqueous humour compartment. The ocular drug clearance value of 4.7-15 
μL/min indicates that drugs are primarily eliminated through blood circulation of anterior 
uvea or/and metabolic pathways. Moreover, the estimated drug half-life of 0.8-3.0 h, a lot 
larger compared to the half-life of aqueous humour (0.77 h), suggests that the drug 
elimination might be slowed down due to drug binding to intraocular tissues and back-
diffusion from tissue reservoirs (Schoenwald, 1990). 
1.1.2. Corneal anatomy 
Cornea is an optically transparent avascular tissue, providing about three-fourths of the 
refractive capacity of the eye. The corneal diameter is about 11.5 mm horizontally and 10.5 
mm vertically. The corneal thickness is about 0.5-0.7 mm, with central part of the cornea 
being thicker than the limbus. Five different layers constitute the corneal tissue, namely, the 
epithelium, Bowman's membrane, stroma, Descemet's membrane and endothelium (Eghrari et 
al., 2015).  
The epithelium, the anterior-most layer of the cornea, is composed of 4-6 layers of 
nonkeratinized stratified squamous cells, measuring approximately 50 μm in thickness. The 
superficial 2-3 layers of corneal epithelium are comprised of polygonally shaped flat cells 
with apical microvilli, covered by a charged glycocalyx layer (Mochizuki et al., 2010). 
Intercellular tight junctions surround the most superficial cells creating a watertight seal 
which acts as a selective barrier for small molecules and prevents the diffusion of 
macromolecules (Leong and Tong, 2015). The central cross section of the corneal epithelium 
consists of 2-3 layers of wing or suprabasal cells, which also demonstrate tight-junctional 
complexes. The posterior-most epithelial layer is composed of basal columnar cells, which are 
responsible for corneal cell division and differentiation. Regular apoptosis and desquamation 
occurs in the corneal epithelium, during which the lost cells are replaced by the division and 
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differentiation of perilimbal basal epithelial cells, resulting in epithelial cells lifespan of 7-10 
days (Hanna et al., 1961). The basal epithelial cells with their hemidesmosomes adhere to the 
epithelial basement membrane underneath, which consists of different structural proteins and 
glycoproteins (Torricelli et al., 2013). Posterior to the epithelial basement membrane lies 8-12 
μm thick acellular nonregenerating Bowman’s layer, composed mainly of collagen fibrils 
(Jacobsen et al., 1984).  
Corneal stroma, situated underneath the Bowman’s membrane, is around 500 μm thick 
highly innervated structure, which comprises around 90% of the corneal thickness. Water 
comprises approximately 85% of the corneal stroma. Collagen fibres, the main structural 
component of the stroma, are of a uniform diameter of around 25 nm and run parallel to each 
other to form specifically arranged collagen lamellae, ensuring thereby both structural support 
and optical transparency. These collagen lamellae of varying width and thickness are 
embedded in an extracellular matrix composed mainly of water, inorganic salts, proteoglycans 
and glycoproteins. The principal stromal cells keratocytes produce extracellular matrix 
components maintaining thereby the structure of the stroma (Torricelli and Wilson, 2014). 
Descemet’s membrane is the basement membrane of the corneal endothelium, located right 
beneath the stroma. Similar to Bowman’s mebrane, it is a two-layer structure, around 10 μm 
thick, composed mainly of collagen, as well as other structural proteins and proteoglycans 
(Johnson et al., 1982). 
Endothelium, an approximately 5 μm thick structure, consists of a single layer of flat 
polygonal cells distributed in a hexagonal pattern. The ionic pumps, which are located at the 
basolateral membrane of endothelial cells, play a key role in maintaining the normal corneal 
hydration (Barry et al., 1995). In contrast to the epithelial cells, endothelial cells do not 
undergo mitosis. In the event of damage or death of endothelial cells, lost endothelial cell 
function is restored by migration and reorganisation of adjacent endothelial cells (Joyce, 
2003). 
1.2. Preclinical in vitro/ex vivo corneal models for the prediction of eye-
related bioavailability 
The animal studies in vivo represent an important step in the ophthalmic drug product 
development during the selection of the ophthalmic formulations proceeding into the clinical 
studies. However, ethical and economical concerns, as well as questionable translation of the 
animal results to humans, have focused researchers on the development of preclinical in vitro 
cell-based and ex vivo tissue-based corneal models for ophthalmic drug permeability testing. 
6 
 
For small moderately lipophilic molecules, which still comprise the majority of commercially 
available topical ophthalmic drugs, the corneal barrier represents the main route to target sites 
located in inner intraocular structures. The evaluation of the ophthalmic drug permeability 
using the in vitro and ex vivo corneal models, with the aim of predicting the ophthalmic drug 
eye-related bioavailability in vivo in the early stages of ophthalmic product development, 
might improve the process of selection of an ophthalmic drug/formulation reaching the 
market. 
Bioequivalence testing of generic topical ophthalmic products poses a significant 
challenge, since the measurements of the drug concentration in the ocular tissues and fluids, 
due to their invasiveness and complexity, most often cannot be performed. For products with 
systemic effect intended for oral and non-oral administration routes, the determination of the 
drug plasma concentration-time profile represents the basis for regulatory approval of generic 
products. For topical ophthalmic products, however, the drug concentration in the systemic 
circulation does not reflect the fate of a drug in intraocular tissues. It is rather a measure of the 
systemic exposure to topically applied ophthalmic drug and should be considered in the 
evaluation of the topical ophthalmic product safety. Current guidelines for bioequivalence 
testing of topical ophthalmic products include clinical end-point studies, pharmacokinetic 
studies in aqueous humour or in vitro studies (microbial kill-rate studies, physico-chemical 
characterization, in vitro release studies), depending on the dosage form type, active 
pharmaceutical ingredient, indication, site of action and mechanism of action (Choi and 
Lionberger, 2016). Obviously, in vitro and ex vivo corneal permeability models predicting the 
topical ophthalmic drug bioavailability in vivo have the potential to be in the future included 
in the regulatory guidelines for the topical ophthalmic product bioequivalence testing (Pepić 
et al., 2014). 
However, in order to be implemented in pharmaceutical industry the in vitro and ex 
vivo models must be in detail characterised regarding the structural barrier properties, 
paracellular and transcellular drug transport route and the expression and functionality of 
membrane transporters and metabolic enzymes, all of which influence the drug transcorneal 
permeability. Moreover, standardization of the experimental conditions is a prerequisite for 
establishing reliable in vitro/ex vivo corneal models yielding reproducible and highly 
predictive results. Especially challenging aspect of the in vitro/ex vivo corneal model 
development is the simulation of the dynamic eye environment in vivo (tear fluid composition 
and dynamics) which determines the residence time of the ophthalmic formulation at the 
corneal surface. The optimisation of the structural and physiological parameters of the in 
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vitro/ex vivo corneal models critical for ocular absorption and bioavailability in vivo may 
ensure the establishment of the correlation between the drug permeability in vitro/ex vivo and 
the drug ocular bioavailability in vivo. The established in vitro/ex vivo/in vivo correlation can 
provide the basis for regulatory approval of both innovative and generic topical ophthalmic 
products (Pepić et al., 2014).  
1.2.1. In vitro cell-based corneal permeability models 
In vitro corneal permeability models range from simple models representing the 
corneal epithelium to more complex models comprising different types of corneal cells and 
reflecting the complex anatomical structure of the entire cornea. Significant advancement in 
the field of the in vitro corneal model development has been made, however, it still remains 
difficult to mimic completely the intricate structure of the cornea in vivo. The in vitro corneal 
models, therefore, represent a less predictive tool for the ocular bioavailability prediction 
compared to ex vivo corneal models. However, the possibility of miniaturization and 
automation makes the in vitro models a high capacity tool which would be valuable in the 
primary high-throughput permeability screening of a large number of ophthalmic drug 
candidates (Pepić et al., 2014).  
For the corneal epithelial model the epithelial cells are cultivated on a semipermeable 
membrane coated with extracellular matrix proteins (Becker et al., 2008; Goskonda et al., 
1999; Hahne and Reichl, 2011; Toropainen et al., 2001). For the cultivation of complex 
organotypic corneal constructs different types of corneal cells are co-cultivated in layers on 
top of a semipermeable membrane, to simulate the structure of the cornea in vivo, composed 
of multi-layered epithelium, collagenous stroma containing fibroblasts and mono-layered 
endothelium (Hahne et al., 2012; Minami et al., 1993; Reichl et al., 2004; Tegtmeyer et al., 
2001). Initially, the cells are cultivated submerged in the medium, followed by the exposure 
of the epithelial cells to the air-liquid interface (ALI), which has been shown to be critical for 
the induction of epithelial cell proliferation and differentiation leading to the formation of a 
multi-layered epithelial structure (Ban et al., 2003; Chang et al., 2000; Hahne and Reichl, 
2011).  
Different in vitro corneal permeability models have been developed, differing in cell 
type and origin (animal/human), semipermeable membrane material, coating protocols, 
culture medium composition, the duration of the period of submerged cultivation and ALI 
exposure (Ban et al., 2003; Chang et al., 2000; Hahne et al., 2012; Hahne and Reichl, 2011; 
Mohan et al., 2003; Reichl and Müller-Goymann, 2003; Tegtmeyer et al., 2001; Toropainen et 
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al., 2001). Regarding the cell type, both primary cells and immortalized cell lines have been 
used in the in vitro corneal model development. Primary cells are isolated from the tissue 
either by cell migration from tissue fragments in culture or mechanical/enzymatical tissue 
disaggregation. Primary cells reflect better biochemical and structural characteristics of the 
tissue in vivo, however, the number of cell division they undergo in culture is finite due to 
senescence process which eventually leads to cell death. Their short lifespan in culture, which 
requires repeated laborious cell isolation from excised tissue, limits their use in the in vitro 
corneal model development. Moreover, it has been shown that primary cells may undergo 
phenotypic changes in culture losing some of their original structural and biochemical 
properties (Vellonen et al., 2014).  
Immortalised cell lines are characterised by almost infinite lifespan due to a mutation 
in the cell genome which enables the evasion of senescence process. Immortalised cell lines 
are derived from tumour cells or can be produced from primary cells by spontaneous 
transformation in culture or by transfection with viral genes interfering with the cell 
senescence process. In contrast to primary cells, immortalized cell lines have almost infinite 
replicative capacity and can be stored in liquid nitrogen for a prolonged period and thawed as 
needed, which makes them more appropriate for the routine use of in vitro corneal models. 
However, genomic and phenotypic changes of immortalized cell lines in culture have been 
reported, leading to the loss of structural and biochemical properties of the parental tissue 
(Vellonen et al., 2014).  
Of all the in vitro corneal epithelial models which have been developed, HCE-T-based 
and commercially available Clonetics™ (Lonza) are the only models that have been shown to 
demonstrate sufficiently tight corneal epithelial barrier (Becker et al., 2008; Reichl, 2008). 
HCE-T immortalised cell line has been the most extensively characterised cell line regarding 
the porosity and pore size of the formed epithelial barrier in vitro, passive paracellular and 
transcellular transport, expression and functionality of membrane transporters and metabolic 
enzymes (Becker et al., 2007; Hahne and Reichl, 2011; Kölln and Reichl, 2016a, 2016b, 2012, 
Toropainen et al., 2003, 2001; Vellonen et al., 2010). The most significant advancement in the 
field of the in vitro corneal model development has been made by Reichl’s research group, 
which has successfully developed the in vitro HCE-T cell-based Hemicornea construct 
cultivated in serum-free medium, resembling native human corneal barrier. The results of the 
prevalidation studies using seven compounds of different physicochemical properties show 
that Hemicornea model exhibits permeation behaviour comparable to human cornea (Hahne et 
al., 2012). Recently, a novel microfluidic cell culture platform, called Dynamic Micro Tissue 
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Engineering System (DynaMiTES), was designed, which enables the analysis of the drug 
permeation through Hemicornea model under dynamic conditions, simulating thereby the 
dynamic precorneal environment in vivo (Beiβner et al., 2017).  
1.2.2. Ex vivo tissue-based corneal permeability models 
Ex vivo corneal permeability models, compared to in vitro models, are of lower 
capacity, with regard to the number of tested samples per time unit, but higher predictability. 
Ex vivo models have been shown to be less sensitive to toxic effects of high concentrations of 
excipients, most probably due to the higher tissue complexity (Ekelund et al., 2005). It is, 
therefore, expected that ex vivo corneal models should be more robust in terms of resilience to 
potential toxic effects of high concentrations of the ophthalmic ingredients, which makes 
them more appropriate for testing a complex mixture of ophthalmic drugs and excipients 
during the later phase of the ophthalmic formulation optimization process. 
Due to limited availability of human corneas, which are generally reserved for 
transplantation purposes, corneas of animal origin are mostly used for ex vivo permeability 
testing. Freshly excised rabbit, porcine and bovine cornea have been most commonly utilised 
in ex vivo permeability testing. The use of rabbit corneas in ex vivo studies may facilitate the 
establishment of ex vivo-in vivo correlations, since rabbits are most often used for studies of 
ocular bioavailability in vivo. However, the permeability through rabbit corneas has been 
shown to be higher compared to human corneas, due to specific structural differences, such as 
the lack of Bowman’s layer and lower thickness of the cornea. The bovine cornea, on the 
other hand, has twice as thick the epithelium as the human cornea, which is presumed to be 
responsible for lower ophthalmic drug permeability compared to rabbit and porcine corneas. 
The porcine cornea has been shown to be structurally the most similar to the human cornea, in 
terms of the globe size, corneal thickness, globe diameter to cornea length ratio and the 
presence of Bowman’s layer (Loch et al., 2012; Myung et al., 2006). Moreover, porcine 
corneas are highly available at the local abattoirs, where they represent by-products in the 
meat production, which eliminates ethical issues related to the use of laboratory animals.  
For the purpose of ex vivo permeability testing freshly enucleated eyeballs are 
transported in moist conditions at 4°C in sterile containers from an abattoir to a laboratory, 
where cornea excision is performed. Specialised diffusion system, such as the Franz diffusion 
cells and vertical/horizontal Ussing diffusion chambers, are used in the ex vivo permeability 
experiment. The excised corneas are mounted onto the diffusion system, with epithelial side 
of the cornea facing the donor compartment, which represents the precorneal area, and the 
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endothelial side facing the receptor compartment, which represents the aqueous humour 
compartment. Tissue viability loss is observed from the moment of its excision. Nutritional 
buffers containing different salts, glucose, antioxidants, of physiological pH 7.4, as well as 
oxygenation of the medium, are thus applied to preserve the corneal tissue viability during the 
4-6 hours of ex vivo permeability testing. Modifications of commercial diffusion system have 
also been applied by, for example, circulating the fluid in the donor and receptor compartment 
or adjusting the pressure in the receptor chamber, with the aim of replicating more closely the 
dynamic eye environment in vivo (Abdulrazik, 1996; Bonferoni et al., 1999). Another 
interesting approach in studying corneal permeability/uptake ex vivo is the application of a 
whole-eye model, in which a small volume of nanoparticle solution is applied to the corneal 
surface and the uptake of nanoparticles is measured in subsequently extracted ocular tissue 
layers and fluids. In addition to corneal permeability, the impact of conjunctival and scleral 
permeability on ophthalmic drug/delivery system distribution to different ocular tissues can 
be as well evaluated. However, fast onset of tissue decay limits the use of the whole-eye 
model to a relatively short period of time (Kompella et al., 2006; Luschmann et al., 2014). 
1.3. Conventional eye drops 
Conventional eye drops comprise majority of marketed topical ophthalmic dosage 
forms. Most commonly conventional eye drops are formulated as solutions due to dose 
uniformity, clarity and ease of manufacturability. Their main disadvantage, however, is rapid 
clearance and short residence time at the ocular surface, as well as limited shelf-life for 
hydrolytically labile drugs. Polymers which undergo a phase transition from liquid to 
semisolid as a consequence of temperature, pH or ionic strength changes upon instillation into 
the eye, may be used in the production of ophthalmic solution which transforms into gel upon 
contact with the ocular surface. This type of ophthalmic dosage form utilizes the advantages 
of both the solution (ease of administration) and gel (prolonged residence time). For drugs of 
low solubility, suspension, which consists of insoluble solid drug particles dispersed in a 
suitable aqueous vehicle, represents a pharmaceutically acceptable alternative. Physical 
instability, which may lead to inhomogeneity and problem with dosage uniformity, is the 
main disadvantage of suspensions, requiring strict control of particle size, sedimentation rate 
and resuspendabillity (Gibson, 2009).  
As for dosage forms for any other administration route, essential requirements such as 
stability, manufacturability, safety and bioavailability must be fulfilled for topical ophthalmic 
dosage forms. However, due to direct contact of topical ophthalmic dosage forms with the 
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corneal absorption surface, formulation factors (pH, buffer capacity, osmolarity, viscosity) 
and formulation composition (the type and concentration of excipients) largely influence their 
tolerability and bioavailability. Additionally, specific requirements, such as sterility, limited 
endotoxin content and particulate matter, must be met, which moreover increases the 
complexity of the topical ophthalmic dosage form development (Ghosh and Ahmed, 2014). 
Physicochemical properties of the drug (solubility, lipophilicity, pKa, compatibility 
with excipients and packaging material) represent the most important factor in the selection of 
a type and composition of the topical ophthalmic dosage form. For ionisable drugs, the pH of 
the ophthalmic formulation, as well as the buffer type and capacity, are some of the critical 
parameters which determine the topical ophthalmic dosage form performance, since they may 
largely influence drug solubility, stability and corneal permeability. For acidic pH adjustment, 
acetate buffer and citrate buffer are most commonly used, while for alkaline pH adjustment 
phosphate buffer or borate buffer are most frequently utilised (Gibson, 2009). The pH range 
which eye can tolerate is 4-8, however, the pH as close to the pH of tear fluid of 7.4 or slight 
alkaline pH is recommended to avoid the risk of possible irritation and induced lachrimation 
effect (Dale and James, 1991).  
Different tonicity agents (e.g., sodium chloride, glycerol, glucose, mannitol) are added 
to topical ophthalmic formulation to ensure optimal osmolality. Although a wider range of 
osmolality is tolerated (160-480 mOsm/kg), isotonic formulations are preferable to minimize 
the risk of potential discomfort during use.  
In order to increase the topical ophthalmic dosage form residence time at the ocular 
surface, different viscosity-increasing agents may be employed. These mostly include 
different synthetic polymers (e.g., cellulose derivatives, povidone, polyvinyl alcohol, 
carbomer), some of which are characterised by mucoadhesive properties, which additionally 
contribute to prolonging the precorneal residence time. However, high-viscosity formulations 
are not well-tolerated, causing lachrimation, blinking and discomfort. The viscosity of most 
commercial topical ophthalmic dosage forms is, therefore, adjusted to 10-25 mPa×s by using 
appropriate viscosity-increasing agents (Gibson, 2009).  
To ensure drug stability, topical ophthalmic dosage forms may additionally include 
different antioxidants, which protect the drug from degradation, or chelating agents, which 
bind metal ions which catalize oxidative reactions (Gibson, 2009). Special attention must be 
given to the sterility of the ophthalmic dosage forms. The ophthalmic dosage forms are 
sterilized during production with a suitable sterilization technique, however, to maintain the 
sterility of the formulation after opening and during its use, antimicrobial preservatives are 
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utilised. A limited number of antimicrobial preservatives is approved for the ophthalmic 
application, among which benzalkonium chloride still remains one of the most commonly 
used, due to its antimicrobial effectiveness over a wide pH range and stability in solution and 
during autoclave sterilization process. Nonetheless, due to increasing evidence of 
benzalkonium chloride toxicity during chronic use, new antimicrobial agents based on 
stabilized chloride and oxygen compounds and sodium perborate, determined to be devoid of 
irritant effects, have been developed and are included in commercial topical ophthalmic 
dosage forms (Kaur et al., 2009).  
With the purpose of enhancing drug solubility to ensure administration of a higher 
drug dose, different so-solvents (e.g., polyethylene glycols, propylene glycol, polyvinyl 
alcohol) may be employed (Gibson, 2009). Moreover, surfactants are another group of 
ophthalmic excipients commonly used for enhancing drug solubility. Due to compatibility, 
stability and toxicity issues encountered with the use of cationic, anionic and amphoteric 
surfactants, nonionic surfactants are preferred for the ophthalmic use. Owing to the 
amphiphilic nature of their structure, non-ionic surfactants possess a broad range of interfacial 
activity. In addition to their role of solubilisation agents, non-ionic surfactants are also used as 
emulsifiers to increase the ophthalmic emulsion stability and as wetting agents in ophthalmic 
suspensions to improve particle wetting, suspension stability and resuspendability (Jiao, 2008). 
1.4. Innovative eye drops 
In order to overcome both dynamic and static anterior eye segment barriers and more 
efficiently deliver the drug to its target site, scientific research has been oriented towards the 
development of nano-sized structures as drug carriers. Nanosystems (of size ranging from few 
to 1000 nanometers) have been shown to incorporate a wide variety of drugs, protect the drug 
from potential degradation in the tear fluid, prolong the drug residence time at the ocular 
surface and enhance the drug corneal permeability (Alvarez-Trabado et al., 2017; Bravo-
Osuna et al., 2016; Reimondez-Troitiño et al., 2015; Suresh and Sah, 2014).  
The research in the field of nanosystems for topical ophthalmic drug delivery began in 
the 1980’s, while over the last decade the number of published papers in this field has 
substantially grown (Reimondez-Troitiño et al., 2015). Initially, the researchers were focused 
on the development of liposomes, spherical vesicles composed of an aqueous core (with the 
affinity to hydrophilic drugs) encircled by concentric phospholipid bilayers (with the affinity 
to lipophilic drugs) (Stratford et al., 1983, 1982). Nowadays, the scientific focus has shifted to 
the development of nanoparticles, solid nanocarriers composed of biocompatible and 
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biodegradable polymers, such as chitosan (De Campos et al., 2001), hyaluronic acid (de la 
Fuente et al., 2008), poly(lactic-co-glycolic acid) (PLGA) (Gupta et al., 2010), Carbopol
®
 and 
Eudragit
®
 (RS100 and RL100) (Pignatello et al., 2002). However, other types of nanosystems 
have been intensively investigated as well, such as oil-in-water nanoemulsions (composed of 
nanosized oil droplets dispersed in aqueous phase) (Ammar et al., 2009), niosomes (vesicles 
structurally similar to liposomes, but composed of nonionic surfactants instead of 
phospholipids) (Aggarwal et al., 2007), nanocapsules (consisting of an oily core enclosed by a 
poly-ε-caprolactone (PCL) wall) (Losa et al., 1993), polymeric micelles (formed by diblock or 
multiblock amphiphilic copolymers that self-assemble into core-shell nanostructures) (Pepić 
et al., 2004a), dendrimers (symmetric structures containing a central core surrounded by 
repetitive branched molecules) (Kambhampati and Kannan, 2013), nanocrystals (consisting of 
a nanosized drug molecule surrounded by stabilizing excipients) (Tuomela et al., 2014) and 
solid lipid nanoparticles (consisting of a solid lipid core stabilized by surfactants) (Sánchez-
López et al., 2017).  
Surface properties of the nanosystems have been shown to be critical in the efficient 
delivery of topical ophthalmic drugs to their site of action, since they determine the 
interaction of nanosystems with the corneal epithelial surface. More precisely, it has been 
shown that surface cationic charge increases the adhesion of nanosystems to ocular surface, 
due to their interaction with the negatively charged mucin layer overlying the conjunctival 
and corneal epithelial cells (Abdelbary, 2011; Jain et al., 2013; Klang et al., 2000). Moreover, 
the interaction of nanosystems with the mucin layer can also be enhanced by the addition of 
mucoadhesive polymers (Fujisawa et al., 2012) or reactive groups (Khutoryanskiy, 2011) to 
nanosystems surface. Furthermore, some of the nanosystems have been assumed to interact 
with the lipid layer of the tear film, which results in prolonged residence time of the 
nanosystems in the conjunctival sac where they act as a drug depot (Alany et al., 2006). In 
addition to prolonging the drug residence time on the ocular surface, nanosystems have been 
shown to increase the drug permeation through corneal tissue by either the interaction of 
surfactants, located at the surface of nanoparticles, with the corneal epithelial cell membranes 
(Jiao, 2008) or by endocytic mechanisms (de la Fuente et al., 2008).  
Different nanosystems have been tested using in vitro/ex vivo corneal models and in 
vivo animal models, in which they have been shown to increase drug in vitro/ex vivo corneal 
permeability and in vivo ocular bioavailability, compared to conventional ophthalmic 
formulations. Moreover, in in vivo animal disease models nanosystems have shown superior 
therapeutic activity in comparison to marketed ophthalmic formulations in the treatment of 
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different anterior eye segment diseases, with the concomitant reduction in the drug systemic 
absorption and side-effects. Several nanosystem-based formulations have been marketed in 
the USA and Europe, most of which are registered for the treatment of dry eye syndrome. 
However, other therapeutic indications (glaucoma, vernal keratoconjunctivitis, ocular 
inflammation) have been receiving increasing attention, with a few nanosystem-based 
formulations currently undergoing clinical trials (Reimondez-Troitiño et al., 2015). 
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Themost extensively characterizedhuman-derived cell line used in transcorneal permeability studies, in termsof
passive transcellular and paracellular transport, transporter expression andmetabolic enzymes, is the immortal-
ized human corneal epithelial cell line (HCE-T). The purpose of this study is to describe the changes in the HCE-T
barrier phenotype in vitro when valid cultivation conditions, in accordance with the standardized HCE-T cell-
based model protocol, were employed. Evaluation of the structural and functional barrier properties revealed
two different HCE-T barrier phenotypes, depending on the polycarbonate membrane pore size. Model I (pore
size 0.4 μm)was characterized by amultilayered HCE-T epithelium at the apical side and a weak barrier function
(70–115 Ω×cm2), whereas Model II (pore size 3 μm) consisted of an apical lipophilic HCE-T monolayer and a
basolateral lipophilic monolayer of migrated HCE-T cells that showed improved barrier properties (1700–2600
Ω×cm2) comparedwithModel I. Considering the permeation of ophthalmic compounds and in vitro/ex vivo cor-
relation, Model II was better able to predict transcorneal drug permeation. This study highlights the important
aspects of HCE-T barrier phenotype variability that should be continuously monitored in the routine application
of HCE-T cell-based models across both academic and pharmaceutical industry research laboratories.
© 2017 Elsevier B.V. All rights reserved.
Keywords:
Cornea
Barrier properties
Drug permeability
In vitro/ex vivo correlation
Ocular delivery
1. Introduction
The experimental techniques used in preclinical studies on eye-
related drug bioavailability generally focus on the cell and tissuemodels
of ocular drug permeability. The cell-basedmodels that have the correct
balance between their predictability and throughput have the potential
to be routinely used in the pharmaceutical industry for the permeability
testing and prediction of eye-related bioavailability (Pepic et al., 2014).
The most extensively characterized human-derived cell line in
transcorneal permeability studies in terms of passive transcellular and
paracellular transport (Toropainen et al., 2003), transporter expression
(Becker et al., 2007; Mannermaa et al., 2006; Reichl et al., 2011;
Vellonen et al., 2010; Verstraelen and Reichl, 2013, 2014) andmetabolic
enzymes (Kölln and Reichl, 2012, 2016a, 2016b) is the immortalized
human corneal epithelial cell line (HCE-T), which was established by
Araki-Sasaki et al. (1995) and is commercially available from the
RIKEN cell bank (Japan) or the ATCC (USA). The HCE-T cells exhibit a
typical epithelial cobblestone morphology and optimal growth
characteristics. Using this HCE-T cell line, Reichl's research group con-
structed a human cornea equivalent (Hemicornea) by co-culturing the
HCE-T cell line with stromal cells in which all cells can interact in vitro
in a similar way as they do in vivo. Thus, Hemicornea strongly reﬂects
the unique tissue characteristics and barrier properties of the human
cornea in vivo (Hahne et al., 2012).
Although HCE-T cell-based models are well-deﬁned and optimized
for drug permeability studies compared with other immortalized
human (CEPI) or rabbit (SIRC) cell lines, it has been reported that
HCE-T cell-based models have some obstacles that limit their imple-
mentation and routineuse across both academic andpharmaceutical in-
dustry research laboratories (Becker et al., 2008; Hahne and Reichl,
2011; Reichl, 2008; Toropainen et al., 2001; Toropainen et al., 2003).
For instance, the variability in HCE-T cell barrier phenotype and the
lack of a standard quality control protocol complicate the interpretation
and comparison of permeability data from different laboratories. It is
known to be very important to follow a standardized model setup and
culture conditions (e.g., growth medium, growth conditions, culture
time and lifting to the air-liquid interface) tomaintain the HCE-T barrier
phenotype in vitro. However, rather unstable HCE-T barrier properties
have been reported depending on the culture conditions (McCanna et
al., 2008; Nagai et al., 2008; Reichl, 2008; Takezawa et al., 2011;
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Toropainen et al., 2001). Thus, further studies should be performed to
clarify the key factors responsible for the variability in the HCE-T cell-
based model barrier phenotype in vitro. The adequate standardization
of these factors should help reduce both the inter- and intra-laboratory
variability in the HCE-T cell-basedmodel barrier phenotype and, conse-
quently, the variability in reported permeability values (Pepic et al.,
2014; Reichl et al., 2011).
The aim of this study is to describe the changes in the HCE-T barrier
phenotype in vitro, where valid cultivation conditions, in accordance
with the standardized HCE-T cell-based model protocol, were followed
(Hahne andReichl, 2011). To obtain deep insight into themorphological
features of HCE-T cells from the HCE-T cell-based models, ﬂuorescence
microscopy imaging was used. The barrier properties of HCE-T cell-
based models and the permeation of ophthalmic compounds (timolol,
diclofenac, chloramphenicol, dexamethasone and ﬂuorescein) were
determined and compared with those obtained using freshly excised
porcine cornea. This study highlights important aspects that should be
carefully considered in the routine application of HCE-T cell-based
models in both academic and pharmaceutical industry research
laboratories.
2. Materials and methods
2.1. Reagents and chemicals
The following compounds were used as received: timolol maleate
(Sicor S.R.L., Milan, Italy), diclofenac sodium (Pharma Greven GmbH,
Greven, Germany), chloramphenicol (AppliChem,Darmstadt, Germany),
dexamethasone (Sanoﬁ, Paris, France) and ﬂuorescein sodium (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany).
Krebs-Ringer buffer (KRB) pH 7.4 was prepared by dissolving the
following substances in double-distilled water: KCl (0.4 mg/ml), NaCl
(6.8 mg/ml), NaHCO3 (2.1 mg/ml), MgSO4×7H2O (0.4 mg/ml), D-
glucose monohydrate (1.1 mg/ml) (all purchased from Kemig, Zagreb,
Croatia), CaCl2×2H2O (0.52 mg/ml) (Sigma-Aldrich), NaH2PO4×2H2O
(0.158 mg/ml) (Kemika, Zagreb, Croatia) and HEPES (3.575 mg/ml)
(AppliChem).
2.2. Cell culture conditions
HCE-T cells (RIKEN Cell Bank, Tsukuba, Japan) were used for the
cultivation of the HCE-T cell-based models. Cells were cultivated in
DMEM/F12 medium (Lonza, Basel, Switzerland) supplemented with
fetal bovine serum (5%, Biosera, Boussens, France), insulin (5 μg/ml,
Sigma-Aldrich), dimethyl sulfoxide (0.5%, Applichem), epidermal
growth factor (10 ng/ml, Sigma-Aldrich) and penicillin/streptomycin/
amphotericin B (Lonza) in a humidiﬁed atmosphere containing 5%
CO2 at 37 °C (Hafner et al., 2015). The cells were subcultured at 80–
90% conﬂuence. The culture medium was changed every 48 h.
2.3. Cultivation of the HCE-T cell-based model
The HCE-T cell-basedmodels were cultivated according to the mod-
iﬁed protocol by Hahne and Reichl (2011). Transwell® polycarbonate
membrane cell culture inserts (0.4 μm pore size (1 × 108 pores/cm2)
and 3.0 μm pore size (2 × 106 pores/cm2), 12 mm diameter, surface
area 1.12 cm2, Corning B.V. Life Sciences, Amsterdam, The Netherlands)
were coated with rat tail type I collagen (225 μg/well; Sigma-Aldrich)
and human ﬁbronectin (4 μg/well; Sigma-Aldrich). HCE-T cells
suspended in the culture medium (105 cells in 0.5 ml) were seeded
onto the coated polycarbonate ﬁlter, and 1.5 ml of culture medium
was added to the basolateral side. The cells were cultivated submerged
in the medium until a sharp increase in TEER was observed (from 4 to
7 days), after which they were exposed to the air-liquid interface
(ALI) for the following 3 days. The culture medium was changed every
2 days during the submerged conditions and every day during exposure
to the ALI. During the ALI exposure, the inserts were lifted on a metal
plate to increase the basolateral volume to 2 ml.
2.4. Histomorphological characterization
For the histomorphological characterization of the HCE-T cell-based
models, the cells were ﬁxed in 4% paraformaldehyde (Sigma-Aldrich)
overnight at 4 °C. The cells were then washed with phosphate-buffered
saline (PBS; Lonza), and the entire ﬁltermembranewas carefully cut out
with a scalpel. The membrane was gently dried on ﬁlter paper and em-
bedded in Kilik (cryostate embeddingmedium, Bio-Optica,Milan, Italy),
after which 5-μm-thick cross sections were cut using a cryostat
(CM1950, Leica, Eisfeld, Germany) (Lovric et al., 2012). The sections
were stored at −20 °C until staining. The slides were mounted with
VECTASHIELD® Mounting Medium containing 4′,6-diamidino-2-
phenylindole (DAPI) (Vector Labs, Burlingame, CA, USA), and the
cover slips were sealed around the perimeter with nail polish. For a
more thorough description of the formed multilayer, HCS CellMask™
red stain (Invitrogen™, Eugene, OR, United States), which labels the en-
tire cell (i.e., the cytoplasm and the nucleus), was used beforemounting
the slides. The cells were permeabilized using a 0.1% Triton® X-100
(Sigma-Aldrich) solution and incubated with the HCS CellMask™
staining solution for 30 min at room temperature according to the
manufacturer's protocol. Cross sections were imaged using an
ImageXpress Micro automated high-content screening microscope
(Molecular Devices, Sunnyvale, CA, USA) equipped with a 4× objective
using ﬂuorescent and transmitted light.
2.5. In vitro permeability assay
The permeability assay using the HCE-T cell-based models was
performed directly in the Transwell plates on a horizontal orbital shaker
(34 °C; 50 rpm) in KRB. The cellswereﬁrst rinsedwithKRB and incubat-
ed for 30 min with 0.4 and 2 ml of KRB in the donor and receptor
compartment, respectively. Then, the KRB was removed from the
donor compartment, and 0.4 ml of the solution containing a test com-
pound was added (Hafner et al., 2015; Hahne and Reichl, 2011). The
concentration of the test compounds in KRB was 100 μg/ml for timolol
maleate, 150 μg/ml for diclofenac sodium, 150 μg/ml for chloramphen-
icol, 60 μg/ml for dexamethasone and 250 μg/ml for ﬂuorescein sodium.
A volume of 400 μl was sampled from the receptor compartment at reg-
ular time intervals over 2 h and replaced at each time point with the
same volume of fresh warmed KRB (34 °C). The donor solution was
also sampled at the end of the permeability experiment to calculate
the mass balance (%). Finally, the cell surface was rinsed with KRB and
exposed to ALI with 2ml of culture medium in the basolateral compart-
ment for the following 24 h.
2.6. MTT assay
MTTassaywas performed on theHCE-T cell-basedmodels according
to the protocol by Pauly et al. (2009). The culture mediumwas aspirat-
ed, and the wells were transferred to a clean 12-well cell culture plate
(Corning B.V. Life Sciences). Seven hundred microliters of MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, Sigma-
Aldrich) solution in culture medium (0.5 mg/ml) was applied to both
the apical and basolateral compartments, and the cells were incubated
for 4 h at 37 °C. Subsequently, the MTT solution was removed and the
formazan was dissolved by the addition of 700 μl of isopropanol
(Kemig) to both compartments. The absorbance was measured at
570 nm by using microplate reader (1420 Multilabel counter VICTOR3,
Perkin Elmer, Waltham, MA, USA).
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2.7. Ex vivo permeability assay
Fresh porcine eyes were obtained from the local slaughterhouse.
After enucleation, each eyeball was rinsed with an isotonic saline
solution (NaCl 0.9%; B. Braun, Melsungen, Germany) and transported
immersed in cold KRB in a container held on ice. Each container
contained gauze onwhich the eyeball was placed so the corneawas fac-
ingupwards and thus remained intact during transport. The transport of
porcine eyeballs and the cornea excision were carried out within 2 h of
the animal's death. Ex vivo permeability assaywas performed according
to the modiﬁed protocol by Hahne and Reichl (2011) and Hahne et al.
(2012). The corneas were excised as corneo-scleral buttons and
mounted on vertical diffusion chambers (Standard Vertical Ussing/Dif-
fusion Chambers, surface area 0.64 cm2, Harvard Apparatus, Holliston,
MA, USA), with the epithelial side facing the donor compartment. The
volume of the donor and receptor compartment was 3.5 ml each.
After 30min of incubation in KRB at 34 °C, KRB from the donor compart-
ment was removed, and 3.5 ml of the solution containing a test com-
pound was added. The concentration of the test compounds in KRB
was 250 μg/ml for timolol maleate, 400 μg/ml for diclofenac sodium,
400 μg/ml for chloramphenicol, 60 μg/ml for dexamethasone and 500
μg/ml for ﬂuorescein sodium. The receptor compartment was sampled
(0.4ml for dexamethasone and ﬂuorescein sodium, 1ml for timololma-
leate, diclofenac sodium and chloramphenicol) at regular time intervals
over 5 h and replaced at each time point with the same volume of fresh
warmed KRB. The donor solution was sampled at the end of the perme-
ability experiment. The medium in both the donor and receptor com-
partments was continuously oxygenated.
2.8. Transepithelial electrical resistance measurement
Transepithelial electrical resistance (TEER) was measured regularly
to monitor barrier integrity during both the cultivation of the HCE-T
cell-basedmodels and the in vitro and ex vivopermeability experiments.
An STX-2 electrode and EVOM (WPI Inc., Sarasota, FL, USA) were used
for the TEER measurement of the HCE-T cell-based models, and Ag/
AgCl electrodes in conjunction with an EC-825A Epithelial Voltage
Clamp (Warner Instruments, Hamden, CT, USA) were used for the ex-
cised cornea. The blank resistance was alsomeasured and subsequently
subtracted to obtain the TEER of the HCE-T cell-based model and ex-
cised cornea.
2.9. Data processing
The apparent permeability coefﬁcients (Papp in cm/s) of all com-
pounds were calculated by plotting the amount of permeated com-
pound per unit area versus time. The Papp was calculated from the
linear portion of the permeation curve according to the following equa-
tion (Hahne et al., 2012; Toropainen et al., 2003):
Papp ¼
∂Q
∂t

1
ACo
ð1Þ
where ∂Q
∂t
is the permeation rate, A is the surface area of the permeation
barrier and Co is the initial concentration of a test compound in the
donor compartment (Eq. (1)).
The mass balance (recovery) (%) was calculated according to the
following equation (Hubatsch et al., 2007):
Mass balance %ð Þ ¼
Cr fð Þ  V r þ∑Cr tð Þ  V s
 
þ Cd fð Þ  Vd Þ
Cd 0ð Þ  Vd
 100 ð2Þ
where Cd and Cr are the concentrations in the donor (d) and receptor (r)
compartment, respectively, at the start (0) or end (f) of the permeability
assay, Cr(t) is the concentration of the samples withdrawn from the re-
ceptor compartment at different time points, Vr and Vd are volumes of
the receptor anddonor compartment, respectively, and Vs is the volume
of the sample withdrawn from the receptor compartment (Eq. (2)).
2.10. Quantiﬁcation
The concentration of ﬂuorescein sodium in samples was determined
using a microplate reader at excitation and emission wavelengths of
485 and 535 nm.
The quantitative determination of ophthalmic drugs was performed
by Ultra-Performance Liquid Chromatography (UPLC) using an Agilent
Inﬁnity 1290 (Agilent, Santa Clara, CA, USA). The Acquity UPLC BEH
Shield RP18 Column (1.7 μm, 2.1 mm × 50 mm) (Waters, Milford, MA,
USA) was used, and the elution was isocratic. Sodium acetate buffer
was prepared by dissolving CH3COONa × 3H2O (Kemika) in Milli-Q™
water (0.3 mg/ml) (Merck-Millipore, Billerica, MA, USA). The pH was
adjusted to 4.5 by acetic acid (glacial) (Merck-Millipore). Sodium
dihydrogen phosphate buffer was prepared by dissolving NaH2PO4×-
H2O (Merck-Millipore) in Milli-Q™ water (1.2 mg/ml) (Merck-
Millipore). The pH was adjusted to 2.5 by phosphoric acid (85%)
(Merck-Millipore). Both buffers were ﬁltered through a regenerated
cellulose membrane ﬁlter (0.2 μm; Whatman, Freiburg, Germany) be-
fore use. A mixture of buffer/acetonitrile (Merck-Millipore) was used
as themobile phase. The details of eachUPLCmethod, developed specif-
ically for the permeability assay purposes in this study, are described in
Table 1.
The stock solutions of ophthalmic drugs were prepared in methanol
(Merck-Millipore) andwere further diluted with water for the prepara-
tion of standard solutions for the donor compartment samples or KRB
for the preparation of standard solutions for receptor compartment
samples. The volume of injection was 20 μl for the receptor compart-
ment samples. For the donor compartment samples the volumeof injec-
tion was 5 μl for timolol maleat, diclofenac sodium, chloramphenicol
and 10 μl for dexamethasone. The receptor compartment samples
were injected directly or were appropriately diluted with KRB, while
thedonor compartment sampleswere dilutedwithwater prior analysis.
All samples and standard solutions were ﬁltrated through 0.2 μm Spar-
tan™ regenerated cellulose ﬁlters (Whatman, United Kingdom) prior
analysis. For each sequence standard solutions were prepared in dupli-
cate and injected alternately. At least ﬁve standard solution injections
were done in each injection sequence. System suitability was evaluated
according to the following criteria: relative standard deviation (RSD) of
the detector response factor for all standard solution injections in the
sequence is not N3.0%, and tailing factor of ophthalmic drug peak is
not N2.0.
All UPLC methods were validated in terms of linearity, accuracy and
repeatability. The methods were found to be linear (R2 ≥ 0.9996), accu-
rate (recovery values 96.4–107.2%) and repeatable (relative standard
deviation of peak area (RSD) 0.1–3.0%) in the following concentration
ranges: 0.10–3.13 μg/ml for the receptor compartment samples and
2.50–15.00 μg/ml for the donor compartment samples for timolol male-
ate, 0.05–2.50 μg/ml for the receptor compartment samples and 5.00–
15.00 μg/ml for the donor compartment samples for diclofenac sodium,
0.05–1.50 μg/ml for the receptor compartment samples and 2.50–15.00
μg/ml for the donor compartment samples for chloramphenicol, 0.01–
2.00 μg/ml for the receptor compartment samples and 0.60–6.00 μg/
ml for the donor compartment samples for dexamethasone.
2.11. Statistical analysis
GraphPad Prism program 5.0 (GraphPad Software Inc., San Diego,
CA, USA; www.graphpad.com) was used for the statistical analysis.
The correlation between the in vitro and ex vivo log Papp values was an-
alyzed by the Pearson correlation, with P=0.05 as the minimal level of
statistical signiﬁcance.
25M. Juretić et al. / European Journal of Pharmaceutical Sciences 104 (2017) 23–30
3. Results and discussion
3.1. Histomorphological features of HCE-T cell-based permeability models
Two HCE-T cell-based models investigated in this study were culti-
vated according to the protocol by Hahne and Reichl, using their condi-
tions for the culture medium, support-coating materials, cell-seeding
density, volumes of the media overlying the apical and basolateral
sides of the epithelial barrier and duration of ALI exposure (Hahne and
Reichl, 2011). However, the relationship between membrane pore size
and HCE-T barrier tightness is not fully understood, as is evident from
the conﬂicting reports on the optimal pore size found within the litera-
ture; i.e., 0.4 μm (Toropainen et al., 2003) or 3 μm (Hahne and Reichl,
2011). To investigate the inﬂuence of membrane pore size on barrier
tightness and the structure of the HCE-T cell-based model, the polycar-
bonate membranes (Transwell) of two different pore sizes, i.e., 0.4 μm
(Model I) and 3 μm (Model II), were used. The HCE-T cells migrated
through the membrane with the pore size of 3 μm, as observed by
ﬂuorescence imaging, whereas migration was not observed in the case
of Model I with the pore size of 0.4 μm (Fig. 1). Thus, Model II consisted
of an apical lipophilic HCE-T epithelial monolayer and a basolateral lipo-
philic monolayer of migrated HCE-T cells. In contrast, Model I had a sig-
niﬁcantly smaller membrane pore size, and the HCE-T cells could not
migrate towards the basolateral side of the membrane. Therefore, the
HCE-T cells formed a stratiﬁed apical epithelial structure on the under-
lyingpolycarbonatematrix characteristic of corneal epithelium. Howev-
er, both models had a number of structural differences compared with
the characteristics of their in vivo counterparts. One of the structural
and functional differences of Model I compared with the cornea is the
lack of the hydrophilic stroma and the innermost lipophilic surface of
the cornea. Model II did not form a multilayered epithelial structure,
which is well-deﬁned for native corneal epithelium. However, Model
II had a unique characteristic, i.e., a basolateral lipophilic layer formed
from the migrated HCE-T cells, which could serve as additional barrier
to drug transport, thereby mimicking the innermost lipophilic surface
of the corneal barrier.
Table 1
UPLC experimental conditions.
Ophthalmic drug Mobile phase Flow (ml/min) Temperature (°C) Detection wavelength (nm) Retention time (min)
Timolol maleate CH3COONa buffer pH 4.5/acetonitrile (85/15%, V/V) 0.6 55 296 0.73
Diclofenac sodium NaH2PO4 buffer pH 2.5/acetonitrile (65/35%, V/V) 0.6 55 276 3.41
Chloramphenicol CH3COONa buffer pH 4.5/acetonitrile (80/20%, V/V) 0.4 50 275 1.84
Dexamethasone CH3COONa buffer pH 4.5/acetonitrile (67/33%, V/V) 0.4 50 254 1.18
Fig. 1. Cross-sections of Model I andModel II during the initial period of submerged conditions (7 days forModel I, 5 days for Model II) and additional exposure to air-liquid interface (ALI)
(3 days). The cross-sectionswere stainedwith 4′,6-diamidino-2-phenylindole (DAPI) and examined by ﬂuorescencemicroscopy (Bar: 100 μm). Additionally, cross sections ofModel I after
3 days of ALI cultivation were labeled by HCS CellMask™ red stain, which labels the entire cell (A). Cross-sections of Model II after 3 days of ALI cultivation stained by DAPI were
subsequently imaged using transmitted and ﬂuorescent light in order to visualize the polycarbonate membrane (B). (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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3.2. Qualitative measure of the HCE-T cell-based model barrier properties
The barrier function of the HCE-T cell-based models investigated in
our laboratory was assessed by measurements of TEER. The measure-
ment of TEER is a well-established method for analyzing the overall
electrical resistance of a cell layer as a measure of the tight connections
between cells (tight junctions), which encircle the cells just below their
apical surface. The electrical resistance of a cell layer consists of
paracellular and transcellular electrical resistance, but the clear distinc-
tion between these different electrical resistances will be possible with
the further development of the impedance spectroscopy technique
(Saaber et al., 2014). Ideally, electrical resistance of the HCE-T cell-
basedmodels should be comparable to the electrical resistance of fresh-
ly excised cornea. Although it is well known that the lifting of HCE-T
cells to the ALI is of crucial importance for the development of a tight
multilayered epithelium in vitro (Ban et al., 2003; Toropainen et al.,
2001), the previously reported TEER values were in ranges of 200–800
Ω×cm2 (Toropainen et al., 2001), 400 Ω×cm2 (Nagai et al., 2008) or
1200Ω×cm2 (Reichl, 2008). Similarly, the twoHCE-T cell-basedmodels
investigated in our laboratory showed clear differences in TEER.
As a quality control for the integrity of HCE-T epithelial barrier, the
TEER was routinely measured during the model cultivation, before the
start of the permeability experiment (30 min after replacing the HCE-
T cell culture medium with KRB, before a test compound is added to
the donor compartment) and both during (at certain sampling time
points after the withdrawn volume was replaced by KRB) and at 24 h
after ﬁnishing the permeability experiments. The conﬂuence of the
HCE-T cells layer is determined by a sharp increase in the TEER. The
TEER values measured for each ﬁlter were averaged and used to calcu-
late the ﬁnal TEER value for each permeability experiment. In addition,
the MTT assay was performed during the cultivation of Model I on the
conﬂuent monolayer both before exposing the cells to the ALI and
after an additional 3 days at the ALI, when a multilayered structure
was formed. The MTT assay measures the activity of the mitochondrial
enzyme succinyl dehydrogenase and, as such, reﬂects themetabolic ac-
tivity of living cells. The results of the assay showed a considerably
higher metabolic activity of a multilayered epithelium compared with
the monolayer, in accordance with the higher number of metabolically
active cells (data not shown). Even macroscopically, a difference was
clearly observed between the light purple cell monolayer in contrast
to the dark purple color of the multilayered epithelium. It would be in-
teresting to investigate in further studieswhether a correlation between
metabolic activity and the histological characteristics of the in vitro
epithelial model exists. Once this relationship is deﬁned, the use of a
simple and fast MTT screening assay, in addition to more complex and
time-consuming histological techniques for monitoring the in vitro
epithelium formation, could be considered. Thus, the MTT assay has
the potential to be routinely used as a well discriminating tool for mul-
tilayer formation.
TEER experiments revealed weak barrier functions for Model I (69–
113 Ω×cm2; Table 2). Although the HCE-T cells formed multiple cell
layers at the apical side of the membrane, the observed range of TEER
values was generally considered insufﬁcient for a tight apical barrier.
In tight HCE-T cell culture models, TEER values are expected to exceed
400 Ω×cm2 (Toropainen et al., 2001). In this model, HCE-T cells were
unable to form a tight barrier, and it is unclear exactly which cultivation
conditions should be changed to maintain the HCE-T barrier phenotype
in vitro. Considering that the total surface area of the ﬁlter pores critical
for basolateral cell nutrient diffusion in both models was comparable,
other factors leading to insufﬁcient barrier properties in Model I could
be the cause. In contrast, Toropainen et al. (2001) demonstrated that
HCE-T cells achieve a tighter barrierwhen cultivated on collagen-coated
polyester than on a collagen-coated polycarbonate membrane, the lat-
ter of which resulted in an epithelial model with lower TEER values of
approximately 100 Ω×cm2. Aiming to improve the barrier properties
of Model I, the culture conditions during ALI exposure were modiﬁed.
More precisely, the period of ALI cultivation was extended
(Toropainen et al., 2003), and moist conditions, which were created
by leaving a thin layer of culture mediummimicking the tear ﬂuid api-
cally during ALI exposure, were used (Ban et al., 2003). Moreover, after
ALI exposure, the cells were re-submerged in the culture medium for
different time periods. Our preliminary results showed that prolonging
the ALI exposure to 5 days and re-submerging Model I in culture medi-
um for an additional 2 days led to an improvement of the TEER values to
approximately 500 Ω×cm2 (data not shown). It is therefore possible
that the Model I barrier properties could be enhanced by ﬁne-tuning
the time of ALI exposure and by re-submerging the formed multilayer
in the culture medium. Recent studies have shown that epithelial barri-
er assembly requires the coordinated activity ofmultiple domains of the
tight junction proteins (Rodgers et al., 2013), but it is still unclear how
the cultivation conditions can be ﬁne-tuned to achieve awell-preserved
HCE-T cell-based model phenotype in vitro. Until then, the obtained
TEER values suggest that Model I is not likely to be suitable for
predicting transcorneal permeation for either drugs alone or drugs
that are incorporated into different drug delivery (nano)systems. It
could be expected that due to the decreased TEER of Model I, the drug
permeability coefﬁcient will be increased, which could result in false
and misleading drug permeability results compared with other models
with appropriate TEER values.
In contrast, Model II showed improved barrier properties (TEER:
1704–2608Ω×cm2; Table 2) in comparisonwith both the barrier prop-
erties of Model I and the excised cornea (TEER: 542–729Ω×cm2; Table
2). One could hypothesize that the extremely high TEER values ob-
served inModel II were a consequence of the presence of the basolateral
lipophilic layer formed from themigrated HCE-T cells. More precisely, it
has been shown that the migrated cells are polarized, retaining junc-
tional complexes, which could contribute to the overall TEER values
(Tucker et al., 1992). Considering such TEER values, it is possible to ex-
pect that Model II should more closely reﬂect the drug transport across
the excised cornea. In addition, these extremely high TEER values have
the potential to discriminate transcorneal drug permeability well, con-
sidering the inﬂuence of different ophthalmic excipients (for instance,
a permeation-enhancing vs. a permeation-retarding effect, depending
on the type and concentration of the excipients) in comparative
transcorneal permeation studies. However, it is reasonable to expect
that this model would be more discriminative for more hydrophilic
Table 2
Apparent permeability coefﬁcients (Papp) of ophthalmic compounds and the corresponding transepithelial electrical resistance (TEER) values for Model I, Model II and excised cornea.
Model I Model II Excised cornea
Papp (10
−7 cm/s) TEERa (Ω×cm2) Papp (10
−7 cm/s) TEERa (Ω×cm2) Papp (10
−7 cm/s) TEERa (Ω×cm2)
Timolol maleate 194.13 ± 7.08 69 ± 21 139.70 ± 16.69 2607 ± 937 89.20 ± 4.68 729 ± 231
Diclofenac sodium 206.17 ± 9.08 109 ± 9 126.13 ± 12.57 2111 ± 1304 17.54 ± 3.13 660 ± 204
Chloramphenicol 74.37 ± 3.79 113 ± 2 18.59 ± 2.27 2608 ± 1284 6.89 ± 1.71 725 ± 382
Dexamethasone 110.83 ± 10.17 85 ± 29 33.84 ± 5.02 1704 ± 783 6.88 ± 2.32 542 ± 130
Fluorescein sodium 26.17 ± 6.59 44 ± 8 1.68 ± 0.81 2393 ± 1655 1.58 ± 0.54 606 ± 199
All values represent the mean ± SD (n = 5–13).
a measured at the start of permeability experiments, before a test compound is added to the donor compartment.
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than formore lipophilic ophthalmic compounds, for whichmodels with
a stroma equivalent would be more appropriate.
3.3. Comparison of drug permeation across the HCE-T cell-based models
and the excised cornea
Knowing the Papp of the ophthalmic compounds across Model I or
Model II compared with their permeation across the excised cornea
will allow a more detailed understanding of the models' suitability for
predicting transcorneal drug permeability. Using the HCE-T model
with the suitable barrier properties in a Transwell set up allows drug
permeability studies to be performed with a high correlation to the in
vivo situation. The relatively wide variation in the HCE-T cell barrier
properties between different laboratories (Nagai et al., 2008; Reichl,
2008) appears to be a disadvantage, and it is necessary to standardize
the way in which such permeability data are analyzed and interpreted.
Thus, in a comparable analysis and interpretation of drug permeability
coefﬁcients, the parameters related to barrier characteristics of the
HCE-T cell-based model and test conditions (static vs. dynamic) need
to be carefully considered.
In this study, low molecular weight (Mw values from 295.3 to
392.46) ophthalmic compounds were used. Their lipophilicities (i.e.,
logDn-octanol/buffer pH 7.4) varied from−1.5 for ﬂuorescein sodium (Sakai
et al., 1997) and−0.2 for timololmaleate (Reichl, 2008) to 1.08 for chlor-
amphenicol (Wu et al., 1996), 1.1 for diclofenac sodium (Chuasuwan et
al., 2009) and 1.5 for dexamethasone (Hahne et al., 2012). The selected
ophthalmic compounds were characterized by different charge states
at the deﬁned permeability assay condition (KRB pH 7.4). Namely,
chloramphenicol and dexamethasone were neutral because these
molecules do not have a relevant ionizable group. Fluorescein and
diclofenac were negatively charged, as these molecules dissociate into
dianionic and anionic forms at a pH above the pKa values of 4.3/6.4
(Sjoback et al., 1995) and 3.8 (Chiarini et al., 1984), respectively. Timo-
lol was positively charged because it accepts a proton below the pKa
value of 9.21.
In both the in vitro and ex vivo experiments,mass balancewas deter-
mined to exclude thepossible loss of test compound (e.g., due to adsorp-
tion to plastic surfaces or drug degradation), which might result in the
underestimation of permeability coefﬁcients. The mass balance for all
ophthalmic compounds in both HCE-T cell-based models and the ex-
cised cornea was in the range of 80–100% (data not shown), which
has been shown to result in an acceptable approximation of the Papp
value (Hubatsch et al., 2007).
Model I had higher Papp values for all ophthalmic compounds in
comparison with their Papp values obtained for both the excised cornea
and Model II. More precisely, the Papp values for timolol, diclofenac,
chloramphenicol, dexamethasone and ﬂuorescein calculated for Model
I were approximately 1.39-, 1.6-, 4.00-, 3.26- and 15.57-fold higher
than the Papp values obtained in Model II, respectively (Table 2). In
this comparison, the considerable discrepancy between the calculated
Papp values was evident for ﬂuorescein. The observed discrepancy was
expected because ﬂuorescein is a hydrophilic marker of the paracellular
pathway; therefore, its permeation is determined by the HCE-T barrier
tightness, whichwas shown to be very low forModel I (i.e., highﬂuores-
cein permeability) compared to the very high barrier tightness for
Model II (i.e., low ﬂuorescein permeability). Furthermore, the exact
mechanisms by which the selected ophthalmic drugs are transported
by the epithelial barrier, both in vitro and in vivo, have not been fully
elucidated. However, it is evident that the Model I showed a higher dif-
ference in permeability compared to Model II for neutral (i.e., chloram-
phenicol and dexamethasone) than for charged (i.e., timolol and
diclofenac) ophthalmic drugs. The observed discrepancies were even
greater when comparing Papp values of theModel I and the excised cor-
nea, i.e., the Papp values for timolol, diclofenac, chloramphenicol, dexa-
methasone and ﬂuorescein calculated for Model I were approximately
2.18-, 11.74-, 10.79-, 16.11- and 16.56-fold higher than the Papp values
obtained for the excised cornea, respectively (Table 2). Speciﬁcally,
using these last comparison results, it is possible to conclude that the
permeation of all of the investigated ophthalmic compounds was pre-
dicted less well by Model I.
A considerably better correlation was achieved in the comparison of
the Papp values obtained forModel II with those obtained for the excised
cornea. More precisely, the Papp values for timolol, diclofenac, chloram-
phenicol, dexamethasone and ﬂuorescein calculated for Model II were
approximately 1.57-, 7.19-, 2.70-, 4.92- and 1.06-fold higher in compar-
ison with the Papp values obtained for the excised cornea, respectively
(Table 2). In this comparison, the considerable discrepancy between
the calculated Papp values was evident primarily for diclofenac and
dexamethasone, whereas the Papp of ﬂuorescein ﬁt well. This discrepan-
cy could be explained by the typical disadvantage of pure epithelial
models (i.e., lack of hydrophilic stroma), even if the TEER is in the
same range as the excised cornea.
Diclofenac and timolol in both in vitromodels exhibited comparable
high Papp values, but in the excised cornea, a 5 times lower permeability
for diclofenac compared with the highly permeable timolol was ob-
served. Several physico-chemical properties are known to affect passive
permeation through biological membranes, namely molecular size,
partition coefﬁcient, hydrogen bond formation and permeant charge
(Kidron et al., 2010). Although a higher permeation of diclofenac
owing to its higher lipophilicity and lower hydrogen bonding capacity
(NCBI PubChem Compound Database) might be expected, the negative
charge of the diclofenac anionic species at physiological pH might ex-
plain the opposite result. Because the native cornea is characterized by
an isoelectric point value of 3.2, its net negative charge at physiological
pH contributes to the higher permeation of cationic compared with
anionic species, as observed by Pescina et al. (2015). Conversely, the
permeation of dexamethasone was 1.5- and 1.8-fold higher compared
to the permeation of chloramphenicol in Model I and II (Table 2), re-
spectively, whereas in the excised cornea, almost equal permeability co-
efﬁcients for the two compounds were found. Considering their similar
molecular size, the same neutral charge and comparable hydrogen
bonding capacity (NCBI PubChem Compound Database), the higher
partition coefﬁcient of dexamethasone, which facilitates its diffusion
through lipophilic epithelial layers, might explain its higher permeation
inModel I and II. However, the difference in the permeation behavior of
the four ophthalmic drugs in the excised cornea compared with both in
vitromodels is somewhat more difﬁcult to explain. Both cell models are
pure epithelial models, only with a different number of epithelial layers
and a lack of a hydrophilic stroma, which certainly inﬂuences the
passive permeation rate of lipophilic compounds. Moreover, the role
of membrane transporters in the observed discrepancy cannot be
completely excluded. Both diclofenac and dexamethasone have been
shown to interact with inﬂux (Maillefert et al., 2000) and efﬂux
(Kindla et al., 2011) membrane transporters in other cell lines; howev-
er, the active transport of these compounds, and of timolol and chloram-
phenicol, has not been studied in the HCE-T epithelial models or the
porcine cornea to date. The expression and functionality of somemem-
brane transporters in the HCE-T cell-based models and excised porcine
cornea have already been determined (Becker et al., 2007; Mannermaa
et al., 2006; Reichl et al., 2011; Vellonen et al., 2010; Verstraelen and
Reichl, 2013, 2014). However, considering the structural alteration of
the HCE-T barrier observed in this study, the expression of transporters,
which was shown to be functional in simple epithelial and more com-
plex HCE-T cell-based models in other studies, might become question-
able in the HCE-T-based Model I and II. In contrast, considering the
relatively high concentrations of ophthalmic compounds used in this
study, active transport, even if it is present, due to membrane trans-
porters' saturation effect, might contribute to the overall permeation
onlymarginally, thusmaking passive diffusion amore feasible transport
mechanism (Mannermaa et al., 2006). In conclusion, more detailed
mechanistic permeability studies regarding the transport mechanism
of the studied compounds and the barrier role of particular structures
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of the corneal model are deﬁnitely required to explain the observed
in vitro and ex vivo permeability differences.
3.4. In vitro/ex vivo correlations
Once in vivo-like barrier properties of cell-based models are opti-
mized, some structural and functional differences compared to excised
tissue may inevitably remain. Therefore, identical permeability values
in these models may not be realistic to expect or necessarily crucial to
obtain. More important is the ability of a particular model to discrimi-
nate well between different transport mechanisms, which determine
the permeation of awide range of compounds across the corneal barrier
in vivo. Thus, the correlation of the cell-based and/or tissue-based
models with in vivo corneal permeability should be established. In this
study, Model II was clearly shown to discriminate better between the
permeation of timolol and ﬂuorescein, determined to be highly and
poorly permeable in the excised cornea, respectively. More precisely,
the difference in their Papp values in Model II was 83.15-fold, which
more closely reﬂects their 56.46-fold difference in the excised cornea.
In contrast, only a 7.42-fold difference was found in the case of Model
I. The good predictability of ex vivo permeation coefﬁcients for Model
II was also conﬁrmed by correlation analyses, the results of which are
shown in Fig. 2. Correlation of in vitro and ex vivo logarithm Papp values
gave a high and statistically signiﬁcant Pearson correlation coefﬁcient
(r= 0.90, P= 0.036).
The further improvement of the HCE-T cell-based permeability
model may consider additional particularities of a unique corneal envi-
ronment to ensure the lower variability of barrier phenotype. Thus, the
dynamics of the precorneal area are lacking in the investigated static
permeability models. Reichl and coworkers observed small ultrastruc-
tural differences with regard to surface morphology between the
HCET cell-based models and the native corneal epithelium, which was
explained by the absence of tear ﬂuid and eyelid wiping during in
vitro cultivation conditions. In this case, themajor aspects of in vitro bar-
rier tightness were preserved (Reichl et al., 2004). Recently, Pretor and
coworkers studied the permeation of lipophilic compound loaded into
lipid nanodispersions across the HCE-T cell-basedmodel under dynam-
ic conditions (i.e., shear stress of 0.1 Pa) to simulate the impact of tear
ﬂow and eyelid wiping during the permeability study. However, the in-
ﬂuence of applied shear stress on the HCE-T cell barrier tightness was
not the target value measured because the lipophilic compounds pene-
trate the cornea by taking the transcellular route (Pretor et al., 2015).
4. Conclusion
Cell-based models have gained considerable popularity for drug
permeability studies across academic and/or pharmaceutical industry
research. As a unique environment, the corneal barrier is difﬁcult to
mimic. Considering that a single factor could be enough to change the
corneal barrier phenotype in vitro, all key factors inﬂuencing experi-
mental outcomes by using HCE-T based model should be controlled
and standardized. Membrane material, speciﬁcally its pore size, was
shown to be an important factor in theHCE-T barrier phenotype. A poly-
carbonatemembranewith a 3 μmpore size (Model II) proved to be bet-
ter than a polycarbonate membrane with a 0.4 μm pore size (Model I)
for tight barrier formationwith HCE-T cells, although a unique structure
for Model II was observed. Model II, which consists of apical lipophilic
HCE-T monolayer and basolateral lipophilic monolayer of migrated
HCE-T cells, generated more predictable permeability results when
compared with the excised cornea.
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a b s t r a c t
In this study, two types of nanosystems, namely lecithin/chitosan nanoparticles and Pluronic
F127/chitosan micelles, have been prepared and evaluated for their potential for the ocular delivery of
melatonin, which is known to exert an ocular hypotensive effect. The melatonin content, particle size,
zeta potential and in vitro drug release properties were studied as a function of the presence of chitosan
in the nanosystem. Lecithin/chitosan nanoparticles were evaluated in terms of the mucoadhesive proper-
ties by a newly establishedmethod based on HCE-T cells, also used in in vitro biocompatibility and permeabil-
ity studies.
Lecithin/chitosan nanoparticles were significantly larger than the corresponding F127/chitosan
micelles (mean diameter of 241.8 vs. 20.7 nm, respectively) and characterised by a higher surface charge
(22.7 vs. 4.3 mV, respectively). The HCE-T cell viability assay did not show significant toxic effects of
nanosystems investigated at the (relevant) chitosan concentration tested. The permeability study results
confirmed the permeation enhancing effect of F127, which was hindered in the presence of chitosan.
Lecithin/chitosan nanoparticles were characterised by prominent mucoadhesive properties and pro-
longed melatonin release, which was shown to control melatonin permeation across an in vitro corneal
epithelial model. Such properties demonstrate the potential for nanoparticles to provide an extended
pre-corneal residence time of melatonin, ensuring higher eye-related bioavailability and extended
intraocular pressure reduction compared to melatonin in both aqueous and micelle solutions.
 2015 Elsevier B.V. All rights reserved.
1. Introduction
Ocular drug delivery is one of the most challenging issues faced
by pharmaceutical researchers because of the specific anatomy,
physiology and biochemistry of the eye that make it practically
inaccessible to drugs. Current research is focused on the develop-
ment of biopharmaceutically improved and safe delivery nanosys-
tems that have high patient compliance and the ability to surpass
ocular barriers and maintain the drug levels in tissues, improving
therapeutic outcomes (Diebold and Calonge, 2010).
Innovative delivery nanosystems are designed to ensure a high
precorneal residence time and sustained drug release, resulting in
enhanced eye-related bioavailability of ophthalmic agents. The
physicochemical properties of nanosystems, such as their size, sur-
face charge, and drug release, determine their biopharmaceutical
properties, including stability in the precorneal area, mucoadhesiv-
ity, biocompatibility and permeability, and therefore their in vivo
performance. However, to direct the development of nanosystems
toward a final ophthalmic formulation with the best therapeutic
performance, reliable and convenient in vitromodels are necessary
to study the mechanisms and/or interactions of interest (Pepic
et al., 2014). Therefore, concomitant with nanosystem develop-
ment, it is important to establish in vitro models of eye barriers,
enabling safe and efficacious screening of formulation candidates.
Melatonin (N-acetyl-5-methoxytryptamine), a neurohormone
secreted by the pineal gland, has pleiotropic bioactivities, including
http://dx.doi.org/10.1016/j.ejps.2015.04.003
0928-0987/ 2015 Elsevier B.V. All rights reserved.
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the ability to modulate the intraocular pressure (IOP) (Bucolo et al.,
2013). Elevated IOP is one of the main risk factors in the develop-
ment of glaucoma, an optic nerve neuropathy that can result in
blindness (Mediero et al., 2009). Melatonin and certain melatonin
analogues were demonstrated to reduce the IOP in several species
(Agorastos and Huber, 2011; Alcantara-Contreras et al., 2011).
Chitosan is a biocompatible and biodegradable polycationic
polymer (Garcia-Fuentes and Alonso, 2012). At a pH below 6.5, it
is positively charged and electrostatically interacts with negatively
charged epithelial surfaces, resulting in mucoadhesion. This pro-
cess provides a longer contact time for drug transport across the
corneal barrier before the drug is cleared due to the rapid and
extensive precorneal elimination. Moreover, chitosan can act as a
permeation enhancer, increasing the paracellular drug permeation
both in vitro and in vivo. Chitosan increases the transepithelial
permeability due to its ability to reversibly disrupt epithelial tight
junctional complexes up to a pH of approximately 6 (Basaran and
Yazan, 2012).
Lecithin is a natural lipid mixture of phospholipids that has fre-
quently been used for the preparation of various delivery nanosys-
tems and is considered as a safe and biocompatible excipient
(Hafner et al., 2009). Due to its lipophilic nature, it is expected to
ensure a relatively high loading of lipophilic drugs as well as sus-
tained drug release (Bhatta et al., 2012).
Pluronic F127, a polyoxyethylated nonionic surfactant, has
been proposed to increase the drug permeability through the cor-
neal epithelial barrier (Pepic et al., 2013). F127 self-aggregates in
aqueous solutions, forming micelles with a core that consists of a
hydrophobic middle polypropylene oxide (PPO) block surrounded
by an outer shell of hydrated hydrophilic polyethylene oxide
(PEO) end blocks (Pepic et al., 2008, 2009). When formulated as
eye drops, F127micelle solutions enhance the ocular bioavailability
of indomethacin (Chetoni et al., 2000), pilocarpine (Pepic et al.,
2004) and plasmid DNA (Liaw et al., 2001; Tong et al., 2007) in rab-
bits. Our group developed F127/chitosanmicelles with dexametha-
sone as a model drug and demonstrated their potential to solubilise
the drug, enhance its precorneal retention and release it in a very
effective manner, reaching high bioavailability levels (Pepic et al.,
2010). However, no further studies have been performed to eluci-
date the exact mechanism(s) by which F127/chitosan micelles
enhance dexamethasone transport across the corneal barrier.
The aim of this study was to develop a colloidal melatonin
nanocarrier with sufficient melatonin entrapment and prominent
mucoadhesive properties to protect embedded photosensitive
melatonin, facilitate its passage through corneal barriers and/or
extend its intraocular activity. For such purposes, two different col-
loidal nanosystems were investigated, namely lecithin/chitosan
nanoparticles and Pluronic F127/chitosan micelles. For both types
of nanosystems investigated, the melatonin content, size and poly-
dispersity, zeta potential and in vitro drug release properties were
studied as a function of the presence of chitosan in the system.
Lecithin/chitosan nanoparticles were also evaluated in terms of
the mucoadhesive properties with a newly established method
based on the HCE-T cells used in the biocompatibility and
permeability in vitro studies. To gain insight into the influence of
nanosystems on melatonin permeation across the in vitro corneal
epithelial barrier, the correlation between melatonin in vitro
release and permeability was evaluated.
2. Materials and methods
2.1. Reagents and chemicals
The following materials were used as received: chitosan in the
form of hydrochloride salt (ProtasanUP CL 113, deacetylation
degree 86%, NovaMatrix, Sandvika Norway); soybean lecithin
Lipoid S45 (fat-free soybean lecithin with 45% phosphatidyl-
choline; a kind gift from Lipoid GmbH, Ludwigshafen, Germany);
Pluronic F127 triblock copolymer (F127) (molecular weight:
12,600, Sigma–Aldrich Chemie GmbH, Steinheim, Germany); and
melatonin (Sigma–Aldrich Chemie GmbH, Steinheim, Germany).
The substances used for the preparation of Hank’s balanced salt
solution (HBSS, pH 6) were prepared by dissolving the following
substances in double-distilled water: MgSO4  7H2O (100 mg l
1),
KCl (400 mg l1), NaHCO3 (350 mg l
1), NaCl (8000 mg l1), D-glu-
cose monohydrate (1100 mg l1) (all purchased from Kemig,
Zagreb, Croatia), CaCl2  2H2O (185 mg l
1) (Sigma–Aldrich),
MgCl2  6H2O (100 mg l
1) (Merck KGaA, Darmstadt, Germany),
KH2PO4 (60 mg l
1) (Kemika, Zagreb, Croatia), Na2HPO4  2H2O
(60 mgl1) (Fluka Chemie AG, Buchs, Switzerland), and HEPES
(7150 mg l1) (Applichem, Darmstadt, Germany). Fluorescein
sodium and rhodamine B were purchased from Sigma–Aldrich.
All other chemicals or solvents were of analytical grade and pur-
chased from Kemika (Zagreb, Croatia) and Merck (Darmstadt,
Germany).
2.2. Methods
2.2.1. HPLC assay of melatonin
The quantitative determination of melatonin was performed by
HPLC. The system consisted of an Agilent 1100 Series instrument
(Agilent Technologies, Waldbronn, Germany) equipped with a
diode array detector set at 224 nm. The mobile phase, consisting
of purified water and acetonitrile in the ratio of 52:48, was applied
at a flow rate of 1 ml/min. The column (Kinetex C18 column
50  4.6 mm, particle size 5 lm, Phenomenex, USA) was equipped
with an inline filter (KrudKatcher Ultra HPLC, 0.5 lm Depth
Filter  0.004 in., Phenomenex, USA) and operated at 30 C. The
sample injection volume was 10 ll. The elution was isocratic,
and the run time was 1 min. Melatonin peaks were separated with
a retention time of 0.6 min.
2.2.2. Preparation of melatonin-loaded lecithin/chitosan nanoparticles
Melatonin-loaded lecithin/chitosan nanoparticles (MLC) were
prepared as previously reported (Hafner et al., 2009). Lecithin
was dissolved in 96% ethanol at concentration of 25 mg ml1.
Melatonin was dissolved in the ethanolic solution of lecithin at
concentration of 5 mg ml1, obtaining a lecithin-to-melatonin
weight ratio of 5:1. Chitosan was solubilised in distilled water at
concentration of 10 mg ml1. The chitosan solution (0.5 ml) was
further diluted with distilled water to a volume of 46 ml. MLC
nanoparticles were obtained with the injection of 4 ml of ethanolic
lecithin/melatonin solution (syringe inner diameter of 0.75 mm)
into 46 ml of diluted chitosan solution with magnetic stirring
(900 rpm). A final chitosan concentration of 100 lg ml1 and
lecithin-to-chitosan weight ratio of 20:1 was obtained in the pre-
pared nanoparticle suspensions. For comparison, melatonin-loaded
lecithin nanoparticles (MLs) were prepared by the injection of
ethanolic melatonin/lecithin solutions into distilled water. Non-
entrapped melatonin was separated from MLC or ML using the
dialysis technique, as described in the Section 2.2.4. Melatonin-free
nanoparticles were prepared following the same procedure as for
melatonin-loaded nanoparticles (L and LC nanoparticles).
2.2.3. Preparation of melatonin-loaded F127 and F127/chitosan
micelles
A stock solution of F127 (100 mg ml1) was prepared by dis-
solving F127 in HBSS at pH 6.0 for 48 h at 4 C. A chitosan stock
solution (10 mg ml1) in water was prepared by stirring for
30 min at room temperature. The F127 micelles (F; 25 mg ml1)
were prepared by diluting the F127 stock solution with HBSS at
A. Hafner et al. / European Journal of Pharmaceutical Sciences 75 (2015) 142–150 143
pH 6.0. The F127/chitosan micelle solutions (FC; 25 mg ml1 and
0.1 mg ml1, respectively) were prepared by mixing the F127 and
chitosan stock solutions followed by dilution with HBSS at pH 6.0.
Melatonin-loaded F127 (MF) and F127/chitosan micelles (MFC)
were prepared by the direct dissolution method. Melatonin
(15 mg) was added to the F or FC micelle system (100 ml) and
gently stirred for 24 h at room temperature. The non-solubilised
melatonin was separated by filtration through 0.22-lmmembrane
filters (Millipore, Zug, Switzerland).
2.2.4. Determination of the melatonin content
For nanoparticles (MLC and ML), melatonin content refers to the
amount of entrapped melatonin, which is separated from non-en-
trapped melatonin by dialysis. For micelles (MFC and MF), melato-
nin content refers to the amount of melatonin left in the micelle
solution after filtration. However, in addition to entrapped melato-
nin, it includes a certain amount of non-entrapped melatonin,
which is determined by its solubility in water (0.1 mg ml1; room
temperature).
The dialysis of nanoparticle suspensions (MLC and ML) was per-
formed as previously reported (Hafner et al., 2009). Briefly, a 4 ml
aliquot of melatonin-loaded nanoparticle suspensions was placed
in a cellulose acetate dialysis bag and sealed (Spectra/Por 4
Dialysis Tubing, MWCO 12–14 kDa, Spectrum Laboratories, Inc.,
Rancho Dominguez, California, USA). The samples were dialysed
against 100 ml of distilled water (receiver phase), under continu-
ous magnetic stirring at 30 rpm and sink conditions. At scheduled
time intervals, the 2 ml samples were withdrawn from the receiver
phase and replaced with the same amount of distilled water. The
dialysis was stopped when constant drug concentration values
were detected in subsequent withdrawals from the receiver phase,
taking into account the progressive dilution of the receiver phase.
Withdrawn samples were assayed for the melatonin content by
HPLC after they were diluted with acetonitrile to obtain a water-
to-acetonitrile volume ratio of 52:48. The dialysed nanoparticle
suspension samples were used in all further studies.
Filtered micelle solutions were disrupted by dissolving the
micelles and melatonin with equal amounts of ethanol. The mela-
tonin content was determined by HPLC. The filtered micelle solu-
tions were used in all further studies.
2.2.5. Physical characterisation of the particle size and surface charge
The size and zeta potential of nanoparticles and micelles were
measured by Photon Correlation Spectroscopy (PCS) using
Zetasizer 3000 HS (Malvern Instruments, Malvern, UK). The nano-
particle samples were diluted with 0.45 lm filtered distilled water
and 10 mM NaCl solution prior to the measurement of the size and
zeta potential, respectively. The pH of diluted samples ranged from
5.8 to 6.0. Zeta-potential measurements were performed at 25 C.
Samples were placed in the electrophoretic cell, where a potential
of 150 mV was established.
2.2.6. In vitro release studies
The release of melatonin from nanosystems was assessed by the
dialysis technique under sink conditions over 5 h. The appropriate
volume of melatonin-loaded nanoparticle suspension or micelle
solution containing 250 lg of melatonin was placed into a cellu-
lose acetate dialysis bag (Spectra/Por 4 Dialysis Tubing, MWCO
12–14 kDa or Dialysis Tubing Visking, MWCO 3.5 kDa, Medicell
International Ltd., London, UK, respectively), which was sealed
from both sides and immersed into 30 ml of pH 5.8 acetate buffer
solution at 37 C that was magnetically stirred at 30 rpm. At sched-
uled time intervals, agitation was stopped and the aliquots (1 ml)
were withdrawn and replaced with equal amounts of fresh buffer
solution. Withdrawn samples were diluted with acetonitrile,
resulting in a water to acetonitrile volume ratio of 52:48, and we
checked for the melatonin content by HPLC. All experiments were
performed in triplicate.
2.2.7. Cell culture conditions
In this study, we used human corneal epithelial cells (HCE-T;
RIKEN Cell Bank, Tsukuba, Japan). This cell line is the most exten-
sively characterised immortalized human corneal epithelial cell
line in terms of passive transcellular and paracellular transport,
transporter expression and metabolic enzyme expression (Hahne
and Reichl, 2011; Pepic et al., 2014). Cells were cultivated using
DMEM/F12 (Lonza, Basel, Switzerland) supplemented with foetal
bovine serum (5%, Biosera, Boussens, France), insulin (5 lg ml1,
Applichem, Darmstadt, Germany), dimethyl sulfoxide (0.5%,
Applichem), epidermal growth factor (10 ng ml1, Applichem),
and Pen/Strep/Fungizone (Lonza).
2.2.8. Cell viability study
To assess the cytotoxicity of nanoparticles and micelles, HCE-T
cells were seeded onto 24-well plates at a density of 2  104 -
cells/well and allowed to reach confluence over 2 days. The sus-
pension of nanoparticles or micelles was mixed with HBSS,
resulting in a (relevant) chitosan concentration of 2.5, 10 or
20 lg ml1. Prior to the nanosystem treatment, the cell culture
medium was withdrawn, and the cells were washed with HBSS.
The cells were then exposed to the nanosystem suspensions for
30 min. Cells incubated in HBSS were used as a negative control.
After 30 min of nanosystem treatment, the cells were washed
twice with HBSS and incubated with fresh medium (500 ll/well)
for 24 h. Cell viability was determined with the colorimetric MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide,
Sigma) assay. A total of 50 ll of MTT stock solution (5 mg ml1)
was added to each well, and the cells were then incubated for
2 h at 37 C. Subsequently, the medium was removed, cells were
lysed and formazan dissolved with acidic isopropanol. The amount
of formazan was quantified spectrophotometrically at 570 nm
(1420 Multilabel counter VICTOR3, Perkin Elmer, Waltham,
Massachusetts, USA).
2.2.9. Permeability assay using an in vitro corneal epithelial model
An in vitro corneal epithelialmodelwas cultivated on Transwell
polycarbonate filter inserts (3.0-lm pore size, 12 mm diameter,
Corning B.V. Life Sciences, Amsterdam, The Netherlands) coated
with type I rat-tail collagen (Sigma–Aldrich) and fibronectin
(Sigma–Aldrich). HCE-T cells suspended in the culture medium
were seeded onto the coated filter (105 cells per well) and culti-
vated submerged for seven days. Subsequently, they were exposed
to the air–liquid interface (ALI) during the following three days to
induce cell differentiation and multilayer growth (Hahne and
Reichl, 2011). The applicability of an in vitro corneal epithelial
model in permeability studies, especially for assessing the interac-
tion of chitosan-based nanosystems with tight junctions, was
evaluated by determining the interdependence between the tem-
perature, transepithelial electrical resistance (TEER) and apparent
permeability coefficient of transcellular and paracellular markers.
Specifically, the apparent permeability coefficients of rhodamine
B and fluorescein sodium were correlated with the TEER values
obtained at two different temperatures (room temperature and
37 C).
The permeability experiments were performed directly in the
Transwell plate on a horizontal orbital shaker (37 C; 50 rpm) in
HBSS (pH 6.0). To determine the barrier integrity and interaction
of nanosystems with tight junctions, TEER was measured during
the experiments (EVOM, WPI Inc., Sarasota, Florida, USA). Test
samples were prepared by diluting melatonin solution (400 lM)
and melatonin-loaded nanosystems with HBSS to a melatonin con-
centration of 50 lM. Prior to the experiment, the cells were
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washed with HBSS and incubated with 400 ll and 2000 ll of HBSS
in the donor and receptor compartments, respectively, during the
subsequent 30 min. At the start of the experiment, HBSS was
removed from the donor compartment, and 400 ll of the test sam-
ple was added. Samples (400 ll) were taken from the receptor
compartment at regular time intervals over 120 min and replaced
with the same volume of fresh buffer. At the end of the experiment,
the solution remaining in the donor compartment was also col-
lected. The cell surface was rinsed with HBSS and exposed to the
air–liquid interface during the subsequent 24 h; then, the final
TEER measurement was performed.
Samples were diluted with acetonitrile to a water:acetonitrile
volume ratio of 52:48; they were then analysed for the melatonin
content by HPLC. The apparent permeability coefficients (Papp in
cm/s) were calculated according to the following equation:
Papp ¼
@Q
@t

1
AC0
where @Q
@t
is the permeation rate, A is the diffusion area of the epithe-
lial barrier, and C0 is the initial concentration of melatonin in the
donor compartment (Sadeghi et al., 2008).
2.2.10. Mucoadhesive properties of lecithin/chitosan nanoparticles
To determine the mucoadhesive properties of MLC, we devel-
oped a method based on the HCE-T cells used in biocompatibility
and permeability in vitro studies. The extent of the particle bioad-
hesion was evaluated by measuring the decrease in melatonin con-
tent in a nanoparticle suspension following the exposure of the cell
monolayer to a melatonin-loaded nanoparticle suspension. HCE-T
cells were seeded onto 24-well plates (TPP, Trasadingen,
Switzerland) at a density of 2  104 cells/well and allowed to reach
confluence over 2 days. Cells were treated with 200 ll of MLC, ML
or the corresponding melatonin aqueous solution after the removal
of culture medium. At scheduled time intervals (6 time points over
90 min), samples (20 ll) were collected for the analysis of the mel-
atonin content. The remaining content of the suspension was then
transferred to the next well upon the removal of cell culture med-
ium. Samples were diluted with acetonitrile to a water:acetonitrile
volume ratio of 52:48; the melatonin content was then determined
by HPLC. All experiments were performed in triplicate.
2.2.11. Statistical analysis
The statistical software package JMP 10.0.2. (SAS Institute, Cary,
North Carolina, USA) was used to perform 1-way ANOVA, followed
by multiparametric Tukey’s post hoc test. Multivariate linear mod-
els were calculated and plots are shown as provided by the general
linear model function of the JMP software package. A P value < 0.05
was considered statistically significant.
3. Results and discussion
3.1. Characterisation of the nanosystems
Two types of nanosystems, namely lecithin/chitosan nanoparti-
cles (MLC) and F127/chitosan micelles (MFC), which have equal
chitosan and similar melatonin content but are significantly differ-
ent in size (241.8 vs. 20.7 nm, respectively), were prepared and
evaluated for their potential for melatonin ocular delivery.
Chitosan-free and/or melatonin-free nanosystems were also pre-
pared and were used as controls when appropriate. The composi-
tion and main characteristics of the nanosystems prepared are
given in Table 1.
Lecithin/chitosan nanoparticles were formed based on the elec-
trostatic interaction between the negatively charged fraction of the
lipid material and the positively charged chitosan, as already
described in the literature (Gerelli et al., 2008; Hafner et al.,
2009; Sonvico et al., 2006). Nanoparticles were separated from
non-entrapped melatonin using the dialysis method. The nanopar-
ticle size and surface charge were determined using dialysed sys-
tems diluted with water and 10 mM NaCl, respectively. The pH
values in the diluted dialysed systems were between 5.8 and 6.0.
The lecithin/chitosan nanoparticles (MLC) obtained were signifi-
cantly larger than the corresponding lecithin nanoparticles (ML)
(241.8 ± 0.8 vs. 91.8 ± 5.1 nm, respectively). The zeta potential
was inverted from negative values for ML (35.9 ± 4.2 mV) to posi-
tive values for MLC (22.7 ± 0.7 mV), which can be ascribed to the
presence of chitosan at the nanoparticle surface. Compared to
ML, MLC were characterised by higher melatonin loading. The data
obtained for melatonin-loaded and melatonin free nanoparticles
indicated that melatonin loading did not influence the average par-
ticle size or zeta potential (Table 1).
The main characteristics of the nanoparticles are consistent
with those reported in our previous studies (Hafner et al., 2011,
2009).
F127 micelle systems are well established and known to
enhance ocular drug delivery (Pepic et al., 2012). Our group has
proposed the use of F127/chitosan micelle systems and their
potential to solubilise the drug and enhance its precorneal reten-
tion, reaching high bioavailability, was demonstrated in vivo
(Pepic et al., 2008, 2009; Pepic et al., 2010). In such systems, pH-
related electrostatic interactions between the electronegative
oxygen atoms of PEO segments and electropositive chitosan chains,
as well as hydrogen bonds, between the oxygen atoms of PEO
segments and the OH groups of chitosan have been proposed.
Melatonin-loaded micelle systems were prepared by the direct
dissolution method. The undissolved melatonin was separated by
filtration. The micelle size and surface charge were determined in
the filtrates with no previous dilution. The average hydrodynamic
diameter of the micelles ranged between 20.7 and 24.5 nm. The
addition of chitosan did not influence the average micelle size.
However, melatonin loading resulted in a slight reduction of the
average micelle size in both the presence and in the absence of chi-
tosan (Table 1), which is probably due to an interaction with F127.
At the same time, an increase in the zeta potential due to melato-
nin loading was observed in the presence of chitosan (MFC vs. FC;
4.3 ± 0.9 vs. 1.5 ± 1.1 mV, respectively).
The zeta potential of MF micelles was close to 0 mV. This value
was expected due to the electroneutral nature of F127. In the case
of MFC micelles, an increase in the zeta potential compared to that
of MF micelles was observed and assigned to the presence of chi-
tosan on the micelle surface. As the parameters of the chitosan
concentration (100 lg ml1) and pH (6.0) were kept constant for
both types of nanosystems prepared, a significantly higher zeta
potential of MLC compared to the zeta potential of MFC can be
assigned to the stronger electrostatic interaction of chitosan with
lecithin than with F127 and the consequently higher charge den-
sity at the particle surface.
For both types of nanosystems prepared, the melatonin content
(109.3–142.4 lg ml1; Table 1) is several times higher than the
melatonin concentration in the solution (100 lM (23.2 lg ml1),
instillation volume of 10 ll) previously reported to ensure the
reduction of the elevated intraocular pressure in rabbits
(Martinez-Aguila et al., 2013).
3.2. In vitro release
The dialysis technique is considered the most suitable method
for determining the drug release profile from drug delivery
nanosystems (Modi and Anderson, 2013; Zambito et al., 2012).
However, the increase in drug concentration in the receiver phase
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is a consequence of two processes, namely, drug release to the con-
tinuous phase inside the dialysis bag and drug diffusion from the
donor to the receiver phase through the dialysis membrane. The
membrane provides some resistance to drug diffusion, affecting
its release rate. Therefore, an in vitro release study was also per-
formed with melatonin aqueous solution to determine the resis-
tance of the dialysis membrane and its influence on the overall
drug release rate.
All nanosystems were characterised by prolonged melatonin
release (Fig. 1), which is a desirable property for achieving
extended IOP reduction (Musumeci et al., 2013). The melatonin
release rate from nanoparticles decreased with the presence of chi-
tosan in the system (t50% values for MLC and ML were 1.75 and
0.75 h, respectively), which is consistent with our previous reports
(Hafner et al., 2009).
For micelles, the opposite effect of chitosan on the melatonin
release rate was observed. Therefore, the melatonin release from
MFC was faster (t50% 0.75 h) than the melatonin release from MF
(t50% = 1.5 h). The influence of chitosan on the melatonin release
rate is probably due to its slight thermodynamic destabilization
of micelle aggregates at pH 6.0, as reported in our previous work
(Pepic et al., 2008, 2009), accompanied by the intermediate posi-
tion of melatonin within micelle compartments (Torchilin, 2001).
The diffusion of melatonin through the diffusion membrane for
melatonin aqueous solution was significantly faster (t50% of 0.25 h)
than for the investigated nanosystems. Therefore, melatonin
release from nanosystems to the continuous phase inside the
dialysis bag is the rate-limiting factor that determines the release
profile obtained for nanoparticles and micelles.
3.3. Mucoadhesive properties of lecithin/chitosan nanoparticles
Evaluation of mucoadhesion is necessary for characterising the
delivery systems aimed to prolong the drug residence time at the
eye surface (Musumeci et al., 2013). In this work, the incorporation
of melatonin into the nanoparticles served as an indicator of nano-
particle mucoadhesion upon the exposure of the HCE-T cell mono-
layer to a melatonin-loaded nanoparticle suspension. Melatonin
aqueous solution was used as a control to distinguish the decrease
in the melatonin content due to the melatonin absorption from its
decrease due tomucoadhesion. Our results confirmed the improved
mucoadhesive properties of MLC compared toML (Fig. 2). This find-
ing is in line with the difference in the surface charge of the com-
pared systems. The MLC nanoparticles were characterised by a
positive charge originating from chitosan at their surface, whereas
the ML nanoparticles were negatively charged (Table 1). The results
obtained with this method confirmed the findings reported in our
previous study using a standardmucus glycoprotein assay to deter-
mine nanoparticle mucoadhesion (Hafner et al., 2009).
Table 1
The composition and the main characteristics of melatonin-loaded nanosystems (nanoparticles and micelles).
The main nanosystem constituent Sample Chitosan conc. (lg/ml) Melatonin content (lg/ml) Size (nm) PDI Zeta-potential (mV)
Lecithin (2 mg/ml) MLC 100 137.3 ± 10.1 241.8 ± 0.8 0.207 ± 0.003 22.7 ± 0.7
(LC) (238.0 ± 1.5) (0.260 ± 0.015) (22.1 ± 0.8)
ML 0 109.3 ± 7.2 91.8 ± 5.1 0.397 ± 0.002 35.9 ± 4.2
(L) (79.1 ± 4.5) (0.405 ± 0.009) (34.4 ± 4.7)
Pluronic F127 (25 mg/ml) MFC 100 138.2 ± 6.9 20.7 ± 0.3 0.176 ± 0.031 4.3 ± 0.9
(FC) (23.3 ± 0.1) (0.340 ± 0.029) (1.5 ± 1.1)
MF 0 142.4 ± 8.5 20.0 ± 0.1 0.213 ± 0.017 0.2 ± 0.6
(F) (24.5 ± 1.0) (0.315 ± 0.054) (0.2 ± 1.6)
Values are mean ± SD (n = 3).
Values in brackets refer to melatonin-free nanosystems.
PDI, polydispersity index.
Fig. 1. Release profiles of melatonin from MLC (d) and ML (j) nanoparticles (A)
and MFC (d) and MF (j) micelles (B) in acetate buffer at pH 5.8. Data are expressed
as the mean ± SD (n = 3).
Fig. 2. Evaluation of the mucoadhesive properties of MLC (N) and ML (j)
nanoparticles by measuring the decrease in the melatonin content in a nanoparticle
suspension following the treatment of a HCE-T cell monolayer. Melatonin aqueous
solution (d) was used as a control. Data are expressed as the mean ± SD (n = 3).
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The mucoadhesive properties of micelles cannot be evaluated
due to their inherent dynamic properties. However, micelle
nanosystems are expected to be superior to melatonin solution
because the surface tension values of F127 (38.1–39.2 mNm1)
and F127/chitosan (37.5–38.8 mNm1) micelle solutions (Pepic
et al., 2008) are relatively close to the surface tension of human
tears (42–46 mNm1) (Nagyova and Tiffany, 1999). This improves
the spreading properties over the ocular surface immediately after
the instillation as well as decreases the contact angle of micelle
nanosystems, and the ocular surface forms a thin layer, minimizing
the possibility for immediate loss due to spillage (overflow), as
observed in our previous in vivo study (Pepic et al., 2010).
3.4. Evaluation of cell viability
Ocular biocompatibility and toxicity should always be consid-
ered when designing ocular drug delivery systems, particularly if
they are intended for chronic administration. Based on the results
observed in rabbits, chitosan in solution has been identified as a
well-tolerated constituent of topical ophthalmic formulations (Di
Colo et al., 2004; Felt et al., 1999). As for the chitosan-based
nanosystems, a number of studies, both in vitro and in vivo, aimed
to assess their biocompatibility and tolerance (de la Fuente et al.,
2010). In vitro tests were performed to determine the toxicological
profile of chitosan-based nanoparticles on immortalized cell lines
obtained from the ocular epithelia, i.e., cornea (HCE) and conjunc-
tiva (Chang and NHC-IOBA cells) (de la Fuente et al., 2008; Diebold
et al., 2007). Initial reports on the cytotoxicity of chitosan nanopar-
ticles indicated acceptable toxicological profiles in vitro; also, the
levels of cell death did not exceed 5% for a polymer concentration
of 2 mg ml1 (de Campos et al., 2004; Enriquez de Salamanca et al.,
2006). In the case of more complex structures, such as chitosan/
hyaluronic acid nanoparticles and complexes of chitosan nanopar-
ticles with liposomes, the cytotoxicity was lower than for chitosan
nanoparticles because of the lower net surface charge (de la Fuente
et al., 2008; Diebold et al., 2007). Pluronics are generally recog-
nized as safe for ophthalmic administration, and they are used as
formulation components of several commercial topical ocular
products (Jiao, 2008). Those with a high content of PEO are
particularly safe. Core-forming blocks, such as polyesters and
poly(L-amino acids), undergo hydrolysis and/or enzymatic degra-
dation in vivo, resulting in biocompatible monomers that are read-
ily eliminated by the kidneys (Kumari et al., 2010).
Here, in vitro cytotoxicity studies have been performed to not
only evaluate the biocompatibility of nanosystems with ocular
epithelial cells, but also define the concentration of nanosystems
that can safely be applied on the in vitro corneal epithelial model
in permeability studies.
A cytotoxicity study of the nanosystems prepared was per-
formed on HCE-T cells at a (relevant) chitosan concentration rang-
ing from 2.5 to 20 lg ml1 and a 0.5 h incubation time. Chitosan
was noted as a key component due to its mucoadhesive properties
and permeation enhancing properties, which are known to depend
on its pH-related net charge. Therefore, it is important to deter-
mine the nanosystem biocompatibility under defined experimen-
tal conditions because the potential cytotoxicity may be a
consequence of the high binding affinity for cellular membranes.
The cell viability assay did not show significant toxic effects of
the nanosystems investigated at the (relevant) chitosan concentra-
tion tested (Fig. 3, P > 0.05). By contrast, concentration-dependent
chitosan cytotoxicity was observed when the cells were treated
with chitosan solution, indicating that chitosan in a free soluble
form is much more cytotoxic than when it is incorporated in the
nanosystem.
The biocompatibility of lecithin/chitosan nanoparticles was pre-
viously investigated in Caco-2, HaCaT and BJ fibroblasts (Hafner
et al., 2011, 2009). Nanoparticles differed in their chitosan content
and the negative charge of lecithin used in the preparation. The dif-
ferences between the cytotoxicity of the nanoparticles have been
ascribed to the differences in the charge density of nanoparticles
and the chitosan content in its free-soluble form in nanoparticle
suspension, both of which may affect the interaction of the systems
with the cell membranes and, therefore, their toxicity. However,
for lecithin S45/chitosan nanoparticles with lecithin to a chitosan
weight ratio of 20:1 (MLC in this study), no influence on cell viabil-
ity was ever observed.
Pluronic F127 solutions at concentrations ranging from 2.5 to
5000 lg ml1, were nontoxic and biocompatible with mouse
fibroblasts in vitro, even at 48 h cell exposure (Arranja et al.,
2014). Accordingly, there was no significant decrease in the viabil-
ity of HCE-T cells treated with micelle systems at F127 concentra-
tions up to 5000 lg ml1. The increase in the F127 concentration
did not decrease the cell viability decrease because F127 unimers
are aggregated into micelles at concentrations above the critical
micelle concentration, and these micelles are potentially less toxic
than the non-aggregate unimer forms.
3.5. Permeability assay using an in vitro corneal epithelial model
The influence of the nanosystems on the melatonin permeabil-
ity was investigated using an in vitro corneal epithelial model
based on HCE-T cells.
Considering the interaction of the chitosan-based nanosystems
with the tight junctions of the epithelial barrier, the applicability of
an in vitro corneal epithelial model in permeability studies was
evaluated by determining the interdependence between the tem-
perature, TEER and apparent permeability coefficient (Papp). The
relationship between the TEER and temperature has been estab-
lished in the literature (Shen et al., 2008) (Gonzalez-Mariscal
et al., 1984). The TEER of MDCK cell monolayer was studied as a
function of the temperature, from 3 to 37 C. The change in the
TEER elicited by a temperature increase was large (for this tem-
perature interval 306%), fast (less than 2 s) and reversible
(Gonzalez-Mariscal et al., 1984).
The permeabilities of fluorescein sodium, as a paracellular mar-
ker, and rhodamine B, as a transcellular marker (Hahne and Reichl,
2011; Toropainen et al., 2001), were investigated at 20 and 37 C
using an in vitro corneal epithelial model that was characterised
by a different initial TEER. To investigate the effect of temperature
on the TEER, corneal epithelial models with initial TEER values of
800–1000X  cm2, measured in culture medium at 37 C, were
selected. After 30 min of incubation in HBSS at 37 C, the TEER
was reduced to 50.0 ± 4.7% of the initial value (n = 24). When the
incubation in HBSS was performed at 20 C, a slight reduction in
the TEER compared to the initial values was observed
(93.0 ± 11.0%). These results confirmed the influence of tempera-
ture on the TEER during incubation in HBSS.
The correlation of the apparent fluorescein sodium permeability
coefficients (Papp) across in vitro corneal epithelial models with
TEER has been established (r = 0.9723 and 0.9519 at 20 and
37 C, respectively). The increase in the Papp of fluorescein sodium
with the reduction of the TEER is expected because fluorescein
sodium is a marker of the paracellular pathway. No influence of
the TEER on the Papp of rhodamine B was observed, indicating the
transcellular pathway of rhodamine B transport across the
in vitro corneal epithelial model. However, the Papp values at
37 C were slightly higher than at 20 C for a similar TEER, owing
to the faster diffusion from the increase in temperature.
The relationship between the fluorescein sodium and rho-
damine B Papp and TEER established here confirms the reliability
and convenience of the corneal epithelial model for in vitro
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permeability studies and bioavailability prediction. Moreover, it
can serve as a basis for the prediction of nanosystems’ transport
pathways and their modes of interaction with epithelial barriers.
Permeability studies were performed using test samples that
were prepared by diluting melatonin-loaded nanosystems (MLC,
ML, MFC, and MF) and melatonin stock solution with HBSS buffer
(pH 6.0), up to an equal melatonin concentration (50 lM). The ocu-
lar administration of 20 ll of melatonin-loaded nanosystem sus-
pension with a melatonin concentration of 50 lM is expected to
ensure a reduction in the elevated intraocular pressure. This con-
clusion is based on the previously reported effective dose of mela-
tonin in solution (Martinez-Aguila et al., 2013). The selected
melatonin concentration refers to the chitosan concentration in
the range of 8.1–10.6 lg ml1 (depending on the content of mela-
tonin in nanosystems), which has been covered in the biocompati-
bility studies (Fig. 3).
The effect of nanosystems on tight junction opening and cell
viability was investigated by monitoring the TEER across the
HCE-T epithelial barrier for 24 h, starting from the application of
test samples. For all test samples used, a decrease in the TEER
was observed, resulting in TEER values that were approximately
60% of the initial value at the end of the experiment. Despite the
known effect of chitosan on tight junction opening (Hafner et al.,
2009), there was no difference in TEER decrease between chi-
tosan-based (MLC and MFC) and chitosan-free (ML and MF)
nanosystems, suggesting the involvement of other TEER-decreas-
ing factors and model limitations. However, 22 h after removing
the test samples from the model surface and its exposure to ALI,
the recovery of the initial TEER values was observed, confirming
that the investigated nanosystems lacked toxic effects.
The permeation of melatonin from aqueous solution and
nanosystem formulations across the in vitro corneal epithelial
model is demonstrated with the Papp (Fig. 4). The results indicated
that, except for MF, the incorporation of melatonin into nanosys-
tems significantly decreased its overall permeability compared to
the melatonin solution (1.40 ± 0.11  105 cm/s). Aside from the
type (size) of the investigated nanosystems, the presence of chi-
tosan seems to influence the melatonin permeability. Therefore,
MLC is characterised by lower melatonin permeability than ML
(0.59 ± 0.04  105 cm/s vs. 0.84 ± 0.09  105 cm/s, respectively).
As already stated, the presence of chitosan in such a system resulted
in slower melatonin release, leading to a lower melatonin permea-
tion rate. In addition, a relatively strong correlation between mela-
tonin in vitro release and permeation rate was observed for the
nanoparticles, as shown in Fig. 5, suggesting that permeation was
controlled by the melatonin release profile. Higher melatonin
permeability was observed for micelles compared to nanoparticles.
Generally, the influence of nanocarriers on the drug permeability is
related to particle size; therefore, micelles (approximately 20 nm in
size) are expected to provide better melatonin permeation than
nanoparticles (91.8 and 241.8 nm). A higher permeability of mela-
tonin from micelle systems is also partially due to the presence of
a certain amount of non-entrapped melatonin (determined by its
solubility in water; 0.1 mg ml1) that is readily absorbed across
the in vitro corneal epithelial barrier. Moreover, improved melato-
nin permeability from micelle systems can be ascribed to the
well-established enhancing effect of amphiphilic copolymers, such
as F127, on transcellular permeability (Pepic et al., 2012; Tian and
Mao, 2012). Unimers that are dissociated from micelles may
perturb the plasma membrane by their incorporation into the
lipid bilayer, resulting in acceleration of drug permeation through
cell membranes (Kim et al., 2010). When the lipid bilayer is
saturated, mixed micelles are formed, resulting in the removal of
phospholipids from the cell membranes and increased tran-
scellular permeability (Jiao, 2008). As the melatonin permeability
from MFC micelles was significantly lower than that from MF
micelles, it seems that chitosan, through its electrostatic interaction
Fig. 3. Influence of melatonin-loaded nanoparticles (MLC and ML) and micelles (MFC and MF) on the viability of HCE-T cells (MTT assay). The suspension of nanoparticles or
micelles was mixed with HBSS, obtaining a (relevant) chitosan concentration of 2.5, 10 or 20 lg ml1. HBSS, melatonin (2.5, 10 and 20 lg ml1) and chitosan solution (2.5, 10
and 20 lg ml1) in HBSS were used as controls. The incubation time was 30 min. Data are expressed as the mean ± SD (n = 3). ⁄Differs from untreated cells incubated in HBSS
(P < 0.05).
Fig. 4. Permeation of melatonin across the corneal epithelial model based on HCE-T
cells from aqueous solution (M), nanoparticle suspensions (MLC and ML), and
micelles (MFC and MF) presented by apparent permeability coefficients (Papp). Test
samples were prepared by diluting MLC, ML, MFC, MF and melatonin stock solution
with HBSS buffer (pH 6.0) up to an equal melatonin concentration (50 lM). Selected
melatonin concentration refers to chitosan concentration in range of 8.1–
10.6 lg ml1. Data are expressed as the mean ± SD (n = 3). Statistically significant
differences between each nanosystem and melatonin aqueous solution were
observed (P < 0.05), except for MF.
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with F127, diminished its enhancing effect on the melatonin tran-
scellular permeability (1.02 ± 0.03  105 cm/s vs. 1.61 ± 0.17 
105 cm/s).
4. Conclusions
Melatonin is readily absorbed across corneal epithelial barriers,
as confirmed by the Papp of melatonin in solution. However, rapid
and extensive precorneal elimination, owing to tear dynamics,
nasolachrymal drainage and nonproductive adsorption/absorption,
results in a limited eye-related bioavailability of melatonin from
solution and a brief pharmacological effect. The enhancing effect
of F127 on melatonin permeation demonstrated in this study is
expected to provide higher eye-related melatonin bioavailability.
However, the permeation-enhancing effect of F127 was hindered
in the presence of chitosan, indicating that the addition of chitosan
in F127 micelle formulation was not beneficial. Lecithin/chitosan
nanoparticles were characterised by prominent mucoadhesive
properties and prolonged melatonin release, which was shown to
control melatonin permeation across an in vitro corneal epithelial
model. Therefore, such a nanosystem shows the potential for pro-
viding an extended precorneal residence time of melatonin, ensur-
ing both higher eye-related bioavailability and extended IOP
reduction compared to melatonin aqueous solution.
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The objective of this study was to systematically investigate the eﬀects of surface active ophthalmic excipients on
the corneal permeation of ophthalmic drugs using in vitro (HCE-T cell-based model) and ex vivo (freshly excised
porcine cornea) models. The permeation of four ophthalmic drugs (i.e., timolol maleate, chloramphenicol, di-
clofenac sodium and dexamethasone) across in vitro and ex vivo corneal models was evaluated in the absence and
presence of four commonly used surface active ophthalmic excipients (i.e., Polysorbate 80, Tyloxapol,
Cremophor® EL and Pluronic® F68). The concentration and self-aggregation-dependent eﬀects of surface active
ophthalmic excipients on ophthalmic drug permeability were studied from the concentration region where only
dissolved monomer molecules of surface active ophthalmic excipients exist, as well as the concentration region
in which aggregates of variable size and dispersion are spontaneously formed. Neither the surface active oph-
thalmic excipients nor the ophthalmic drugs at all concentrations that were tested signiﬁcantly aﬀected the
barrier properties of both corneal models, as assessed by transepithelial electrical resistance (TEER) monitoring
during the permeability experiments. The lowest concentration of all investigated surface active ophthalmic
excipients did not signiﬁcantly aﬀect the ophthalmic drug permeability across both of the corneal models that
were used. For three ophthalmic drugs (i.e., chloramphenicol, diclofenac sodium and dexamethasone), depressed
in vitro and ex vivo permeability were observed in the concentration range of either Polysorbate 80, Tyloxapol,
Cremophor® EL or Pluronic® F68, at which self-aggregation is detected. The eﬀect was the most pronounced for
Cremophor® EL (1 and 2%, w/V) and was the least pronounced for Pluronic® F68 (1%, w/V). However, all
surface active ophthalmic excipients over the entire concentration range that was tested did not signiﬁcantly
aﬀect the in vitro and ex vivo permeability of timolol maleate, which is the most hydrophilic ophthalmic drug that
was investigated. The results of the dynamic light scattering measurements point to the association of oph-
thalmic drugs with self-aggregates of surface active ophthalmic excipients as the potential mechanism of the
observed permeability-depressing eﬀect of surface active ophthalmic excipients. A strong and statistically sig-
niﬁcant correlation was observed between in vitro and ex vivo permeability of ophthalmic drugs in the presence
of surface active ophthalmic excipients, which indicates that the observed permeability-altering eﬀects of surface
active ophthalmic excipients were comparable and were mediated by the same mechanism in both corneal
models.
1. Introduction
The eye-related bioavailability of topically applied drugs is aﬀected
by a complex interplay of biological factors (e.g., the dynamics of the
precorneal area and a tight corneal barrier), formulation factors (pH,
buﬀer, tonicity, viscosity, preservatives and stabilizers) and drug
characteristics (e.g., lipophilicity, charge, size and shape of the drug
molecule). The experimental techniques used in preclinical studies on
eye-related drug bioavailability generally focus on the cell- and tissue-
based models of ocular drug permeability (Pepic et al., 2014). For-
mulation factors aﬀecting ophthalmic drug permeability across corneal
barriers are very complex and depend on the total composition of the
ingredients in ophthalmic formulation, as well as on their interaction
and supramolecular organization (Davies, 2000). The use of surfactants
as excipients in ophthalmic formulations has long been a preferred
approach for enhancing drug solubility, improving solution clarity and
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stabilizing suspensions of drugs with poor solubility (Jiao, 2008).
However, there is still a lack of systematic investigations regarding the
eﬀects of surface active ophthalmic excipients on drug permeability
using standard conditions and testing protocols.
For other routes of application (i.e., oral), the in vitro or ex vivo drug
permeability results have shown that the use of surfactants may lead to
decreased, increased or unchanged drug permeability. For example,
Caco-2 permeability of ketoprofen and nadolol were found to be de-
creased by a non-ionic surfactant Pluronic® F68 due to drug-micelle
association in a concentration-dependent manner (Fischer et al.,
2011a). Furthermore, ex vivo jejunal permeability of digoxin as a P-gp
substrate was increased in the presence of a non-ionic surfactant Cre-
mophor® EL due to its potential P-gp inhibitory eﬀects, while the per-
meability of digoxin in the presence of Polysorbate 80 remained un-
changed due to the absence of P-gp inhibition over the concentration
range that was tested (Katneni et al., 2007). Moreover, slightly in-
creased in vitro corneal permeability of melatonin from Pluronic® F127
micelle systems compared to melatonin solution has been reported
(Hafner et al., 2015). In addition to the in vitro/ex vivo drug perme-
ability studies, signiﬁcant work has been done on studying the in vivo
eﬀect of drug-loaded nanocarriers containing surface active ophthalmic
excipients on eye-related bioavailability. Speciﬁcally, Pluronic® F127
micelle formulation has been shown to enhance the ocular bioavail-
ability of indomethacin (Chetoni et al., 2000) and pilocarpine (Pepic
et al., 2004) in a rabbit eye model. Equally, plasmid DNA/Pluronic®
F68 micelle formulation provided eﬃcient and stable intraocular
transfer of the functional gene in rabbit and mouse eye models (Liaw
et al., 2001). Furthermore, Pluronic®F127/chitosan micelle formulation
with dexamethasone demonstrated their potential to solubilize the
drug, enhance its precorneal retention and release it in a very eﬀective
manner while also reaching high eye-related bioavailability levels
(Pepic et al., 2010). Additionally, glucocorticoid nanosuspension for-
mulation stabilized with Pluronic® F68 has shown the enhanced rate
and extent of ophthalmic drug absorption, as well as the intensity of
drug action in a rabbit eye model (Kassem et al., 2007). The above-
mentioned results from the in vitro/ex vivo and in vivo studies may seem
contradictory because a particular non-ionic surfactant (e.g., Pluronic®
F68) has been shown to decrease in vitro permeability and increase in
vivo eye-related bioavailability. Even though diﬀerent models were
employed to test transcorneal drug transport, the in vivo studies have
been performed with the ﬁnal ophthalmic formulation in which the
solubility-permeability balance was optimized during formulation de-
velopment. Nonetheless, without a systematic and standardized ap-
proach allowing comparison of permeability/bioavailability data from
diﬀerent laboratories, it remains diﬃcult to precisely identify the eﬀect
of surface active ophthalmic excipients on transcorneal drug perme-
ability.
The aim of the present study is to systematically investigate the
eﬀects of type and concentration of surface active ophthalmic ex-
cipients on the corneal permeation of ophthalmic drugs using in vitro
and ex vivo corneal permeability models. For these purposes, four dif-
ferent types of surface active ophthalmic excipients at three diﬀerent
concentrations were investigated. Because non-ionic surfactants are
preferred for ophthalmic use, Polysorbate 80 (0.0005, 0.1 and 0.2%, w/
V), Tyloxapol (0.0005, 0.05 and 0.1%, w/V), Cremophor® EL (0.01, 1
and 2%, w/V) and Pluronic® F68 (0.025, 0.1 and 1%, w/V) were se-
lected and evaluated over the concentration range approved for oph-
thalmic use (FDA database: Inactive Ingredients). Additionally, a higher
concentration of Pluronic® F68 outside the approved concentration
range was tested since the in vivo ocular tolerability of Pluronic® F68 at
higher concentrations up to 20% was demonstrated (Al Khateb et al.,
2016; Asasutjarit et al., 2011). To obtain the information on the surface
active ophthalmic excipient self-organization over the investigated
concentration range and determine its inﬂuence on ophthalmic drug
permeation across in vitro and ex vivo corneal models, the concentra-
tion-dependent formation of self-aggregates was monitored.
2. Materials and methods
2.1. Reagents and chemicals
The following compounds were used as received: timolol maleate
(Sicor S.R.L., Milan, Italy), diclofenac sodium (Pharma Greven GmbH,
Greven, Germany), chloramphenicol (AppliChem, Darmstadt,
Germany), dexamethasone (Sanoﬁ, Paris, France), Polysorbate 80
(Sigma-Aldrich, Chemie GmbH, Steinheim, Germany), Tyloxapol
(Sigma-Aldrich, Chemie GmbH, Steinheim, Germany), Cremophor® EL
(BASF, Ludwigshafen, Germany) and Pluronic® F68 (Sigma-Aldrich).
For the preparation of Krebs-Ringer buﬀer (KRB), pH 7.4, the fol-
lowing substances were dissolved in double-distilled water: KCl
(0.4 mg/ml), NaCl (6.8 mg/ml), NaHCO3 (2.1 mg/ml), MgSO4×7H2O
(0.4mg/ml), D-glucose monohydrate (1.1 mg/ml) (all purchased from
Kemig, Zagreb, Croatia), CaCl2×2H2O (0.52mg/ml) (Sigma-Aldrich),
NaH2PO4×2H2O (0.158mg/ml) (Kemika, Zagreb, Croatia) and HEPES
(3.575mg/ml) (AppliChem).
The following substances were used for preparing the mobile phases
for UPLC analyses: NaH2PO4×H2O (Merck-Millipore, Billerica, MA,
USA), sodium acetate trihydrate (Kemika), and acetonitrile (Merck-
Millipore).
2.2. Preparation of test samples
Stock solutions of Polysorbate 80 (2%, w/V), Tyloxapol (2%, w/V)
and Cremophor® EL (5%, w/V) were prepared by dissolving surface
active ophthalmic excipients in KRB at room temperature. A stock so-
lution of Pluronic® F68 (2%, w/V) was prepared by dissolving Pluronic®
F68 in KRB at 4 °C overnight. Test samples of surface active ophthalmic
excipients without the addition of ophthalmic drugs were prepared by
dilution of stock solutions with KRB to obtain the following con-
centrations: 0.0005, 0.1 and 0.2%, (w/V) for Polysorbate 80, 0.0005,
0.05 and 0.1, (w/V) for Tyloxapol, 0.01, 1.0 and 2.0%, (w/V) for
Cremophor® EL and 0.025, 0.1 and 1.0%, (w/V) for Pluronic® F68.
Similarly, test samples of ophthalmic drugs without the addition of
ophthalmic excipients were prepared by dissolving a drug in KRB to
obtain the following concentrations: 100 μg/ml for timolol maleate,
150 μg/ml for diclofenac sodium, 150 μg/ml for chloramphenicol,
60 μg/ml for dexamethasone for in vitro permeability testing; 250 μg/ml
for timolol maleate, 400 μg/ml for diclofenac sodium, 400 μg/ml for
chloramphenicol and 60 μg/ml for dexamethasone for ex vivo perme-
ability testing. Test samples of ophthalmic drugs with the addition of
surface active ophthalmic excipients were prepared from surface active
ophthalmic excipient stock solutions with the ﬁnal constant ophthalmic
drug concentration (as deﬁned above) and variable surface active
ophthalmic excipient concentrations (as deﬁned above) by diluting
samples with KRB.
2.3. Hydrodynamic diameter measurements
The hydrodynamic diameter (dh) and polydispersity index (PDI) of
the surface active ophthalmic excipient solutions in the absence and in
the presence of ophthalmic drugs were determined by dynamic light
scattering (DLS) (Zetasizer 3000 HSA, Malvern Instruments, Malvern,
UK). The size measurements were performed at a scattering angle of 90°
and a temperature of 25 °C. The hydrodynamic diameter and PDI were
calculated from the autocorrelation function of the intensity of light
scattered from particles. The samples were ﬁltered through a 0.45-μm
membrane ﬁlter (Isolab, Wertheim, Germany) before measurement.
2.4. Cell culture conditions
HCE-T cells (RIKEN Cell Bank, Tsukuba, Japan) were cultivated in
DMEM/F12 medium (Lonza, Basel, Switzerland) supplemented with
fetal bovine serum (5%, Biosera, Boussens, France), insulin (5 μg/ml,
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Sigma-Aldrich), dimethyl sulfoxide (0.5%, Applichem), epidermal
growth factor (10 ng/ml, Sigma-Aldrich) and penicillin/streptomycin/
amphotericin B (Lonza). The cells were grown in a humidiﬁed atmo-
sphere containing 5% CO2 at 37 °C (Hafner et al., 2015). The culture
medium was changed every 48 h, and the cells were subcultured at
80%–90% conﬂuence.
2.5. Cultivation of the HCE-T cell-based model
The HCE-T cell-based model was cultivated according to the pro-
tocol described by Juretić and coworkers (Juretic et al., 2017), as well
as Hahne and Reichl (Hahne and Reichl, 2011). Brieﬂy, Transwell®
polycarbonate membrane cell culture inserts (3.0 μm pore size, 12-mm
diameter, surface area 1.12 cm2, Corning B.V. Life Sciences, Am-
sterdam, The Netherlands) were coated with rat tail type I collagen
(Sigma-Aldrich) and human ﬁbronectin (Sigma-Aldrich). HCE-T cells
(105 cells in 0.5 ml of culture medium) were seeded onto the coated
polycarbonate ﬁlter, and 1.5ml of culture medium were added to the
basolateral side. The cultivation of cells submerged in the medium was
conducted in the initial 4 to 7 days (until a sharp increase in the
transepithelial electrical resistance (TEER) was observed). Afterwards,
the exposure of cells to the air-liquid interface (ALI), shown to be cri-
tical for inducing the cell proliferation and diﬀerentiation into a mul-
tilayered epithelial structure, was performed during the following
3 days. The culture medium was changed every 2 days during the
submerged conditions and every day during exposure to the ALI. During
the ALI exposure, the inserts were lifted on a metal plate to increase the
basolateral volume to 2ml.
2.6. In vitro permeability assay
The in vitro permeability assay using the HCE-T cell-based model has
been described by Juretić and coworkers (Juretic et al., 2017). Brieﬂy,
the assay was performed directly in the Transwell® plates on a hor-
izontal orbital shaker (34 °C; 50 rpm) in KRB. After rinsing the cells
with KRB, the cells were incubated in the following 30min with 0.4 and
2ml of KRB in the donor and receptor compartment, respectively. The
KRB was later removed from the donor compartment, and 0.4 ml of a
test solution was added. The receptor compartment was sampled
(0.4 ml) at regular time intervals over 2 h and replaced at each time
point with the same volume of fresh warmed KRB (34 °C). The donor
solution was also sampled at the end of the permeability experiment.
2.7. Ex vivo permeability assay
The ex vivo permeability assay using freshly excised porcine corneas
has been described by Juretić and coworkers (Juretic et al., 2017).
Brieﬂy, for the purpose of the ex vivo permeability assay, fresh porcine
eyes were obtained from Large White pigs (age 6–7months, weight
90–115 kg, both female and male animals) from a local slaughterhouse.
Porcine eyeballs were enucleated, rinsed with an isotonic saline solu-
tion (NaCl 0.9%; B. Braun, Melsungen, Germany) and transported in
cold KRB in a container held on ice. The transport of porcine eyeballs
and the cornea excision were performed within 2 h of the animal's
death. The corneoscleral buttons were mounted on vertical diﬀusion
chambers (Standard Vertical Ussing/Diﬀusion Chambers, surface area
0.64 cm2, made from acrylic, Harvard Apparatus, Holliston, MA, USA),
with the epithelial side facing the donor compartment. The volume of
the donor and receptor compartment was 3.5 ml each. The corneas
were ﬁrst incubated for 30min in KRB at 34 °C, after which KRB from
the donor compartment was removed, and 3.5 ml of a test solution was
added. A sample (0.4 ml for dexamethasone, 1ml for timolol maleate,
diclofenac sodium and chloramphenicol) was withdrawn from the re-
ceptor compartment at regular time intervals over 5 h and replaced at
each time point with the same volume of fresh warmed KRB. The donor
solution was sampled at the end of the permeability experiment to
calculate the mass balance (%). The medium in both the donor and
receptor compartments was continuously oxygenated (2–3 bubbles/s),
which provided both the tissue oxygenation and mixing of the medium.
2.8. Transepithelial electrical resistance measurement
To monitor barrier integrity during the in vitro and ex vivo perme-
ability experiments, transepithelial electrical resistance (TEER) was
measured. For the TEER measurement of the HCE-T cell-based model,
an STX-2 electrode and EVOM (WPI Inc., Sarasota, FL, USA) were used.
Ag/AgCl electrodes in conjunction with an EC-825A Epithelial Voltage
Clamp (Warner Instruments, Hamden, CT, USA) were used for the ex-
cised cornea. The blank resistance was also measured and subsequently
subtracted to obtain the TEER of the HCE-T cell-based model and ex-
cised cornea-based model.
2.9. Data processing
The apparent permeability coeﬃcients (Papp in cm/s) of all com-
pounds were calculated by plotting the amount of permeated com-
pound per unit area versus time. The Papp was calculated from the linear
portion of the permeation curve according to the following equation
(Hahne et al., 2012; Toropainen et al., 2003):
=
∂
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is the permeation rate, A is the surface area of the permeation
barrier and Co is the initial concentration of a test compound in the
donor compartment (Eq. (1)).
For the purpose of examining the inﬂuence of the surface active
ophthalmic excipients on the ophthalmic drug permeability the PappR
value was calculated according to the following formula:
=
+
P
P ophthalmic drug ophthalmic excipient
P ophthalmic drug
R
( )
( )
app
app
app (2)
where Papp (ophthalmic drug+ ophthalmic excipient) is the mean of the
Papp value of an ophthalmic drug in the presence of a surface active
ophthalmic excipient and Papp (ophthalmic drug) is the mean of the Papp
value of an ophthalmic drug in the absence of a surface active oph-
thalmic excipient (Eq. (2)).
The mass balance (recovery) (%) was calculated according to the
following equation (Hubatsch et al., 2007):
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where Cd and Cr are the concentrations in the donor (d) and receptor (r)
compartment, respectively, at the start (0) or end (f) of the permeability
assay, Cr(t) is the concentration of the samples withdrawn from the
receptor compartment at diﬀerent time points, Vr and Vd are volumes
of the receptor and donor compartment, respectively, and Vs is the
volume of the sample withdrawn from the receptor compartment (Eq.
(2)).
2.10. Quantiﬁcation
The quantitative determination of ophthalmic drugs in the samples
from in vitro and ex vivo permeability experiments was performed by
Ultra-Performance Liquid Chromatography (UPLC) using an Agilent
Inﬁnity 1290 (Agilent, Santa Clara, CA, USA). The Acquity UPLC BEH
Shield RP18 Column (1.7 μm, 2.1 mm×50mm) (Waters, Milford, MA,
USA) was used, and the elution was isocratic. For the quantitative
analysis of each ophthalmic drug, the following UPLC conditions were
applied: timolol maleate (CH3COONa buﬀer pH 4.5/acetonitrile (85/
15%, V/V), 0.6 ml/min, 55 °C, 296 nm), diclofenac sodium (NaH2PO4
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buﬀer pH 2.5/acetonitrile (65/35%, V/V), 0.6ml/min, 55 °C, 276 nm),
chloramphenicol (CH3COONa buﬀer pH 4.5/acetonitrile (80/20%, V/
V), 0.4ml/min, 50 °C, 275 nm), and dexamethasone (CH3COONa buﬀer
pH 4.5/acetonitrile (67/33%, V/V), 0.4 ml/min, 50 °C, 254 nm). The
volume of injection was 20 μl for the receptor compartment samples.
For the donor compartment samples, the injection volume was 5 μl for
timolol maleate, diclofenac sodium, chloramphenicol and 10 μl for
dexamethasone. For each sequence, standard solutions were prepared
in duplicate and injected alternately. At least ﬁve standard solution
injections were performed in each injection sequence. System suit-
ability was evaluated according to the following criteria: the relative
standard deviation (RSD) of the detector response factor for all standard
solution injections in the sequence is no more than 3.0%, and the tailing
factor of ophthalmic drug peak is no more than 2.0. All UPLC methods
have been previously validated in terms of linearity, accuracy and re-
peatability (Juretic et al., 2017).
2.11. Statistical analysis
GraphPad Prism program 5.0 (GraphPad Software Inc., San Diego,
CA, USA; www.graphpad.com) was used for the statistical analysis.
Statistical data analyses were performed on in vitro and ex vivo per-
meability data using a one-way ANOVA followed by Dunnet's post-hoc
test with P < 0.05 set as the minimal level of signiﬁcance. The cor-
relation between the in vitro and ex vivo ophthalmic drug permeability
in the presence of surface active ophthalmic excipients was analyzed by
the Pearson correlation with P= 0.05 set as the minimal level of sta-
tistical signiﬁcance.
3. Results and discussion
3.1. In vitro/ex vivo ophthalmic drug permeability
The HCE-T cell-based model as an in vitro model for transcorneal
permeability studies has been widely accepted and well-characterized
(Kölln and Reichl, 2016; Reichl et al., 2011; Toropainen et al., 2003;
Verstraelen and Reichl, 2013, 2014). In our previous work, the varia-
bility in the barrier phenotype of HCE-T cell-based permeability model
has been reported and characterized in detail (Juretic et al., 2017). This
variability strongly inﬂuences the comparison of data from diﬀerent
laboratories and should be carefully considered in routine application
of HCE-T cell-based permeability models across both academic and
pharmaceutical industry research laboratories. Speciﬁcally, our model
consists of an apical lipophilic HCE-T epithelial monolayer and a ba-
solateral lipophilic monolayer of migrated HCE-T cells, which shows
suitable barrier properties (1700–2600Ω×cm2) and good correlation
with the drug permeability results obtained in the ex vivo corneal
model.
In this study, the permeability of ophthalmic drugs was evaluated in
the presence and absence of surface active ophthalmic excipients using
in vitro and ex vivo corneal models. The selected physicochemical
parameters of ophthalmic drugs and surface active ophthalmic ex-
cipients are shown in Tables 1 and 2, respectively. At the deﬁned per-
meability assay conditions (KRB pH 7.4), chloramphenicol and dex-
amethasone were neutral because these molecules do not have a
relevant ionizable group, while diclofenac and timolol were negatively
and positively charged, respectively. The Papp values for all ophthalmic
drugs obtained in both in vitro and ex vivo models (Table 3) in com-
parison with the Papp values obtained in our previous work (Juretic
et al., 2017) are reproducible, which indicates acceptable intra-la-
boratory variability of the models. Similar ex vivo Papp values have been
reported for timolol and dexamethasone (Hahne et al., 2012), as well as
the in vitro Papp value for timolol (Becker et al., 2008). However, Loch
and coworkers (Loch et al., 2012) reported around an 8-fold higher ex
vivo Papp value for dexamethasone and 2-fold lower ex vivo Papp value
for timolol. Furthermore, around a 3-fold higher ex vivo Papp value for
diclofenac was obtained in the study conducted by Pescina and col-
leagues (Pescina et al., 2015). Considering the literature data for
chloramphenicol, no studies on its permeability either in the in vitro or
ex vivo corneal model have been conducted to date. The variability in
the reported ophthalmic drug Papp values ex vivo might be ascribed to
the diﬀerences in the animal species characteristics (breed, age, sex),
the tissue collection and handling procedure, as well as the experi-
mental setup. Evidently, the observed inter-laboratory variability pro-
vides an opportunity for future collaboration among research labora-
tories in this area with the aim of overcoming the diﬃculties in
interpreting the results that are possibly leading to wrong conclusions.
3.2. The inﬂuence of surface active ophthalmic excipients on the in vitro/ex
vivo barrier properties
To monitor the possible concentration-dependent eﬀects of both
ophthalmic drugs and surface active ophthalmic excipients on the
barrier properties of in vitro and ex vivo corneal models, the TEER
measurements were performed starting from the application of test
samples to the end of the experiments. Prior to the addition of test
samples, the corneal models were characterized by diﬀerent initial
TEER values. For the in vitro model, the initial TEER values were in the
range of 2074–2510Ω×cm2, while for ex vivomodels, they were in the
range of 604–829Ω×cm2. The obtained initial TEER values for both
corneal models indicate suitable barrier properties for permeability
experiments (Toropainen et al., 2003). At the end of both in vitro and ex
vivo permeability experiments, both increases and decreases in the
TEER value for the ophthalmic drug test samples with or without
ophthalmic excipients compared to KRB alone were observed.
Table 1
Physicochemical parameters of ophthalmic drugs used in in vitro and ex vivo
permeability experiments.
Ophthalmic drug Mw of acid/
base moiety
(g/mol)
Aqueous
solubility
(mg/mL)
pKa
e LogDn-
octanol/buﬀer
pH7.4
e
Timolol maleate 316.42 30–100a 9.21 −0.20
Diclofenac sodium 296.15 5.15b 3.80 1.10
Chloramphenicol 323.13 2.5c Without
ionisable
groups
1.08
Dexamethasone 392.46 0.093d Without
ionisable
groups
1.50
a Brittain (2012).
b Chuasuwan et al. (2009).
c Anderson et al. (2012).
d Colombo et al. (2017).
e References for verifying the source of the ophthalmic drug pKa and logD
values are provided by Juretic et al. (2017).
Table 2
Selected characteristics of surface active ophthalmic excipients used in in vitro
and ex vivo permeability experiments.
Surface active
ophthalmic
excipient
Mw (g/
mol)a
Hydrophilic-
lipophilic balance
(HLB)a
Maximal concentrations in
diﬀerent ophthalmic dosage
forms approved by FDAb
Polysorbate 80 1310 15.0 Solution; 0.2%
Suspension; 0.1%
Emulsion; 4.0%
Tyloxapol 4500 12.5 Solution; 0.1%
Suspension; 0.1%
Cremophor® EL 2560 12–14 Solution; 5%
Pluronic® F68 8400 29 Solution; 0.1%
a Jiao (2008).
b FDA Drug Databases (n.d.).
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However, the observed diﬀerences in the TEER values of approximately
30% compared to KRB alone were not statistically signiﬁcant (data not
shown), which indicates that neither the test samples without oph-
thalmic excipients nor the test samples with ophthalmic excipients
signiﬁcantly aﬀected the barrier properties of both models under the
investigated experimental conditions.
3.3. The self-aggregation properties of surface active ophthalmic excipients
To obtain the information on the self-aggregation properties of the
surface active ophthalmic excipients in a complex KRB solution in the
presence of ophthalmic drugs, the dynamic light scattering measure-
ments were performed (Table 4). At the lowest concentration of the
tested surface active ophthalmic excipients (i.e., 0.0005%, w/V, for
both Polysorbate 80 and Tyloxapol, 0.01%, w/V, for Cremophor® EL,
0.025% as well as 0.1%, w/V, for Pluronic® F68) a poor signal-to-noise
ratio was observed, which indicates the absence of self-aggregates in
these test samples. However, at higher concentrations of Polysorbate 80
(0.1 and 0.2%, w/V), Tyloxapol (0.05 and 0.1%, w/V) and Pluronic®
F68 (1%, w/V), self-aggregates of variable sizes were observed. None-
theless, the quality control parameters of the measurements suggested
the existence of metastable self-aggregates instead of stable micelles. In
contrast, for two higher concentrations of Cremophor® EL (1 and 2%,
w/V), the quality control parameters of the measurements suggested
the presence of stable micelles with suitable dispersity. The comparable
results of the dynamic light scattering measurements of the surface
active ophthalmic excipients in KRB solution in the absence of oph-
thalmic drugs (data not shown) suggest that the presence of ophthalmic
drugs did not inﬂuence the size and dispersity properties of surfactant
self-aggregates/micelles.
3.4. The inﬂuence of surface active ophthalmic excipients on the in vitro/ex
vivo ophthalmic drug permeability
The results of the in vitro and ex vivo permeability studies of four
ophthalmic drugs in the presence of surface active ophthalmic ex-
cipients are shown in Table 4 and are presented as the ratio between the
Papp values of an ophthalmic drug in the presence and absence of sur-
face active ophthalmic excipients (PappR). In order to determine that no
signiﬁcant loss of a drug occurs during the in vitro and ex vivo perme-
ability studies (due to, e.g., drug adsorption to plastic surfaces, drug
degradation/metabolisation, drug accumulation inside corneal barrier)
the mass balance was calculated. The mass balance for all ophthalmic
drugs in both in vitro and ex vivo corneal models was in the range of
80% to 100% (data not shown), which was shown to result in accep-
table approximation of the ophthalmic drug Papp value (Hubatsch et al.,
2007). Moreover, no statistical signiﬁcance was found in the diﬀerence
between the mass balance for an ophthalmic drug in the absence and
the mass balance for an ophthalmic drug in the presence of an oph-
thalmic excipient. In Fig. 1, the permeation proﬁles of one of the
ophthalmic drug in the absence and in the presence of one of the sur-
face active ophthalmic excipient, both in in vitro and ex vivo corneal
models, are shown. It can be observed that the presence of Cremophor®
EL (1%, w/V) had no eﬀect on the shape of the diclofenac permeation
curve regarding the linearity of the portion of the curve reﬂecting the
steady-state conditions. However, the slope of the linear portion of the
curve in the presence of Cremophor® EL was reduced, yielding lower
diclofenac Papp value compared to the diclofenac Papp value in the ab-
sence of Cremophor® EL. The presented permeation curves are re-
presentative of all the in vitro and ex vivo permeation proﬁles obtained
in this study. More precisely, in the presence of a surface active oph-
thalmic excipient the linearity of the portion of the ophthalmic drug
permeation curve characteristic for steady-state conditions has been
preserved, however, the slope of the linear portion of the curve has
been either decreased, increased or unchanged, which resulted in the
calculated lower, higher or equal Papp value, respectively, compared to
the Papp value of an ophthalmic drug in the absence of a surface active
ophthalmic excipient.
The permeability of timolol in the presence of all surface active
ophthalmic excipients over the whole concentration range showed only
slight changes in both in vitro and ex vivo corneal models. However,
these slight changes of the Papp value of timolol have not been statis-
tically signiﬁcant, which demonstrates that the permeability of timolol
has not been aﬀected by the presence of surface active ophthalmic
excipients. A similar trend of PappR values was observed for chlor-
amphenicol. A statistically signiﬁcant 41% increase in the chlor-
amphenicol Papp value, however, was observed in the presence of 0.2%
(w/V) Polysorbate 80 in the in vitro but not in the ex vivo corneal model.
Moreover, at the higher concentrations of Cremophor® EL that were
investigated (i.e., 1% and 2%, w/V), a statistically signiﬁcant decrease
of the chloramphenicol Papp value up to 50% was detected in the ex vivo
model. Conversely, no statistically signiﬁcant inﬂuence on the perme-
ability of chloramphenicol was detected for the same concentrations of
Cremophor® EL in the in vitro corneal model.
As opposed to timolol and chloramphenicol, a strong inﬂuence of
Polysorbate 80, Tyloxapol and Cremophor® EL on the permeability of
diclofenac was established in both the in vitro and ex vivo corneal
models. At the lowest concentration of these surface active ophthalmic
excipients, no statistically signiﬁcant change in the diclofenac Papp
value was observed. At higher surface active ophthalmic excipient
concentrations, however, the diclofenac Papp values substantially de-
creased. Speciﬁcally, the observed Papp value decrease was approxi-
mately 30% in the presence of Polysorbate 80 (0.1 and 0.2%, w/V),
approximately 50% in the presence of Tyloxapol (0.05 and 0.1%, w/V)
and up to approximately 90% in the presence of Cremophor® EL (1 and
2%, w/V). The extent of the permeation-depressing eﬀect of the three
surface active ophthalmic excipients in the in vitro and ex vivo corneal
models was comparable. Pluronic® F68, on the other hand, at a con-
centration of 1% (w/V) reduced the diclofenac Papp value in the ex vivo,
but not in the in vitro corneal model. The 35%-reduction in the diclo-
fenac ex vivo Papp value, however, was not statistically signiﬁcant. At
the lower concentrations tested in this study, Pluronic® F68 showed no
inﬂuence on diclofenac permeability in both corneal models.
The permeability of dexamethasone in the presence of surface active
ophthalmic excipients was aﬀected in a manner similar to the perme-
ability of diclofenac. At the lowest concentration of Polysorbate 80,
Table 3
Apparent permeability coeﬃcients (Papp) of ophthalmic drugs and corresponding transepithelial electrical resistance (TEER) values for in vitro and ex vivo corneal
models. All values represent the mean ± SD (n= 11–22).
In vitro corneal model Ex vivo corneal model
Papp (10
−7 cm/s) TEERa (Ω×cm2) Papp (10
−7 cm/s) TEERa (Ω×cm2)
Timolol maleate 134.23 ± 17.79 2274 ± 1058 107.68 ± 21.28 756 ± 259
Diclofenac sodium 129.09 ± 12.36 2279 ± 1372 17.38 ± 3.74 816 ± 346
Chloramphenicol 18.79 ± 3.11 2510 ± 1207 7.62 ± 2.81 829 ± 464
Dexamethasone 32.02 ± 6.09 2074 ± 1085 8.82 ± 2.97 604 ± 273
a Measured at the start of permeability experiments.
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Tyloxapol and Cremophor® EL, the slight changes in the dexamethasone
Papp value were not statistically signiﬁcant, whereas at higher con-
centrations, the permeability-decreasing eﬀect of surface active oph-
thalmic excipients was observed. More precisely, Polysorbate 80 and
Tyloxapol at the highest concentrations of 0.2% and 0.1% (w/V) re-
duced the dexamethasone Papp value by approximately 30%–40% in
both corneal models. The observed Papp reduction, however, was not
statistically signiﬁcant in all cases. As was observed for diclofenac so-
dium, Cremophor® EL of all of the tested surface active ophthalmic
excipients showed the strongest inﬂuence on the permeation of dex-
amethasone. There was up to a 60%–70% decrease in the dex-
amethasone Papp value in the presence of 1% and 2% (w/V) of
Cremophor® EL in both corneal models.
The negative eﬀect of surface active excipients on the permeability
of drugs with poor water solubility has already been reported and was
primarily ascribed to the interaction of surface active excipient micelles
and drugs. More precisely, the incorporation of lipophilic drugs into the
hydrophobic core of surface active excipient micelles reduces the
fraction of free drug available for permeation across a biological bar-
rier, which results in a decrease in the overall drug permeability
(Fischer et al., 2011b; Yano et al., 2010). In our study, the lowest
concentration of surface active ophthalmic excipients without self-ag-
gregates demonstrated no inﬂuence on ophthalmic drug permeability.
However, at higher concentrations of surface active ophthalmic ex-
cipients, at which dynamic light scattering measurements pointed to
the presence of metastable self-aggregates or stable micelles, a strong
Table 4
The inﬂuence of surface active ophthalmic excipients on the permeability of ophthalmic drugs (presented as PappR value) in in vitro and ex vivo corneal models. The
self-aggregation properties of the surface active ophthalmic excipients in the presence of ophthalmic drugs were monitored by dynamic light scattering (DLS) and are
presented as hydrodynamic diameter (dh) and polydispersity index (PDI).
Ophthalmic drug Surface active ophthalmic
excipient
Surface active ophthalmic excipient concentration (%,
m/V)
PappR
In vitro
PappR
Ex vivo
dh (nm) (mean ± SD) PDI (mean ± SD)
Timolol maleate Polysorbate 80 0.0005 0.97 0.89 nd nd
0.1 1.13 0.97 17.1 ± 0.4 0.263 ± 0.01
0.2 1.33 0.99 14.7 ± 0.3 0.251 ± 0.014
Tyloxapol 0.0005 0.92 0.80 nd nd
0.05 1.12 0.88 12.3 ± 0.2 0.233 ± 0.023
0.1 1.08 1.23 16.1 ± 1.1 0.239 ± 0.020
Cremophor® EL 0.01 1,19 1.26 nd nd
1 1.04 1.11 14.0 ± 0.5 0.096 ± 0.083
2 0.95 1.00 13.3 ± 0.1 0.076 ± 0.012
Pluronic® F68 0.025 0.94 1.00 nd nd
0.1 0.95 0.93 nd nd
1 0.87 0.94 13.9 ± 1.8 0.220 ± 0.023
Diclofenac sodium Polysorbate 80 0.0005 0.88 1.17 nd nd
0.1 0.66⁎ 0.73 11.6 ± 1.3 0.192 ± 0.005
0.2 0.68⁎ 0.74 10.5 ± 0.3 0.196 ± 0.065
Tyloxapol 0.0005 0.98 0.87 nd nd
0.05 0.54⁎ 0.45⁎ 15.2 ± 1.3 0.230 ± 0.021
0.1 0.42⁎ 0.53⁎ 10.2 ± 1.7 0.153 ± 0.023
Cremophor® EL 0.01 0.92 0.92 nd nd
1 0.26⁎ 0.18⁎ 14.4 ± 0.1 0.165 ± 0.004
2 0.18⁎ 0.09⁎ 13.2 ± 0.3 0.043 ± 0.024
Pluronic® F68 0.025 0.88 0.78 nd nd
0.1 1.02 0.86 nd nd
1 1.14 0.65 12.5 ± 3.3 0.184 ± 0.039
Chloramphenicol Polysorbate 80 0.0005 0.94 1.21 nd nd
0.1 0.98 1.15 16.8 ± 0.7 0.252 ± 0.009
0.2 1.41⁎ 1.09 11.9 ± 0.7 0.227 ± 0.061
Tyloxapol 0.0005 0.85 0.84 nd nd
0.05 0.88 1.01 21.7 ± 1.0 0.272 ± 0.001
0.1 0.91 0.91 15.7 ± 2.2 0.230 ± 0.035
Cremophor® EL 0.01 0.94 0.86 nd nd
1 0.88 0.62⁎ 14.1 ± 0.0 0.121 ± 0.006
2 0.81 0.47⁎ 13.2 ± 0.1 0.072 ± 0.033
Pluronic® F68 0.025 0.92 1.18 nd nd
0.1 1.07 1.12 nd nd
1 1.09 0.96 12.5 ± 0.7 0.216 ± 0.001
Dexamethasone Polysorbate 80 0.0005 0.79 1.27 nd nd
0.1 0.85 0.72 14.6 ± 0.7 0.207 ± 0.011
0.2 0.66 0.59 13.3 ± 1.0 0.217 ± 0.016
Tyloxapol 0.0005 1.14 1.08 nd nd
0.05 0.92 1.24 17.09 ± 1.2 0.299 ± 0.019
0.1 0.59⁎ 0.76 14.3 ± 0.9 0.249 ± 0.021
Cremophor® EL 0.01 1.08 1.02 nd nd
1 0.54⁎ 0.43⁎ 13.7 ± 0.3 0.108 ± 0.048
2 0.41⁎ 0.27⁎ 13.2 ± 0.1 0.056 ± 0.033
Pluronic® F68 0.025 0.90 0.80 nd nd
0.1 0.96 0.90 nd nd
1 1.26 0.80 26.0 ± 2.1 0.383 ± 0.018
PappR= ratio between the mean value of the apparent permeability coeﬃcient of an ophthalmic drug in the presence and the mean value of the apparent per-
meability coeﬃcient of an ophthalmic drug in the absence of a surface active ophthalmic excipient (n=3). nd= self-aggregates of surface active ophthalmic
excipients not detected.
⁎ Statistically signiﬁcant diﬀerence of the Papp value of an ophthalmic drug in the presence of a surface active ophthalmic excipient compared to the Papp value of
an ophthalmic drug in the absence of a surface active ophthalmic excipient (P < 0.05).
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permeability-depressing eﬀect for certain surface active ophthalmic
excipient-drug combinations was observed. This outcome indicates that
the association of drugs with self-aggregates of surface active oph-
thalmic excipients, which results in reduced drug thermodynamic ac-
tivity, might be responsible for the observed decrease in drug perme-
ability. Of the four tested surface active ophthalmic excipients,
Cremophor® EL exerted the strongest permeability-decreasing eﬀect
followed by Polysorbate 80 and Tyloxapol, which both reduced the
ophthalmic drug permeation rate to a smaller but comparable extent
over the tested concentration range. In contrast, Pluronic® F68 de-
monstrated no statistically signiﬁcant inﬂuence on the permeability of
the tested ophthalmic drugs over the whole concentration range. Even
at the highest concentration of 1% (w/V), at which the presence of self-
aggregates was established, the Papp value changes were not statistically
signiﬁcant and pointed to the absence of interaction between Pluronic®
F68 and the ophthalmic drugs. The results are in agreement with the
previously published study in which both Polysorbate 80 and Cremo-
phor® EL over the concentration range of 0.01–1% (w/V) reduced the
permeation rate of low-soluble drugs in an ex vivo rat jejunal model
(Katneni et al., 2007). Furthermore, Pluronic® F68 at a concentration of
1% (w/V) was reported to have no inﬂuence on the permeability of
ketoprofen and nadolol in in vitro intestinal epithelial models. However,
at higher concentrations of Pluronic® F68 up to 5% (w/V), the inter-
action between the drugs and Pluronic® F68 micelles resulted in the
reduced drug permeation rate (Fischer et al., 2011a; Fischer et al.,
2011b).
In this study, the permeability of a weakly basic drug timolol
characterized by high solubility and low lipophillicity was not aﬀected
by the presence of surface active ophthalmic excipients over the entire
concentration range that was tested. On the other hand, for the more
lipophilic and low soluble neutral drug dexamethasone, a permeability
decrease in the presence of self-aggregates of surface active ophthalmic
excipients was observed that was in line with the results of the afore-
mentioned permeability studies. Somewhat unexpectedly, however, the
reduction in the permeation rate in the presence of self-aggregates of
surface active ophthalmic excipients was even greater for the weakly
acidic drug diclofenac, which is characterized by higher solubility and
lower lipophilicity compared to dexamethasone. However, the overall
results of the in vitro and ex vivo permeability studies of the neutral
compound chloramphenicol, which has solubility and lipophilicity
properties comparable to diclofenac, point to the absence of its inter-
action with self-aggregates of surface active ophthalmic excipients.
Although it has been shown that the surfactant micelles preferentially
solubilize more lipophilic compounds, the situation might become more
complex for acidic and basic drugs at physiological pH when the io-
nized molecular form is dominant. More precisely, solubilization stu-
dies have demonstrated that under certain conditions, the ionized form
may exhibit even greater solubility in micelles than its unionized
Fig. 1. The permeation proﬁles of diclofenac sodium in the absence and in the presence of Cremophor® EL (1%, w/V), in in vitro (A) and ex vivo (B) corneal models.
Data are expressed as mean ± SD (n= 3).
M. Juretić et al. European Journal of Pharmaceutical Sciences 120 (2018) 133–141
139
equivalent (Li et al., 1999).
In contrast to the permeability-decreasing eﬀect of Polysorbate 80
in the in vitro permeability studies of diclofenac sodium and dex-
amethasone, a statistically signiﬁcant increase of the chloramphenicol
Papp value in the presence of 0.2% (w/V) Polysorbate 80 in the in vitro
corneal model was detected. The permeability-enhancing eﬀect of
surface active excipients, including Polysorbate 80, in the in vitro and ex
vivo models for both hydrophilic and lipophilic compounds has been
reported in the literature. The permeability enhancement was either
related to the modulation of tight junctions, which increases para-
cellular transport of a hydrophilic compound (Ujhelyi et al., 2012), or
to the interference with the activity of inﬂux and eﬄux membrane
transporters, which increases transcellular transport of more lipophilic
compounds (Katneni et al., 2007). To the best of our knowledge, the
literature data regarding the in vitro and ex vivo permeability of chlor-
amphenicol, which includes the mechanism of its transport across
corneal or other biological barriers, is lacking. The potential mechanism
of the Polysorbate 80-induced increase of chloramphenicol perme-
ability, therefore, has yet to be investigated.
3.5. The in vitro/ex vivo correlation of the inﬂuence of surface active
ophthalmic excipients on the ophthalmic drug permeability
In Fig. 2, the correlation between the in vitro and ex vivo PappR va-
lues for four ophthalmic drugs in the presence of three diﬀerent con-
centrations of four surface active ophthalmic excipients obtained in this
study is shown. A statistically signiﬁcant and strong correlation be-
tween the in vitro and ex vivo PappR values was observed (Pearson's
r=0.74, P < 0.0001), which additionally conﬁrms the comparability
of the in vitro and ex vivo permeability results obtained in this study.
The strong in vitro and ex vivo PappR value correlation shows that the
observed changes of the ophthalmic drug in vitro and ex vivo perme-
ability in the presence of surface active ophthalmic excipients were
detected as a Papp value decrease for the majority of surface active
ophthalmic excipient-drug combinations, and the decreases had com-
parable magnitudes. Furthermore, the results indicate that the eﬀects of
the tested surface active ophthalmic excipients on the ophthalmic drug
permeability might be mediated by the same mechanism in both cor-
neal models. The results of this study demonstrate that with further
optimization these in vitro and ex vivo corneal models have the potential
to be used for permeability testing and ocular bioavailability evaluation
in the early phases of ophthalmic product development.
4. Conclusions
Ophthalmic product development requires an in-depth under-
standing of the factors aﬀecting ophthalmic drug permeability across
corneal barriers. In this study, four surface active ophthalmic excipients
commonly used in ophthalmic formulations have been evaluated for the
inﬂuence on the permeability of four ophthalmic drugs using in vitro
and ex vivo corneal models. The presence of surface active ophthalmic
excipients over the investigated concentration range resulted in either
no change or a decrease in ophthalmic drug in vitro and ex vivo per-
meability. The observed permeability-depressing eﬀect of surface active
ophthalmic excipients might be caused by the association of ophthalmic
drugs with self-aggregates of surface active ophthalmic excipients, as
indicated by dynamic light scattering measurements. A strong correla-
tion of the inﬂuence of surface active ophthalmic excipients on oph-
thalmic drug permeability was observed between in vitro and ex vivo
corneal models, which indicates that the observed eﬀects had com-
parable sizes and were mediated by the same mechanism in both cor-
neal models. The structural diﬀerences in the in vitro and ex vivo corneal
barrier (e.g. the lack of stroma in the in vitro model), as well as the
potential functional diﬀerences (e.g. the expression of membrane
transporters) may possibly explain the observed in vitro/ex vivo corre-
lation discrepancies, however, further more detailed histomorpholo-
gical, functional and mechanistic permeability studies are required for
establishing the exact underlying cause.
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Given the direct application of topical ophthalmic formulations to corneal surface, 
ophthalmic formulation composition, including the type and concentration of each excipient, 
their interaction and supramolecular organization, largely impacts the ophthalmic drug 
permeation through corneal barrier and consequently its eye-related bioavailability. 
Understanding the influence of the ophthalmic excipients on ocular 
permeability/bioavailability is, therefore, of crucial importance for the efficient development 
of topical ophthalmic products. Ideally, the establishment of a biopharmaceutical 
classification system categorizing the ophthalmic excipients with respect to their effect on 
ophthalmic drug permeability/bioavailability would enable more prudent selection of the type 
and concentration of ophthalmic excipients during the early phase of ophthalmic formulation 
composition optimization, with positive impact on the economical and ethical aspect of the 
overall topical ophthalmic product development. 
In addition to their application in conventional topical ophthalmic formulations, the 
excipients approved for the ophthalmic use, as well as novel excipients, are increasingly 
utilized in the development of innovative nanosystem-based topical ophthalmic formulations. 
Under particular conditions excipients specifically interact with each other to form 
supramolecular nano-sized structures, which have the potential to circumvent the ocular 
barriers limiting the efficacy of conventional topical ophthalmic formulations. In the 
nanosystem development excipients can serve as nanosystem structural components (Mandal 
et al., 2017), stabilizing agents to stabilize energetically unstable nanosystems by adsorption 
to nanosystem surface (Ammar et al., 2009; Sharma et al., 2016) or coating agents to direct 
the nanosystem delivery to the target site (Singh and Lillard, 2009). The main goal of the 
nanosystem design is to achieve prolonged drug precorneal residence time, sustained drug 
release and enhanced permeation of a drug across corneal barrier, with the result of improved 
drug eye-related bioavailability and therapeutic outcome (Reimondez-Troitiño et al., 2015). 
Knowledge of the ophthalmic excipients influence on the ophthalmic drug permeability 
would surely contribute to their more efficient selection in the process of the nanosystem 
composition optimization in the early phase of development. However, for the evaluation of 
biopharmaceutical properties of the final nano-sized supramolecular structures of excipients, 
in vitro studies of their interactions with the precorneal biological environment are needed.  
For small moderately lipophilic molecules, which still comprise the majority of 
commercially available ophthalmic drugs, the corneal barrier represents the main route to 
their target site. The evaluation of drug permeability across the corneal barrier represents, 
therefore, an essential step in the assessment of drug eye-related bioavailability. The in vitro 
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corneal cell-based and ex vivo tissue-based permeability models for eye-related bioavailability 
prediction have the potential to substantially improve the screening process of ophthalmic 
drug and formulation candidates in the early phases of development and to contribute thereby 
to higher efficiency of the overall topical ophthalmic product development. However, detailed 
characterization and standardization of the in vitro and ex vivo models is a prerequisite for 
their implementation in the routine use in pharmaceutical industry during preclinical phases of 
topical ophthalmic product development (Pepić et al., 2014).  
Different cell-based models mimicking the corneal epithelium or the entire corneal 
tissue using different cell lines and culture conditions have been developed and used for the 
permeability testing of ophthalmic drugs and drug delivery systems (Attama et al., 2008; Ban 
et al., 2003; Chang et al., 2000; Hahne et al., 2012; Hahne and Reichl, 2011; Mohan et al., 
2003; Reichl and Müller-Goymann, 2003; Tegtmeyer et al., 2001; Toropainen et al., 2001). 
However, cell-based models using the HCE-T cell line have been the most extensively 
characterized regarding the membrane porosity and intercellular pore size, paracellular and 
transcellular passive transport, the expression of membrane transporters and metabolic 
enzymes (Becker et al., 2007; Hahne and Reichl, 2011; Kölln and Reichl, 2016a, 2016b, 2012, 
Toropainen et al., 2003, 2001; Vellonen et al., 2010). Nonetheless, variability of the barrier 
properties of the HCE-T cell-based models, most probably related to the use of different 
culture conditions, has been reported in the literature (Hahne and Reichl, 2011; McCanna et 
al., 2008; Nagai et al., 2008; Takezawa et al., 2011; Toropainen et al., 2001), which 
substantially complicates the comparison of the HCE-T cell-based permeability results from 
different laboratories, potentially resulting in the misleading conclusions. Further studies are, 
therefore, required to identify and standardize the cultivation factors with critical influence on 
the HCE-T cell barrier phenotype, with the final goal of establishing a standardized in vitro 
corneal model yielding reliable and reproducible permeability results. 
The aim of this thesis was to evaluate the effect of unimers and supramolecular 
aggregates of the ophthalmic excipients on corneal barrier properties and ophthalmic drug 
permeability, using in vitro (HCE-T cell-based) and/or ex vivo (excised porcine cornea) 
corneal models. For this purpose, further characterization of the barrier phenotype of the 
HCE-T cell-based model, cultivated according to the previously developed and optimized 
protocol, was performed (Hahne and Reichl, 2011). The culture medium, support-coating 
materials, cell-seeding density, volumes of the medium in the apical and basolateral 
compartment and the duration of ALI exposure, all of which were determined to influence the 
corneal model barrier properties (Hahne and Reichl, 2011), were used as defined in the 
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protocol. However, contradictory results on the optimal pore size of the supporting membrane 
(i.e., 0.4 µm (Toropainen et al., 2001) and 3.0 µm (Hahne and Reichl, 2011) pore size) have 
been reported in the literature. Polycarbonate membranes of two different pore sizes, 0.4 and 
3.0 µm, were thus used to investigate the pore size influence on barrier properties of the HCE-
T cell-based model, considering the model histological structure, barrier tightness and the 
permeability of five ophthalmic compounds (timolol maleate, diclofenac sodium, 
chloramphenicol, dexamethasone and fluorescein sodium) differing in physicochemical 
properties. For the barrier tightness evaluation, a well-established method of transepithelial 
electrical resistance (TEER) monitoring was performed, which analyzes the overall electrical 
resistance of a cell barrier as a measure of the tight connections between the epithelial cells 
(tight junctions) (Saaber et al., 2014).  
Two different HCE-T barrier phenotypes depending on the pore size were revealed, 
namely Model I (0.4 µm pore size) and Model II (3.0 µm pore size). 
Model I consisted of a multilayered epithelium on top of the supporting polycarbonate 
membrane. Despite the formation of a multilayered epithelium reflecting well the structural 
properties of the corneal epithelium in vivo, TEER measurements revealed weak barrier 
function for Model I, which points to the lack of expression or dysfunction of intercellular 
tight-junctional complexes. As a result of insufficient barrier properties, Model I exhibited 
substantially higher permeability of all the tested ophthalmic compounds, compared to both 
Model II and excised porcine cornea, which confirms lack of its suitability in predicting 
transcorneal drug permeation. 
On the other hand, Model II was comprised of an apical lipophilic monolayer of HCE-
T cells overlying the supporting membrane and a basolateral lipophilic monolayer of migrated 
HCE-T cells. Model II was characterized by improved barrier tightness compared to both 
Model I and excised porcine cornea, which might possibly be related to the presence of a 
basolateral layer of migrated HCE-T cells, since it was shown that migrated cells exhibit 
polarized phenotype and tight-junctional complexes (Tucker et al., 1992). Moreover, Model II 
reflected better the barrier properties of the excised porcine cornea in terms of permeation 
behavior of ophthalmic compounds. Model II exhibited ophthalmic compounds permeability 
more similar to the one for excised porcine cornea. Moreover, the ability to discriminate 
between the permeability of timolol and fluorescein, determined to be highly and poorly 
permeable compounds in excised porcine cornea, was significantly improved for Model II. 
The results of the histomorphological and functional characterization of the HCE-T 
cell-based model conducted in this thesis demonstrate significant variability of the model 
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regarding the histological structure and tightness of the corneal barrier formed under 
particular cultivation conditions (Hahne and Reichl, 2011; Toropainen et al., 2001). It has, 
however, been demonstrated that, although initially derived from a single clone, the HCE-T 
cells undergo genomic alterations in culture resulting in a heterogenous cell line composed of 
a number of cell subpopulations, which were determined to differ in morphology, cell growth 
kinetics and tight barrier forming properties (Yamasaki et al., 2009). Moreover, it has been 
shown that migration through filter pores might be selective and limited to a more invasive 
subpopulation of parental cell line (Tucker et al., 1992), which might additionally explain the 
observed differences in HCE-T cell line behavior. These findings highlight the obvious need 
for more thorough investigation of the influence of cultivation conditions on HCE-T cell line 
and HCE-T cell-based corneal model phenotype, which is of crucial importance for 
establishing reproducible and reliable HCE-T cell-based permeability model. 
Passive permeation across biological membranes has been shown to be influenced by 
physicochemical properties such as molecular size, partition coefficient, hydrogen bond 
formation capacity and permeant charge (Kidron et al., 2010). The difference in the partition 
coefficient and charge of compounds might explain the observed permeability rank order of 
the ophthalmic compounds in Model II and excised porcine cornea, with higher partition 
coefficient and positive charge facilitating the permeation through lipophilic and negatively 
charged corneal barrier. However, some discrepancies in the permeability rank order for 
Model II and excised porcine cornea were observed, which may be explained by the lack of 
stroma in Model II, shown to be a rate-limiting permeation barrier for highly lipophilic 
compounds (Shih and Lee, 1990), and potential functional differences in terms of the 
expression of membrane transporters. More detailed mechanistic permeability studies 
regarding the transport mechanism of the tested compounds and the barrier role of particular 
structures of the corneal models are required to clarify the in vitro/ex vivo permeability 
differences. Nonetheless, correlation analysis of the ophthalmic compounds permeability for 
Model II and excised porcine cornea resulted in very strong and statistically significant 
correlation. This, in addition to improved barrier tightness, points to the suitability of the 
Model II for evaluating transcorneal permeation of ophthalmic drugs alone and ophthalmic 
drugs in the presence of different ophthalmic excipients. 
Regarding the potential interaction of excipients with tight-junctional complexes of 
corneal epithelial barrier and their consequent effect on the drug transcorneal permeability, 
the suitability of the in vitro Model II was further determined by establishing the 
interdependence of temperature, TEER and the permeability of paracellular and transcellular 
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compounds. The TEER values were shown to be inversely related to temperature changes, in 
accordance with the reports in the literature (González-Mariscal et al., 1984), which allowed 
for permeability testing of the two compounds across corneal barrier of different TEER values, 
indicating its different tight-junctional integrity and paracellular leakiness. The permeability 
of a hydrophilic compound fluorescein sodium was shown to be inversely correlated with 
TEER of the Model II at both temperature studied, which confirms the paracellular transport 
as the main mechanism of its permeation across corneal epithelial barrier. On the other hand, 
no influence of TEER on the permeability of a lipophilic compound rhodamine B was found, 
which points to its transcellular transport across corneal epithelial barrier (Hahne et al., 2012). 
However, higher permeability was observed at 37°C than at 25°C, most probably due to faster 
transcellular diffusion of rhodamine B at higher temperature. The established relation between 
TEER and fluorescein sodium and rhodamine B permeability indicates the suitability of the 
Model II for the evaluation of the interaction of excipients with corneal epithelial barrier and 
its related impact on ophthalmic drug permeability. It can, moreover, serve as a basis for 
studying the mechanism of transport across corneal barrier of both ophthalmic drugs alone 
and ophthalmic drugs incorporated into drug delivery nanosystems. 
For evaluating the influence of excipients on biopharmaceutical properties of different 
drug delivery nanosystems for melatonin, an intraocular pressure (IOP)-reducing agent, 
Model II in conjunction with other in vitro biopharmaceutical studies was used. Melatonin-
loaded lecithin/chitosan nanoparticles (MLC) and Pluronic
®
 F127/chitosan micelles (MFC) 
were prepared and characterized, with the final aim of developing a nanosystem which would 
prolong precorneal residence time and promote transcorneal transport of melatonin, with 
consequent intraocular activity enhancement. The formation of nanosystems arises from 
electrostatic interaction between the negatively charged lecithin and positively charged 
chitosan in MLC (Hafner et al., 2009), and both electrostatic and hydrogen bond interaction 
between the electronegative oxygen atoms of Pluronic
®
 F127 and electropositive chitosan 
chains in MFC (Pepić et al., 2010). Lecithin, a natural lipid mixture of phospholipids, has 
been frequently used as excipient in the preparation of various nanosystems, and was, due to 
lipophilic nature, expected to provide high loading of lipophilic drugs and sustained drug 
release (Bhatta et al., 2012). Pluronic
®
 F127, a polyoxyethylated nonionic surfactant approved 
for the ophthalmic use, was suggested to promote the drug permeation across corneal 
epithelial barrier (Pepić et al., 2010). Formulated as eye drops, Pluronic® F127 micelles were 
shown to enhance eye-related bioavailability of both small and large drug molecules (Chetoni 
et al., 2000; Liaw et al., 2001; Pepić et al., 2004b). Chitosan, a biodegradable and 
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biocompatible excipient, known to exert mucoadhesive and permeability-enhancing 
properties due to its polycationic and polymeric nature (Garcia-Fuentes and Alonso, 2012), 
was identified as a critical component regarding the interaction of nanoparticles with the 
corneal barrier and melatonin ocular bioavailability in vivo. Lecithin nanoparticles (ML) and 
Pluronic
® 
F127
 
micelles (MF) were, therefore, additionally prepared to examine the chitosan 
influence on nanoparticles biopharmaceutical properties.  
MLC and MFC were shown to significantly differ in size (241.8 ± 0.8 nm and 20.7 ± 
0.3 nm, respectively) and surface charge properties (zeta potential of 22.7 ± 0.7 mV and 4.3 ± 
0.9 mV, respectively). Both types of nanosystems were shown to possess prolonged-release 
behavior, determined to be a desirable attribute for accomplishing extended IOP reduction 
(Musumeci et al., 2013), with MFC exhibiting faster melatonin release (t50% = 0.75 h) than 
MLC (t50% = 1.75 h). Each of the component of the nanosystems investigated have been 
proved as a biocompatible and safe excipient for topical ophthalmic administration (Garcia-
Fuentes and Alonso, 2012; Hafner et al., 2009; Jiao, 2008), however, biocompatibility studies 
of final nanosystems should always be conducted to ensure no toxic effects are present as a 
result of the potential interaction of the excipients and their presence in a nano-sized 
supramolecular form. The HCE-T cell-based viability studies showed all the investigated 
nanosystems were biocompatible with the corneal epithelial cells, which indicates their safe 
use for topical ophthalmic administration and confirms the absence of toxicity during both 
mucoadhesivity and permeability HCE-T cell-based studies.  
The mucoadhesivity of nanoparticles is one of the mechanisms of prolonging the 
precorneal residence time (Musumeci et al., 2013) and was in this study evaluated using a 
newly-established HCE-T cell monolayer-based mucoadhesivity assay. Chitosan, due to its 
positive charge at pH below 6.5, has been shown to interact with the negatively-charged 
epithelial cells, which can attenuate the effect of tear drainage and extend the residence time 
of nanoparticles at the ocular surface in vivo (de la Fuente et al., 2010). Indeed, the results 
show that MLC exhibit mucoadhesive properties, which are most probably related to their 
positive surface charge originating from chitosan located at their surface. This confirms the 
previous findings of the MLC mucoadhesivity obtained by a standard mucus glycoprotein 
assay (Hafner et al., 2009), which demonstrates the potential of the HCE-T cell-based 
mucoadhesivity assay to be further optimized for the purpose of nanoparticle mucoadhesivity 
testing. 
Previous studies have shown that chitosan can induce tight-junction opening and 
promote transcorneal drug transport (Hafner et al., 2009), however, no difference in the 
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decrease of TEER values was observed for nanosystems with and without chitosan, which 
points to other mechanisms of TEER decrease. The recovery of the initial TEER values after 
the permeability study indicates that the interaction of nanosystems with epithelial barrier is 
reversible, confirming their non-toxic nature observed in biocompatibility studies. The 
permeability of melatonin incorporated into nanosystems was, except for MF, decreased 
compared to melatonin in solution, with micelles demonstrating higher overall melatonin 
permeability compared to nanoparticles. The higher permeability of melatonin incorporated 
into micelles might be related to the smaller size of these nanosystems, the presence of non-
entrapped melatonin in the micellar solution, as well as the transcellular permeability-
enhancing effect of Pluronic
®
 F127 (Pepić et al., 2010). In addition, the presence of chitosan 
in both nanoparticles and micelles seems to be linked to the observed decrease in the 
melatonin permeability. For MFC the presence of chitosan seems to have diminished the 
permeability-enhancing effect of Pluronic
®
 F127, which resulted in lower permeability 
compared to MF. On the other hand, for nanoparticles the permeability-decreasing effect of 
chitosan seems to reflect its influence on melatonin release rate, which in in vitro release 
studies was determined to be lower for MLC than for ML. Strong correlation between 
melatonin in vitro release and transcorneal permeation rate was established, which indicates 
that the melatonin permeation across HCE-T epithelial barrier is controlled by the melatonin 
release profile.  
Overall, the conducted HCE-T cell based permeability studies in conjunction with 
other in vitro biopharmaceutical and physicochemical studies revealed chitosan as a key 
excipient providing the MLC with desirable biopharmaceutical properties. Prominent 
mucoadhesive properties and prolonged melatonin release, which was shown to control 
melatonin permeation across in vitro corneal barrier, demonstrated the potential of MLC to 
provide prolonged melatonin precorneal residence time and extended IOP reduction, with 
overall improved eye-related bioavailability and therapeutic outcome, compared to micelles 
and aqueous melatonin solution.   
Surface active excipients are commonly used in ophthalmic formulations as 
solubilization agents for increasing drug solubility and improving solution clarity or as 
wetting agents for stabilizing drug suspensions. A number of in vitro/ex vivo studies on the 
influence of surface active excipients on drug permeability have been conducted. The studies 
demonstrated that the presence of surface active excipients can lead to increased, decreased or 
unchanged drug permeability, as a result of their interaction with the biological barrier (the 
intercellular tight-junctional complexes, cell membrane influx/efflux transporters and cell 
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membrane phospholipid bilayer) or with the drug itself. Majority of these studies were, 
however, focused on investigating the effect of surface active excipients on the permeability 
of drugs intended for oral administration route, using in vitro and ex vivo intestinal 
permeability models (Fischer et al., 2011a, 2011b; Katneni et al., 2007; Legen et al., 2006; 
Rege et al., 2002; Saha and Kou, 2000). Additionally, in vivo studies on the effect of drug 
loaded nanosystems containing surface active excipients on eye-related bioavailability have 
been performed, in which surface active excipients demonstrated the potential to solubilize a 
drug, prolong the drug precorneal retention time, enhance the rate and extent of drug 
absorption, reaching thereby high eye-related bioavailability levels (Chetoni et al., 2000; 
Kassem et al., 2007; Liaw et al., 2001; Pepić et al., 2010, 2004a). However, to identify 
precisely the effect of surface active ophthalmic excipients on transcorneal drug permeability, 
systematic, but simpler in vitro and ex vivo studies, examining the influence of a type and 
concentration of surface active ophthalmic excipient on the transcorneal permeability of 
different ophthalmic drugs, are needed.  
In this thesis, in vitro Model II in conjunction with ex vivo corneal model (excised 
porcine cornea) was used for investigating the effect of the type and concentration of four 
different nonionic surface active ophthalmic excipients on the transcorneal permeation of 
ophthalmic drugs. The transcorneal permeability of the four ophthalmic drugs, namely, 
timolol maleate, diclofenac sodium, chloramphenicol and dexamethasone, was determined in 
previous work of this thesis and was found to strongly correlate between Model II and excised 
porcine cornea. Additional studies on self-aggregation properties of surface active ophthalmic 
excipients, using dynamic light scattering measurement, were conducted to obtain insight into 
their interaction with ophthalmic drugs, influencing potentially the drug transcorneal 
permeation rate. 
The in vitro and ex vivo permeability of the four ophthalmic drugs obtained in this 
study are in agreement with the permeability results from the previous work of this thesis, 
which points to the acceptable intra-laboratory reproducibility of both corneal models. 
However, a 2-8-fold difference between the ex vivo permeability reported in the literature and 
ex vivo permeability measured in this study is observed (Loch et al., 2012; Pescina et al., 
2015), which might be ascribed to the differences in animal species characteristics (breed, age, 
sex), the tissue collection and handling procedure, as well as the experimental setup. The 
observed ex vivo inter-laboratory variability obviously points to a compelling need for in-
depth studies defining the critical parameters of the ex vivo corneal model and establishing 
standardized ex vivo transcorneal permeability testing protocols. 
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In this study no interaction of the surface active ophthalmic excipients with corneal 
epithelial barrier in both Model II and excised porcine cornea was observed, as indicated by 
statistically insignificant TEER changes. However, ophthalmic drug permeability was 
generally either unchanged or decreased, depending on the surface active ophthalmic 
excipient concentration. Decreasing effect of surface active excipients on the permeability of 
poorly soluble drugs was reported in the literature and was ascribed to the interaction of drugs 
and micelles of surface active excipients. More precisely, lipophilic poorly soluble drugs 
associate with the micelle hydrophobic core which reduces the free drug fraction available for 
permeation across a biological barrier, resulting in an overall drug permeability decrease 
(Fischer et al., 2011b; Yano et al., 2010). Accordingly, in our study the association of drugs 
with the self-aggregates/micelles of surface active ophthalmic excipients might be a potential 
mechanism of the observed ophthalmic drug permeability decrease, as indicated by the 
dynamic light scattering measurements. More precisely, at the lowest concentration of surface 
active ophthalmic excipients, at which absence of self-aggregates was established, no 
influence of surface active ophthalmic excipients on drug permeability was observed. 
However, at higher surface active ophthalmic excipients concentrations, a strong permeability 
depressing effect was observed for certain drug-surface active ophthalmic excipient 
combinations, which might possibly be linked to the drug interaction with the formed surface 
active ophthalmic excipients self-aggregates. The strongest permeability-decreasing effect 
was observed for Cremophor EL, 2.0% w/V (up to around 90%), followed by Tyloxapol, 0.1% 
w/V (up to around 50%)  and Polysorbate 80, 0.2% w/V (up to around 30%). Pluronic
®
 F68, 
on the other hand, had no statistically significant effect on the ophthalmic drug permeability 
over the entire investigated concentration range, which is in agreement with the results of the 
studies on ex vivo intestinal permeability models (Fischer et al., 2011a, 2011b; Katneni et al., 
2007). 
The measured permeability-decreasing effect of surface active ophthalmic excipients 
was more pronounced for lipophilic ophthalmic drugs. Less lipophilic and highly soluble 
weakly basic drug timolol exhibited no interaction with surface active ophthalmic excipients 
over the whole surface active ophthalmic excipients concentration range tested, as indicated 
by unchanged timolol permeability in both corneal models. In contrast, for more lipophilic 
and poorly soluble neutral drug such as dexamethasone, up to around 70% decrease in in 
vitro/ex vivo permeation rate was measured, most probably related to the drug association 
with surface active ophthalmic excipient self-aggregates, formed at higher surface active 
ophthalmic excipient concentrations. On the other hand, for weakly basic drug diclofenac 
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sodium, characterized by higher solubility and lower lipophilicity compared to 
dexamethasone, even greater up to around 90% reduction in permeation rate in the presence 
of surface active excipients in both corneal models was measured, which may be explained by 
previous solubilization studies demonstrating greater solubility of the ionized species 
compared to its unionized equivalent (Li et al., 1999).  
Strong and statistically significant in vitro/ex vivo correlation of the influence of 
surface active ophthalmic excipients on ophthalmic drug permeability was obtained in this 
study, which indicates that the observed influence is of comparable extent and mediated by 
the same mechanism in both corneal models. The structural differences and potential 
functional differences of the Model II and excised porcine cornea might be linked to the 
observed in vitro/ex vivo discrepancies, which require additional histological, functional and 
mechanistic permeability studies to establish the exact underlying cause. Nonetheless, the 
obtained results give valuable insight into the effect of surface active ophthalmic excipients 
on the ophthalmic drug transcorneal permeability, influencing potentially ophthalmic drug 
eye-related bioavailability, which may contribute to their more efficient and directed use in 
the future topical ophthalmic product development.  
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6. CONCLUSIONS 
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In this thesis, the effect of unimers and supramolecular aggregates of the ophthalmic 
excipients on corneal barrier properties and ophthalmic drug permeability was evaluated, 
using in vitro (HCE-T cell-based) and/or ex vivo (excised porcine cornea) corneal models. 
Histological and functional characterization of the HCE-T cell-based model revealed the 
membrane pore size to be an important factor influencing HCE-T barrier phenotype. The use 
of a 3.0 µm pore size resulted in HCE-T corneal epithelial phenotype of improved functional 
barrier properties, but of a specific histological structure consisting of an apical lipophilic 
HCE-T monolayer and a basolateral lipophilic layer of migrated HCE-T cells. The increased 
barrier tightness and very strong in vitro/ex vivo correlation of the ophthalmic compounds 
permeability suggests that Model II is suitable for the ophthalmic drug transcorneal 
permeability evaluation. The established interdependence of temperature, TEER and 
permeability of a paracellular and transcellular compound indicates furthermore the suitability 
of Model II for biopharmaceutical evaluation of ophthalmic excipients regarding their 
interaction with the corneal epithelial barrier and consequent impact on the drug transcorneal 
permeability.  
Model II-based permeability studies were proved valuable in the biopharmaceutical 
characterization of melatonin-loaded lecithin/chitosan nanoparticles and Pluronic
®
 
F127/chitosan micelles, by allowing the evaluation of the contribution of each excipient to the 
overall impact of nanosystems on the melatonin transcorneal permeability. Significant 
influence of chitosan on the transcorneal permeability of melatonin incorporated into 
nanosystems was revealed. In micelles chitosan hindered the Pluronic
®
 F127 permeation-
enhancing effect, while for nanoparticles the presence of chitosan ensured prolonged 
melatonin release rate, which was shown to control melatonin permeation rate across corneal 
epithelial barrier. HCE-T cell-based mucoadhesivity assay revealed prominent mucoadhesive 
properties of the lecithin-chitosan nanoparticles, which were ascribed to the positive surface 
charge originating from chitosan located at the nanoparticles surface. This attribute, together 
with prolonged release and controlled transcorneal permeation of melatonin, demonstrated the 
potential of lecithin/chitosan nanoparticles to provide extended melatonin precorneal 
residence time, ensuring high eye-related bioavailability and extended intraocular pressure 
reduction, compared to micelle and aqueous melatonin solution. 
Using in vitro Model II in conjunction with excised porcine cornea the concentration- 
and self-aggregation-dependent influence of four nonionic surface active ophthalmic 
excipients on the permeability of four ophthalmic drugs was investigated. None of the 
nonionic surface active ophthalmic excipients over the entire concentration range 
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demonstrated interaction with epithelial barrier of the corneal models. The in vitro/ex vivo 
permeability of the ophthalmic drugs was, however, affected, depending on the nonionic 
surface active ophthalmic excipients concentration. At the lowest concentration of all four 
surface active ophthalmic excipients the permeability of ophthalmic drugs was unchanged, 
while at higher concentrations a permeability-decreasing effect was observed. The results of 
the dynamic light scattering studies point to the interaction of the ophthalmic drugs with self-
aggregates of surface active ophthalmic excipients as a potential mechanism of the observed 
ophthalmic drug permeability decrease. Strong in vitro/ex vivo correlation of the influence of 
surface active ophthalmic excipients on the ophthalmic drugs permeability suggests that the 
observed permeability-altering effects of surface active ophthalmic excipients were of 
comparable magnitude and were mediated by the same mechanism in both corneal models.  
In conclusion, the results of this thesis demonstrate the suitability of Model II for drug 
transcorneal permeability evaluation, considering the influence of excipients in either 
monomolecular or supramolecular nano-sized form. However, variability of the HCE-T 
corneal epithelial barrier phenotype was observed which points to a pressing need for 
identification and standardization of cultivation factors influencing the HCE-T barrier 
properties in further optimization of the HCE-T cell-based corneal model. Nonetheless, the in 
vitro/ex vivo permeability results obtained in this thesis give valuable insight into the 
influence of ophthalmic excipients on the ophthalmic drug transcorneal permeability, which 
potentially impacts the topical ophthalmic drug eye-related bioavailability. Biopharmaceutical 
classification of ophthalmic excipients with respect to their effect on ophthalmic drug 
transcorneal permeability and eye-related bioavailability is a crucial step towards a more 
efficient process of optimization of topical ophthalmic formulation composition in the early 
development phases, with positive impact on the economic aspect of the overall topical 
ophthalmic product development.   
  
58 
 
 
7. REFERENCE LIST 
  
59 
 
Abdelbary, G., 2011. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated 
liposomes. Pharm. Dev. Technol. 16, 44–56. 
https://doi.org/10.3109/10837450903479988 
Abdulrazik, M., 1996. Diffusion cell for ex-vivo pressure-controlled transcorneal drug 
penetration studies. US5789240A. 
Aggarwal, D., Pal, D., Mitra, A.K., Kaur, I.P., 2007. Study of the extent of ocular absorption 
of acetazolamide from a developed niosomal formulation, by microdialysis sampling of 
aqueous humor. Int. J. Pharm. 338, 21–26. https://doi.org/10.1016/j.ijpharm.2007.01.019 
Ahmed, I., Patton, T.F., 1985. Importance of the noncorneal absorption route in topical 
ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26, 584–7. 
Alany, R.G., Rades, T., Nicoll, J., Tucker, I.G., Davies, N.M., 2006. W/O microemulsions for 
ocular delivery: Evaluation of ocular irritation and precorneal retention. J. Control. 
Release 111, 145–152. https://doi.org/10.1016/j.jconrel.2005.11.020 
Alvarez-Trabado, J., Diebold, Y., Sanchez, A., 2017. Designing lipid nanoparticles for topical 
ocular drug delivery. Int. J. Pharm. 532, 204–217. 
https://doi.org/10.1016/j.ijpharm.2017.09.017 
Ammar, H.O., Salama, H.A., Ghorab, M., Mahmoud, A.A., 2009. Nanoemulsion as a 
potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS 
PharmSciTech 10, 808–19. https://doi.org/10.1208/s12249-009-9268-4 
Attama, A.A., Reichl, S., Müller-Goymann, C.C., 2008. Diclofenac sodium delivery to the 
eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea 
construct. Int. J. Pharm. 355, 307–313. https://doi.org/10.1016/j.ijpharm.2007.12.007 
Ban, Y., Cooper, L.J., Fullwood, N.J., Nakamura, T., Tsuzuki, M., Koizumi, N., Dota, A., 
Mochida, C., Kinoshita, S., 2003. Comparison of ultrastructure, tight junction-related 
protein expression and barrier function of human corneal epithelial cells cultivated on 
amniotic membrane with and without air-lifting. Exp. Eye Res. 76, 735–43. 
Barry, P.A., Petroll, W.M., Andrews, P.M., Cavanagh, H.D., Jester, J. V, 1995. The spatial 
organization of corneal endothelial cytoskeletal proteins and their relationship to the 
apical junctional complex. Invest. Ophthalmol. Vis. Sci. 36, 1115–24. 
Becker, U., Ehrhardt, C., Daum, N., Baldes, C., Schaefer, U.F., Ruprecht, K.W., Kim, K.-J., 
Lehr, C.-M., 2007. Expression of ABC-Transporters in Human Corneal Tissue and the 
Transformed Cell Line, HCE-T. J. Ocul. Pharmacol. Ther. 23, 172–181. 
https://doi.org/10.1089/jop.2006.0095 
Becker, U., Ehrhardt, C., Schneider, M., Muys, L., Gross, D., Eschmann, K., Schaefer, U.F., 
Lehr, C.-M., 2008. A comparative evaluation of corneal epithelial cell cultures for 
assessing ocular permeability. Altern. Lab. Anim. 36, 33–44. 
Beiβner, N., Mattern, K., Dietzel, A., Reichl, S., 2017. DynaMiTES – A dynamic cell culture 
platform for in vitro drug testing PART 2 – Ocular DynaMiTES for drug absorption 
studies of the anterior eye. Eur. J. Pharm. Biopharm. 
https://doi.org/10.1016/j.ejpb.2017.03.021 
Bhatta, R.S., Chandasana, H., Chhonker, Y.S., Rathi, C., Kumar, D., Mitra, K., Shukla, P.K., 
60 
 
2012. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro 
and pharmacokinetics studies. Int. J. Pharm. 432, 105–112. 
https://doi.org/10.1016/j.ijpharm.2012.04.060 
Bonferoni, M.C., Rossi, S., Ferrari, F., Caramella, C., 1999. A Modified Franz Diffusion Cell 
for Simultaneous Assessment of Drug Release and Washability of Mucoadhesive Gels. 
Pharm. Dev. Technol. 4, 45–53. https://doi.org/10.1080/10837459908984223 
Bravo-Osuna, I., Andrés-Guerrero, V., Pastoriza Abal, P., Molina-Martínez, I.T., Herrero-
Vanrell, R., 2016. Pharmaceutical microscale and nanoscale approaches for efficient 
treatment of ocular diseases. Drug Deliv. Transl. Res. 6, 686–707. 
https://doi.org/10.1007/s13346-016-0336-5 
Chang, J.E., Basu, S.K., Lee, V.H., 2000. Air-interface condition promotes the formation of 
tight corneal epithelial cell layers for drug transport studies. Pharm. Res. 17, 670–6. 
Chetoni, P., Panichi, L., Burgalassi, S., Benelli, U., Saettone, M.F., 2000. Pharmacokinetics 
and Anti-Inflammatory Activity in Rabbits of a Novel Indomethacin Ophthalmic 
Solution. J. Ocul. Pharmacol. Ther. 16, 363–372. 
https://doi.org/10.1089/jop.2000.16.363 
Choi, S.H., Lionberger, R.A., 2016. Clinical, Pharmacokinetic, and In Vitro Studies to 
Support Bioequivalence of Ophthalmic Drug Products. AAPS J. 18, 1032–1038. 
https://doi.org/10.1208/s12248-016-9932-z 
Dale, R.M., James, P.M., 1991. pH tolerance of rabbit corneal epithelium in tissue culture. J. 
Toxicol. Cutan. Ocul. Toxicol. 10, 43–57. https://doi.org/10.3109/15569529109057903 
De Campos, A.M., Sánchez, A., Alonso, M.J., 2001. Chitosan nanoparticles: a new vehicle 
for the improvement of the delivery of drugs to the ocular surface. Application to 
cyclosporin A. Int. J. Pharm. 224, 159–68. 
de la Fuente, M., Raviña, M., Paolicelli, P., Sanchez, A., Seijo, B., Alonso, M.J., 2010. 
Chitosan-based nanostructures: A delivery platform for ocular therapeutics. Adv. Drug 
Deliv. Rev. 62, 100–117. https://doi.org/10.1016/j.addr.2009.11.026 
de la Fuente, M., Seijo, B., Alonso, M.J., 2008. Novel Hyaluronic Acid-Chitosan 
Nanoparticles for Ocular Gene Therapy. Investig. Opthalmology Vis. Sci. 49, 2016. 
https://doi.org/10.1167/iovs.07-1077 
Eghrari, A.O., Riazuddin, S.A., Gottsch, J.D., 2015. Overview of the Cornea: Structure, 
Function, and Development, 1st ed, Progress in Molecular Biology and Translational 
Science. Elsevier Inc. https://doi.org/10.1016/bs.pmbts.2015.04.001 
Ekelund, K., Östh, K., Påhlstorp, C., Björk, E., Ulvenlund, S., Johansson, F., 2005. 
Correlation Between Epithelial Toxicity and Surfactant Structure as Derived From the 
Effects of Polyethyleneoxide Surfactants on Caco-2 Cell Monolayers and Pig Nasal 
Mucosa. J. Pharm. Sci. 94, 730–744. https://doi.org/10.1002/jps.20283 
Fischer, S.M., Brandl, M., Fricker, G., 2011a. Effect of the non-ionic surfactant Poloxamer 
188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. Eur. 
J. Pharm. Biopharm. 79, 416–422. https://doi.org/10.1016/j.ejpb.2011.04.010 
Fischer, S.M., Flaten, G.E., Hagesaether, E., Fricker, G., Brandl, M., 2011b. In-vitro 
61 
 
permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation 
assay: the influence of nonionic surfactants. J. Pharm. Pharmacol. 63, 1022–1030. 
https://doi.org/10.1111/j.2042-7158.2011.01301.x 
Fujisawa, T., Miyai, H., Hironaka, K., Tsukamoto, T., Tahara, K., Tozuka, Y., Ito, M., 
Takeuchi, H., 2012. Liposomal diclofenac eye drop formulations targeting the retina: 
Formulation stability improvement using surface modification of liposomes. Int. J. 
Pharm. 436, 564–567. https://doi.org/10.1016/j.ijpharm.2012.07.024 
Garcia-Fuentes, M., Alonso, M.J., 2012. Chitosan-based drug nanocarriers: Where do we 
stand? J. Control. Release 161, 496–504. https://doi.org/10.1016/j.jconrel.2012.03.017 
Ghosh, M., Ahmed, I., 2014. Chemistry, Manufacturing, and Control of Ophthalmic 
Formulations, in: Gilger C., B. (Ed.), Ocular Pharmacology and Toxicology. Humana 
Press, pp. 53–79. 
Gibson, M., 2009. Ophthalmic dosage forms, in: Gibson, M. (Ed.), Pharmaceutical 
Preformulation and Formulation : A Practical Guide from Candidate Drug Selection to 
Commercial Dosage Form. Informa Healthcare, pp. 431–455. 
González-Mariscal, L., Chávez de Ramírez, B., Cereijido, M., 1984. Effect of temperature on 
the occluding junctions of monolayers of epithelioid cells (MDCK). J. Membr. Biol. 79, 
175–84. 
Goskonda, V.R., Khan, M.A., Hutak, C.M., Reddy, I.K., 1999. Permeability characteristics of 
novel mydriatic agents using an in vitro cell culture model that utilizes sirc rabbit corneal 
cells. J. Pharm. Sci. 88, 180–184. https://doi.org/10.1021/js980362t 
Gupta, H., Aqil, M., Khar, R.K., Ali, A., Bhatnagar, A., Mittal, G., 2010. Sparfloxacin-loaded 
PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine Nanotechnology, 
Biol. Med. 6, 324–333. https://doi.org/10.1016/j.nano.2009.10.004 
Hafner, A., Lovrić, J., Voinovich, D., Filipović-Grčić, J., 2009. Melatonin-loaded 
lecithin/chitosan nanoparticles: Physicochemical characterisation and permeability 
through Caco-2 cell monolayers. Int. J. Pharm. 381, 205–213. 
https://doi.org/10.1016/j.ijpharm.2009.07.001 
Hahne, M., Reichl, S., 2011. Development of a serum-free human cornea construct for in 
vitro drug absorption studies: The influence of varying cultivation parameters on barrier 
characteristics. Int. J. Pharm. 416, 268–279. 
https://doi.org/10.1016/j.ijpharm.2011.07.004 
Hahne, M., Zorn-Kruppa, M., Guzman, G., Brandner, J.M., Haltner-Ukomado, E., Wätzig, H., 
Reichl, S., 2012. Prevalidation of a Human Cornea Construct as an Alternative to 
Animal Corneas for In Vitro Drug Absorption Studies. J. Pharm. Sci. 101, 2976–2988. 
https://doi.org/10.1002/jps.23190 
Hämäläinen, K.M., Kananen, K., Auriola, S., Kontturi, K., Urtti, A., 1997. Characterization of 
paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest. 
Ophthalmol. Vis. Sci. 38, 627–34. 
Hanna, C., Bicknell, D.S., O’Brien, J.E., 1961. Cell turnover in the adult human eye. Arch. 
Ophthalmol. (Chicago, Ill.  1960) 65, 695–8. 
62 
 
Huang, A.J., Tseng, S.C., Kenyon, K.R., 1989. Paracellular permeability of corneal and 
conjunctival epithelia. Invest. Ophthalmol. Vis. Sci. 30, 684–9. 
Jacobsen, I.E., Jensen, O.A., Prause, J.U., 1984. Structure and composition of Bowman’s 
membrane. Study by frozen resin cracking. Acta Ophthalmol. 62, 39–53. 
Jain, K., Kumar, R.S., Sood, S., Dhyanandhan, G., 2013. Betaxolol hydrochloride loaded 
chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy. Curr. Drug 
Deliv. 10, 493–9. 
Järvinen, K., Järvinen, T., Urtti, A., 1995. Ocular absorption following topical delivery. Adv. 
Drug Deliv. Rev. 16, 3–19. https://doi.org/10.1016/0169-409X(95)00010-5 
Jiao, J., 2008. Polyoxyethylated nonionic surfactants and their applications in topical ocular 
drug delivery. Adv. Drug Deliv. Rev. 60, 1663–1673. 
https://doi.org/10.1016/j.addr.2008.09.002 
Johnson, D.H., Bourne, W.M., Campbell, R.J., 1982. The ultrastructure of Descemet’s 
membrane. I. Changes with age in normal corneas. Arch. Ophthalmol. (Chicago, Ill.  
1960) 100, 1942–7. 
Joyce, N.C., 2003. Proliferative capacity of the corneal endothelium. Prog. Retin. Eye Res. 22, 
359–89. 
Kambhampati, S.P., Kannan, R.M., 2013. Dendrimer Nanoparticles for Ocular Drug Delivery. 
J. Ocul. Pharmacol. Ther. 29, 151–165. https://doi.org/10.1089/jop.2012.0232 
Kassem, M., Abdelrahman, A., Ghorab, M., Ahmed, M., Khalil, R., 2007. Nanosuspension as 
an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340, 126–
133. https://doi.org/10.1016/j.ijpharm.2007.03.011 
Katneni, K., Charman, S.A., Porter, C.J.H., 2007. Impact of Cremophor-EL and Polysorbate-
80 on Digoxin Permeability across Rat Jejunum: Delineation of Thermodynamic and 
Transporter Related Events Using the Reciprocal Permeability Approach. J. Pharm. Sci. 
96, 280–293. https://doi.org/10.1002/jps.20779 
Kaur, I.P., Lal, S., Rana, C., Kakkar, S., Singh, H., 2009. Ocular preservatives: associated 
risks and newer options. Cutan. Ocul. Toxicol. 28, 93–103. 
https://doi.org/10.1080/15569520902995834 
Khutoryanskiy, V. V., 2011. Advances in Mucoadhesion and Mucoadhesive Polymers. 
Macromol. Biosci. 11, 748–764. https://doi.org/10.1002/mabi.201000388 
Kidron, H., Vellonen, K.-S., del Amo, E.M., Tissari, A., Urtti, A., 2010. Prediction of the 
Corneal Permeability of Drug-Like Compounds. Pharm. Res. 27, 1398–1407. 
https://doi.org/10.1007/s11095-010-0132-8 
Klang, S., Abdulrazik, M., Benita*, S., 2000. Influence of Emulsion Droplet Surface Charge 
on Indomethacin Ocular Tissue Distribution. Pharm. Dev. Technol. 5, 521–532. 
https://doi.org/10.1081/PDT-100102035 
Kölln, C., Reichl, S., 2016a. Cytochrome P450 Activity in Ex Vivo Cornea Models and a 
Human Cornea Construct. J. Pharm. Sci. 105, 2204–2212. 
https://doi.org/10.1016/j.xphs.2016.04.010 
63 
 
Kölln, C., Reichl, S., 2016b. Expression of glutathione transferases in corneal cell lines, 
corneal tissues and a human cornea construct. Int. J. Pharm. 506, 371–381. 
https://doi.org/10.1016/j.ijpharm.2016.04.053 
Kölln, C., Reichl, S., 2012. mRNA Expression of Metabolic Enzymes in Human Cornea, 
Corneal Cell Lines, and Hemicornea Constructs. J. Ocul. Pharmacol. Ther. 28, 271–277. 
https://doi.org/10.1089/jop.2011.0124 
Kompella, U.B., Sundaram, S., Raghava, S., Escobar, E.R., 2006. Luteinizing hormone-
releasing hormone agonist and transferrin functionalizations enhance nanoparticle 
delivery in a novel bovine ex vivo eye model. Mol. Vis. 12, 1185–98. 
Legen, I., Kračun, M., Salobir, M., Kerč, J., 2006. The evaluation of some pharmaceutically 
acceptable excipients as permeation enhancers for amoxicillin. Int. J. Pharm. 308, 84–89. 
https://doi.org/10.1016/j.ijpharm.2005.10.036 
Leong, Y.-Y., Tong, L., 2015. Barrier Function in the Ocular Surface: From Conventional 
Paradigms to New Opportunities. Ocul. Surf. 13, 103–109. 
https://doi.org/10.1016/j.jtos.2014.10.003 
Li, P., Tabibi, S.E., Yalkowsky, S.H., 1999. Solubilization of ionized and un‐ionized 
flavopiridol by ethanol and polysorbate 20. J. Pharm. Sci. 88, 507–509. 
https://doi.org/10.1021/js980433o 
Liaw, J., Chang, S.-F., Hsiao, F.-C., 2001. In vivo gene delivery into ocular tissues by eye 
drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-
PEO) polymeric micelles. Gene Ther. 8, 999–1004. https://doi.org/10.1038/sj.gt.3301485 
Loch, C., Zakelj, S., Kristl, A., Nagel, S., Guthoff, R., Weitschies, W., Seidlitz, A., 2012. 
Determination of permeability coefficients of ophthalmic drugs through different layers 
of porcine, rabbit and bovine eyes. Eur. J. Pharm. Sci. 47, 131–138. 
https://doi.org/10.1016/j.ejps.2012.05.007 
Losa, C., Marchal-Heussler, L., Orallo, F., Vila Jato, J.L., Alonso, M.J., 1993. Design of new 
formulations for topical ocular administration: polymeric nanocapsules containing 
metipranolol. Pharm. Res. 10, 80–7. 
Luschmann, C., Tessmar, J., Schoeberl, S., Strau, O., Luschmann, K., Goepferich, A., 2014. 
Self-Assembling Colloidal System for the Ocular Administration of Cyclosporine A. 
Cornea 33, 77–81. https://doi.org/10.1097/ICO.0b013e3182a7f3bf 
Mandal, A., Bisht, R., Rupenthal, I.D., Mitra, A.K., 2017. Polymeric micelles for ocular drug 
delivery: From structural frameworks to recent preclinical studies. J. Control. Release 
248, 96–116. https://doi.org/10.1016/j.jconrel.2017.01.012 
McCanna, D.J., Harrington, K.L., Driot, J.-Y., Ward, K.W., Tchao, R., 2008. Use of a Human 
Corneal Epithelial Cell Line for Screening the Safety of Contact Lens Care Solutions In 
Vitro. Eye Contact Lens Sci. Clin. Pract. 34, 6–12. 
https://doi.org/10.1097/ICL.0b013e31804fa141 
Minami, Y., Sugihara, H., Oono, S., 1993. Reconstruction of cornea in three-dimensional 
collagen gel matrix culture. Invest. Ophthalmol. Vis. Sci. 34, 2316–24. 
Mochizuki, H., Fukui, M., Hatou, S., Yamada, M., Tsubota, K., 2010. Evaluation of ocular 
64 
 
surface glycocalyx using lectin-conjugated fluorescein. Clin. Ophthalmol. 4, 925–30. 
Mohan, R.R., Possin, D.E., Mohan, R.R., Sinha, S., Wilson, S.E., 2003. Development of 
genetically engineered tet HPV16-E6/E7 transduced human corneal epithelial clones 
having tight regulation of proliferation and normal differentiation. Exp. Eye Res. 77, 
395–407. 
Musumeci, T., Bucolo, C., Carbone, C., Pignatello, R., Drago, F., Puglisi, G., 2013. 
Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. 
Int. J. Pharm. 440, 135–140. https://doi.org/10.1016/j.ijpharm.2012.10.014 
Myung, D., Derr, K., Huie, P., Noolandi, J., Ta, K.P., Ta, C.N., 2006. Glucose Permeability of 
Human, Bovine, and Porcine Corneas in vitro. Ophthalmic Res. 38, 158–163. 
https://doi.org/10.1159/000090726 
Nagai, N., Inomata, M., Ito, Y., 2008. Contribution of Aldehyde Dehydrogenase 3A1 to 
Disulfiram Penetration through Monolayers Consisting of Cultured Human Corneal 
Epithelial Cells. Biol. Pharm. Bull. 31, 1444–1448. https://doi.org/10.1248/bpb.31.1444 
Pepić, I., Hafner, A., Lovrić, J., Pirkić, B., Filipović-Grcčić, J., 2010. A Nonionic 
Surfactant/Chitosan Micelle System in an Innovative Eye Drop Formulation. J. Pharm. 
Sci. 99, 4317–4325. https://doi.org/10.1002/jps.22137 
Pepić, I., Jalšenjak, N., Jalšenjak, I., 2004a. Micellar solutions of triblock copolymer 
surfactants with pilocarpine. Int. J. Pharm. 272, 57–64. 
https://doi.org/10.1016/j.ijpharm.2003.11.032 
Pepić, I., Jalšenjak, N., Jalšenjak, I., 2004b. Micellar solutions of triblock copolymer 
surfactants with pilocarpine. Int. J. Pharm. 272, 57–64. 
https://doi.org/10.1016/J.IJPHARM.2003.11.032 
Pepić, I., Lovrić, J., Cetina-Čižmek, B., Reichl, S., Filipović-Grčić, J., 2014. Toward the 
practical implementation of eye-related bioavailability prediction models. Drug Discov. 
Today 19, 31–44. https://doi.org/10.1016/j.drudis.2013.08.002 
Pescina, S., Govoni, P., Potenza, A., Padula, C., Santi, P., Nicoli, S., 2015. Development of a 
Convenient ex vivo Model for the Study of the Transcorneal Permeation of Drugs: 
Histological and Permeability Evaluation. J. Pharm. Sci. 104, 63–71. 
https://doi.org/10.1002/jps.24231 
Pignatello, R., Bucolo, C., Spedalieri, G., Maltese, A., Puglisi, G., 2002. Flurbiprofen-loaded 
acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 23, 3247–55. 
Rege, B.D., Kao, J.P.Y., Polli, J.E., 2002. Effects of nonionic surfactants on membrane 
transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16, 237–46. 
Reichl, S., 2008. Cell culture models of the human cornea - a comparative evaluation of their 
usefulness to determine ocular drug absorption in-vitro. J. Pharm. Pharmacol. 60, 299–
307. https://doi.org/10.1211/jpp.60.3.0004 
Reichl, S., Bednarz, J., Müller-Goymann, C.C., 2004. Human corneal equivalent as cell 
culture model for in vitro drug permeation studies. Br. J. Ophthalmol. 88, 560–5. 
Reichl, S., Müller-Goymann, C.C., 2003. The use of a porcine organotypic cornea construct 
65 
 
for permeation studies from formulations containing befunolol hydrochloride. Int. J. 
Pharm. 250, 191–201. 
Reimondez-Troitiño, S., Csaba, N., Alonso, M.J., de la Fuente, M., 2015. Nanotherapies for 
the treatment of ocular diseases. Eur. J. Pharm. Biopharm. 95, 279–293. 
https://doi.org/10.1016/j.ejpb.2015.02.019 
Saaber, D., Wollenhaupt, S., Baumann, K., Reichl, S., 2014. Recent progress in tight junction 
modulation for improving bioavailability. Expert Opin. Drug Discov. 9, 367–381. 
https://doi.org/10.1517/17460441.2014.892070 
Saha, P., Kou, J.H., 2000. Effect of solubilizing excipients on permeation of poorly water-
soluble compounds across Caco-2 cell monolayers. Eur. J. Pharm. Biopharm. 50, 403–11. 
Sánchez-López, E., Espina, M., Doktorovova, S., Souto, E.B., García, M.L., 2017. Lipid 
nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the 
eye – Part II - Ocular drug-loaded lipid nanoparticles. Eur. J. Pharm. Biopharm. 110, 58–
69. https://doi.org/10.1016/j.ejpb.2016.10.013 
Schoenwald, R.D., 1990. Ocular drug delivery. Pharmacokinetic considerations. Clin. 
Pharmacokinet. 18, 255–69. 
Schoenwald, R.D., Huang, H.S., 1983. Corneal penetration behavior of beta-blocking agents I: 
Physiochemical factors. J. Pharm. Sci. 72, 1266–72. 
Sharma, O.P., Patel, V., Mehta, T., 2016. Nanocrystal for ocular drug delivery: hope or hype. 
Drug Deliv. Transl. Res. 6, 399–413. https://doi.org/10.1007/s13346-016-0292-0 
Shih, R.L., Lee, V.H., 1990. Rate limiting barrier to the penetration of ocular hypotensive 
beta blockers across the corneal epithelium in the pigmented rabbit. J. Ocul. Pharmacol. 
6, 329–36. 
Singh, R., Lillard, J.W., 2009. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 
86, 215–223. https://doi.org/10.1016/j.yexmp.2008.12.004 
Stratford, R.E., Yang, D.C., Redell, M.A., Lee, V.H.L., 1983. Effects of topically applied 
liposomes on disposition of epinephrine and inulin in the albino rabbit eye. Int. J. Pharm. 
13, 263–272. https://doi.org/10.1016/0378-5173(83)90075-3 
Stratford, R.E., Yang, D.C., Redell, M.A., Lee, V.H.L., 1982. Ocular distribution of 
liposome-encapsulated epinephrine and inulin in the albino rabbit. Curr. Eye Res. 2, 
377–386. https://doi.org/10.3109/02713688209000783 
Suresh, P.K., Sah, A.K., 2014. Nanocarriers for ocular delivery for possible benefits in the 
treatment of anterior uveitis: focus on current paradigms and future directions. Expert 
Opin. Drug Deliv. 11, 1747–1768. https://doi.org/10.1517/17425247.2014.938045 
Takezawa, T., Nishikawa, K., Wang, P.-C., 2011. Development of a human corneal 
epithelium model utilizing a collagen vitrigel membrane and the changes of its barrier 
function induced by exposing eye irritant chemicals. Toxicol. Vitr. 25, 1237–1241. 
https://doi.org/10.1016/J.TIV.2011.05.021 
Tegtmeyer, S., Papantoniou, I., Müller-Goymann, C.C., 2001. Reconstruction of an in vitro 
cornea and its use for drug permeation studies from different formulations containing 
66 
 
pilocarpine hydrochloride. Eur. J. Pharm. Biopharm. 51, 119–25. 
Toropainen, E., Ranta, V.-P., Vellonen, K.-S., Palmgrén, J., Talvitie, A., Laavola, M., 
Suhonen, P., Hämäläinen, K.M., Auriola, S., Urtti, A., 2003. Paracellular and passive 
transcellular permeability in immortalized human corneal epithelial cell culture model. 
Eur. J. Pharm. Sci. 20, 99–106. 
Toropainen, E., Ranta, V.P., Talvitie, A., Suhonen, P., Urtti, A., 2001. Culture model of 
human corneal epithelium for prediction of ocular drug absorption. Invest. Ophthalmol. 
Vis. Sci. 42, 2942–8. 
Torricelli, A.A.M., Singh, V., Santhiago, M.R., Wilson, S.E., 2013. The Corneal Epithelial 
Basement Membrane: Structure, Function, and Disease. Investig. Opthalmology Vis. Sci. 
54, 6390. https://doi.org/10.1167/iovs.13-12547 
Torricelli, A.A.M., Wilson, S.E., 2014. Cellular and extracellular matrix modulation of 
corneal stromal opacity. Exp. Eye Res. 129, 151–160. 
https://doi.org/10.1016/j.exer.2014.09.013 
Troy, D.B., Beringer, P., 2006. Remington: The Science and Practice of Pharmacy, 21st ed. 
Lippincott Williams & Wilkins, Philadelphia, PA. 
Tsubota, K., 1998. Tear dynamics and dry eye. Prog. Retin. Eye Res. 17, 565–96. 
Tucker, S.P., Melsen, L.R., Compans, R.W., 1992. Migration of polarized epithelial cells 
through permeable membrane substrates of defined pore size. Eur. J. Cell Biol. 58, 280–
90. 
Tuomela, A., Liu, P., Puranen, J., Rönkkö, S., Laaksonen, T., Kalesnykas, G., Oksala, O., 
Ilkka, J., Laru, J., Järvinen, K., Hirvonen, J., Peltonen, L., 2014. Brinzolamide 
nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular 
pressure in vivo. Int. J. Pharm. 467, 34–41. 
https://doi.org/10.1016/j.ijpharm.2014.03.048 
Vellonen, K.-S., Malinen, M., Mannermaa, E., Subrizi, A., Toropainen, E., Lou, Y.-R., 
Kidron, H., Yliperttula, M., Urtti, A., 2014. A critical assessment of in vitro tissue 
models for ADME and drug delivery. J. Control. Release 190, 94–114. 
https://doi.org/10.1016/j.jconrel.2014.06.044 
Vellonen, K.-S., Mannermaa, E., Turner, H., Häkli, M., Wolosin, J.M., Tervo, T., Honkakoski, 
P., Urtti, A., 2010. Effluxing ABC transporters in human corneal epithelium. J. Pharm. 
Sci. 99, 1087–98. https://doi.org/10.1002/jps.21878 
Watsky, M.A., Jablonski, M.M., Edelhauser, H.F., 1988. Comparison of conjunctival and 
corneal surface areas in rabbit and human. Curr. Eye Res. 7, 483–486. 
https://doi.org/10.3109/02713688809031801 
Yamasaki, K., Kawasaki, S., Young, R.D., Fukuoka, H., Tanioka, H., Nakatsukasa, M., 
Quantock, A.J., Kinoshita, S., 2009. Genomic Aberrations and Cellular Heterogeneity in 
SV40-Immortalized Human Corneal Epithelial Cells. Investig. Opthalmology Vis. Sci. 
50, 604. https://doi.org/10.1167/iovs.08-2239 
Yano, K., Masaoka, Y., Kataoka, M., Sakuma, S., Yamashita, S., 2010. Mechanisms of 
Membrane Transport of Poorly Soluble Drugs: Role of Micelles in Oral Absorption 
67 
 
Processes. J. Pharm. Sci. 99, 1336–1345. https://doi.org/10.1002/jps.21919 
 
68 
 
8. BIOGRAPHY 
  
69 
 
Marina Juretić was born on 3rd of September 1987 in Zagreb, Croatia. She finished 
elementary school and the VII
th
 Gymnasium in Zagreb. She graduated from the Faculty of 
Pharmacy and Biochemistry, University of Zagreb, in 2011. During her studies she was 
awarded the Dean's Prize for scientific work “Antitumour and antimicrobial effects of 
Epilobium angustifolium Schreb. and Epilobium Parviflorum L.“ and the “Dean’s award for 
excellence in academic year of 2010/2011”. From 2011. to 2012. she worked at Hanžić 
Pharmacies in Zagreb as a pharmacist-intern. In 2013. she started working as a research 
assistant at the Department of Pharmaceutical technology, Faculty of Pharmacy and 
Biochemistry, University of Zagreb, on the project entitled “Development of in vitro and ex 
vivo models for permeability testing of new topical ophthalmic formulations“ (Partnership in 
research: 04.01/56, Croatian science foundation and PLIVA Croatia Ltd.), as part of which 
she enrolled in postgraduate doctoral study “Pharmaceutical-Biochemical Sciences” at the 
Faculty of Pharmacy and Biochemistry, University of Zagreb. In 2013. she visited Technical 
University in Braunschweig, Germany, to receive training in the field of in vitro cell-based 
corneal model cultivation and transcorneal permeability testing. In 2014. she made a short 
stay at the Institute for Applied Ophthalmobiology (IOBA), University of Valladolid, Spain, 
where she received education in the field of primary porcine corneal/conjunctival cell 
isolation. From 2015. to 2016. she worked as a research assistant at the Department of 
Pharmaceutical technology, Faculty of Pharmacy and Biochemistry, University of Zagreb, on 
the project “Modelling of the Pharmaceutical Spray Drying Process of the Emulsions in 
Laboratory and Pilot Scale” (industrial partner PLIVA Croatia Ltd.). From 2016. to 2017. she 
was employed as a teaching assistant at the Department of Pharmaceutical technology, 
Faculty of Pharmacy and Biochemistry, University of Zagreb. In 2017. she started working as 
Lead Research Analyst in PLIVA Croatia Ltd. (Research and Development). Marina is a 
member of Croatian Chamber of Pharmacists. She co-authored 6 peer-reviewed papers and 
participated in different international scientific conferences. 
List of Publications: 
Juretić, M., Cetina-Čižmek, B., Filipović-Grčić, J., Hafner, A, Lovrić, J, Pepić, I., 2018. Bio-
pharmaceutical evaluation of surface active ophthalmic excipients using in vitro and ex vivo 
corneal models. European Journal of Pharmaceutical Sciences, 120, 133-141.  
70 
 
Juretić, M., Jurišić Dukovski, B., Krtalić, I., Reichl, S., Cetina-Čižmek, B., Filipović-Grčić, 
J., Lovrić, J., Pepić, I., 2017. HCE-T cell-based permeability model: A well- maintained or a 
highly variable barrier phenotype? European Journal of Pharmaceutical Sciences. 104, 23-30.  
Jurišić Dukovski, B., Plantić, I., Čunčić, I., Krtalić, I.; Juretić, M., Pepić, I., Lovrić, J., Haf-
ner, A., 2017. Lipid/alginate nanoparticle-loaded in situ gelling system tailored for 
dexamethasone nasal delivery. International Journal of Pharmaceutics. 533, 480-487. 
Hotujac Grgurević, M., Juretić, M., Hafner, A., Lovrić, J., Pepić, I., 2017. Tear fluid-eye 
drops compatibility assessment using surface tension. Drug Development and Industrial 
Pharmacy. 43, 275-282. 
Blažević, F., Milekić, T., Duvnjak Romić, M., Juretić, M., Pepić, I., Filipović-Grčić, J., Lov-
rić, J., Hafner, A., 2016. Nanoparticle-mediated interplay of chitosan and melatonin for im-
proved wound epithelialisation. Carbohydrate Polymers. 146, 445-454. 
Hafner, A., Lovrić, J., Duvnjak Romić, M., Juretić, M., Pepić, I., Cetina-Čižmek, B., Filipo-
vić- Grčić, J., 2015. Evaluation of cationic nanosystems with melatonin using an eye-related 
bioavailability prediction model. European Journal of Pharmaceutical Sciences. 75, 142-150. 
   
  
Basic documentation card 
 
University of Zagreb 
Faculty of Pharmacy and Biochemistry 
Department of Pharmaceutical Technology 
A. Kovačića 1, 10000 Zagreb, Croatia 
Doctoral dissertation 
 
BIOPHARMACEUTICAL EVALUATION OF OPHTHALMIC EXCIPIENTS USING IN 
VITRO AND EX VIVO CORNEAL MODELS 
 
Marina Juretić 
 
SUMMARY 
 
Bioavailability of topical ophthalmic products is substantially determined by the type and concentration of excipients. 
In addition to the use in conventional ophthalmic formulations, excipients are increasingly utilized in the development 
of innovative nanosystem-based ophthalmic formulations, in which excipients are supramolecularly organized into 
nano-sized structures, which can specifically interact with the anterior eye segment barriers and enhance the drug eye-
related bioavailability. Evaluation of the drug transcorneal permeability is a critical step in predicting eye-related 
bioavailability of topical ophthalmic drugs. In this thesis, the effect of unimers and supramolecular aggregates of the 
ophthalmic excipients on corneal barrier properties and ophthalmic drug permeability was evaluated, using in vitro 
(HCE-T cell-based) and/or ex vivo (excised porcine cornea) corneal models. Histological and functional 
characterization of the in vitro corneal model revealed variability of the HCE-T barrier phenotype, which highlights 
the important aspects to be considered in the further model development. HCE-T cell-based model of a specific 
histological structure, but showing improved barrier tightness and a very strong correlation of ophthalmic compounds 
permeability with excised porcine cornea, was shown to be suitable for the ophthalmic drug permeability evaluation 
considering the influence of ophthalmic excipients. Biopharmaceutical evaluation of melatonin-loaded nanosystems 
using HCE-T cell-based models revealed significant influence of chitosan on nanosystem biopharmaceutical 
properties. In lecithin/chitosan nanoparticles the presence of chitosan ensured mucoadhesive properties and prolonged 
melatonin release, controlling melatonin in vitro transcorneal permeation, which may provide enhanced melatonin 
eye-related bioavailability and therapeutic effect. The in vitro/ex vivo evaluation of the effect of nonionic surface 
active ophthalmic excipients on the ophthalmic drug permeability revealed their concentration-dependent 
permeability-decreasing effect, which was potentially related to the association of ophthalmic drugs with self-
aggregates of surface active ophthalmic excipients. The results of this thesis provide valuable insight into the effect of 
ophthalmic excipients on ophthalmic drug transcorneal permeability, which may contribute to more directed and 
economical development of both conventional and innovative topical ophthalmic products.  
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 BIOFARMACEUTSKA ISPITIVANJA OFTALMIČKIH EKSCIPIJENSA NA IN VITRO I 
EX VIVO MODELIMA ROŽNICE 
 
Marina Juretić 
 
SAŽETAK 
 
Bioraspoloživost topikalnih oftalmičkih pripravaka značajno je određena vrstom i udjelom eskcipijensa. Osim u 
konvencionalnim oftalmičkim oblicima, ekscipijensi primjenu pronalaze i u izradi inovativnih oftalmičkih oblika 
temeljenih na nanosustavima za dostavu lijeka. Interakcija ekscipijensa rezultira tvorbom supramolekulskih struktura 
nanodimenzija, koje mogu povećati bioraspoloživost lijeka u oku prevladavanjem barijera prednjeg segmenta oka. 
Ispitivanje permeabilnosti lijeka preko barijere rožnice ključan je korak u određivanju bioraspoloživosti topikalnih 
oftalmičkih lijekova. Cilj ovog doktorskog rada je bio ispitati utjecaj unimera i supramolekulskih agregata oftalmičkih 
ekscipijensa na barijerna svojstva rožnice i permeabilnost oftalmičkih lijekova korištenjem in vitro HCE-T modela 
epitela humane rožnice i ex vivo tkivnog modela rožnice svinje. Histološkom i funkcionalnom karakterizacijom in 
vitro modela utvrđena je određena varijabilnost fenotipa HCE-T barijere, što ukazuje na potrebu za dodatnom 
karakterizacijom čimbenika uzgoja s utjecajem na barijerna svojstva modela. HCE-T model specifične histološke 
strukture, ali čvršćih međustaničnih veza te vrlo dobre korelacije permeabilnosti oftalmičkih supstancija s ex vivo 
tkivnim modelom rožnice svinje, pokazao se prikladnim za ispitivanje učinka oftalmičkih ekscipijensa na 
permeabilnost oftalmičkih lijekova. Biofarmaceutskom karakterizacijom nanosustava za dostavu melatonina 
korištenjem in vitro HCE-T modela utvrđen je značajan utjecaj kitozana na biofarmaceutska svojstva nanočestica. U 
slučaju lecitinsko-kitozanskih nanočestica kitozan je osigurao mukoadhezivna svojstva, produljeno oslobađanje i 
kontroliranu permeaciju melatonina preko HCE-T barijere rožnice, što može pospješiti bioraspoloživost i terapijski 
učinak melatonina. U in vitro/ex vivo ispitivanjima uočeno je smanjenje permeabilnosti oftalmičkih lijekova ovisno o 
vrsti i koncentraciji neionskih površinski aktivnih oftalmičkih ekscipijensa, što je potencijalno uzrokovano 
interakcijom lijeka s agregatima površinski aktivnih oftalmičkih ekscipijensa. Rezultati ovog doktorskog rada značajan 
su doprinos razumijevanju učinka oftalmičkih ekscipijensa na permeabilnost oftalmičkih lijekova, što može pridonijeti 
usmjerenijem i ekonomičnijem razvoju konvencionalnih i inovativnih topikalnih oftalmičkih pripravaka. 
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